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 Abstract 
Introduction & Hypothesis 
Recurrent urinary tract infection (rUTI) is a debilitating problem affecting 5% of women. 
Current treatment using intermittent or long-term antibiotics gives limited symptomatic 
benefit and encourages bacterial resistance. The aetiology of rUTI is unclear but may 
involve altered innate defence mechanisms in susceptible individuals.  
Colonisation of vaginal mucosa by uropathogenic Escherichia coli (UPEC) is the initiating 
event for UTI, with subsequent migration up the urethra and attachment to bladder 
epithelium. Protective innate immunological mechanisms include epithelial synthesis of 
cationic antimicrobial peptides (AMPs) such as the beta defensins. These may be 
expressed constitutively or induced via Toll-like-receptor (TLR) activation by pathogen 
associated molecular patterns (PAMPs).  
This study investigates the hypothesis that women suffering from rUTI have altered 
tolerance to infecting bacteria related to differences in expression of endogenous AMPs 
and that identification of such deficiency gives a potentially useful opportunity for novel 
preventive therapy. 
Methods and Patients 
A synergistic methodological approach of in vitro modelling with validation in clinical 
samples from the relevant patient group and controls was used. 
In vitro, cell culture was carried out using RT4 immortalised urothelial-cells, VK2 E6/E7 
immortalised vaginal cells and finite primary culture of normal human urothelium. Cells 
were challenged with E. coli and PAMPs. Assays for Beta defensin AMP gene expression, 
secretion and antimicrobial activity were carried out. 
Clinically, 98 women (60 rUTI, 38 controls) were recruited with ethical approval. All 
subjects provided symptom and health state questionnaires; blood for single nucleotide 
polymorphism (SNP) analysis; vaginal and bladder biopsies for AMP gene expression 
analysis; plus vaginal washings and overnight urine samples for AMP peptide secretion 
assays. 
Results 
In vitro, cell culture experiments demonstrated that beta defensin 1 (BD1) was 
constitutively expressed and secreted in urothelial and vaginal cells. Beta defensin 2 (BD2) 
expression and secretion was induced by E. coli flagellin and is a potent antimicrobial 
against UPEC. In vaginal cells, BD2 expression and secretion was enhanced by estrogen. 
Clinically, women with rUTI were identified as having significantly lower basal levels of 
vaginal BD2 expression and secretion than controls but no difference in BD1 expression. 
Postmenopausal women had significantly lower BD2 levels than pre-menopausal women. 
During active UTI, women with history of rUTI and the TLR5392Stop SNP showed significantly 
lower BD2 expression and secretion in both the bladder and vagina than women with wild 
type TLR5 gene and rUTI.  
Discussion 
This study identifies flagellin induced BD2 expression as a novel and important urogenital 
innate immune response against invading E. coli, which is reduced in a significant 
proportion of women with rUTI particularly those with the TLR5392Stop SNP. Observations in 
vitro on the BD2 inducing effect of estrogen, and clinically in pre- and post-menopausal 
women, raise the possibility that BD2 expression can be modulated by exogenous factors. 
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1. Urinary Tract Defence 
The normally sterile urinary tract is constantly challenged by microbes through 
retrograde urethral spread.  A number of defensive mechanisms have evolved in 
response to this threat comprising physical factors such as urine flow, pH and ionic 
urinary composition together with innate immune response characterized by the 
constitutive or inducible expression of host defence peptides with antimicrobial 
activity.  In contrast, adaptive cellular and humoral immune elements are not thought 
to play a defensive role but remain crucial in combating established infection.  Interest 
in endogenous molecular defence has been stimulated by increasing concern regarding 
the overuse of antibiotics with the expectation that enhancement of natural 
mechanisms will be an exciting and novel therapeutic avenue in the management of 
urinary tract infection (UTI).    
1.1. The importance of cystitis and urinary tract infection 
Urinary tract infection (UTI) is one of the most common bacterial infections 
encountered in clinical practice. An estimated 150 million cases of UTI occur annually 
worldwide resulting in over £4 billion (€5 billion, $8 billion) of healthcare expenditure 
(Kucheria et al, 2005). Women are most commonly affected with an estimated mean 
incidence of 0.5-0.7 episodes per year whilst other higher risk groups include children, 
the elderly, people with structural abnormalities of the urinary tract and those having 
urinary tract intervention such as catheter insertion (Foxman, 2002).  
The incidence of UTI increases with age and the cumulative probability of a woman 
having had a UTI by the age of 50 is approximately 50% (Foxman et al, 2000). The 
normally sterile urinary tract is the site of an on-going, but complex interplay between 
 2 
 
an evolving pathogen and a highly developed host immune defence system such that 
the pathogenesis of UTI generally requires either greater virulence in the pathogen or 
deficient host immune defences. Typically the process of infection begins with 
attachment of the uropathogen to the epithelial surface, it subsequently forms 
colonies which then disseminate and invade through the urothelial tissue. This 
dissemination is usually associated with ascent up the urinary tract which may 
manifest symptomatically as cystitis (in the bladder) or pyelonephritis (in the kidney). 
This bacterial process in turn evokes a powerful immune response and the interplay 
between pathogen and host continues, influencing the extent and level of invasion as 
well as the duration of infection and extent of tissue damage caused (Kaper et al, 
2004). 
The occurrence and severity of UTI can be related to genetic, hormonal and 
behavioural factors together with the virulence of the invading organism, chiefly 
uropathogenic Escherichia coli (UPEC), (Foxman, 2002). Although these infections 
rarely cause long term damage they are associated with a high burden of troublesome 
symptoms and healthcare costs, and also give a major contribution to the problem of 
nosocomial infection. Current treatment consisting of preventive behavioural advice 
and intermittent or long-term use of antibiotics, (Franco, 2005), gives limited symptom 
benefit and encourages emergence of resistant organisms - consequently there is a 
real need for alternative therapies (Stapleton, 1999). 
1.2. Routes of Infection 
The ascending route is the commonest mode of infection of the urinary tract with 
most bacteria originating from the individual’s own lower bowel and subsequently 
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colonising the periurethral tissue before ascending through the urethra and into the 
bladder (Handley et al, 2002). Colonisation of the periurethral mucosa with bowel flora 
is particularly problematic in females where the shorter urethra provides a convenient 
conduit for invading pathogens and rapid entry to the lower urinary tract. Even small 
variations in perineal anatomy in females can increase susceptibility; Hooton and 
colleagues for example demonstrated increased risk of female UTI where anal to 
urethral distance was less than 4.5 cm (Hooton et al, 1999).  These anatomical risks 
can be further increased by the influence of external agents such as spermicides, faecal 
contamination of the perineum and the use of urethral catheters (Hooton et al, 1996; 
Foxman, 2002).  
UTI is most frequently present only in the bladder (cystitis) but up to a half of 
infections may demonstrate some signs indicative of upper urinary tract involvement 
(Busch and Huland, 1984). Pyelonephritis is usually caused by ascent of bacteria from 
the bladder up the ureter and into the renal pelvis from where there is subsequent 
invasion of the renal parenchyma through the collecting ducts and disruption of the 
renal tubules. Certain pathogenic virulence factors including P-fimbriae and endotoxins 
can enhance the ability of bacteria to ascend the urinary tract as can host factors such 
as pregnancy and ureteral obstruction as these conditions inhibit ureteral peristalsis. 
Haematogenous infection of the urinary tract is uncommon in normal individuals. 
However, patients with primary foci of infection elsewhere in the body involving 
Staphylococcus aureus, Candida spp., Salmonella spp. and Mycobacterium tuberculosis 
can cause secondary infection in the kidney. The risk of such infection is enhanced 
when urine drainage from the kidney is obstructed (Smellie et al, 1975). Infection via 
the lymphatic route is rare, but can be caused by direct invasion of bacteria from 
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adjacent organs in conditions that result in retroperitoneal sepsis and suppuration. The 
lymphatic route is not thought to play a significant role in the majority of UTIs. 
1.2.1. Urinary Pathogens 
The organisms that cause cystitis are surprisingly limited to a small number of bacterial 
species, which include Escherichia coli isolated in around 75-90% of cases (Ronald, 
2002) and Staphylococcus saprophyticus, a skin commensal, isolated in around 5-10% 
of cases (Jordon et al 1980).  Other enterobacteriacea such as Proteus sp. and 
Klebsiella sp are also occasionally isolated as are gram-positive cocci such as 
Enterococcus faecalis (Naber et al 2008). Positive cultures in cystitis usually consist of a 
single organism, but occasionally two organisms may be isolated such as when a gram 
positive like bacteria Enterococcus faecalis is isolated with a gram-negative 
uropathogen. Any more than two strains would suggest external contamination and 
repeat culture is required. 
1.3. Pathogen Virulence Factors  
As mentioned previously, at the heart of UTI, is the interplay between host and 
pathogen. UPEC strains are highly adaptable encoding a number of virulence factors 
that can be variably expressed, and which enable the bacteria to colonise the urinary 
tract and persist in the face of host defences. In recent years, great strides have been 
made in the understanding of these virulence factors. Prior to their migration, these 
bacteria will typically have come from a commensal site such as bowel where they do 
not generally have pathogenic effects.  The role of virulence factors is therefore critical 
in the understanding of how commensals at one site act as pathogens at another. 
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UPEC strains exhibit a high degree of genetic diversity facilitated by the possession of 
specialised virulence genes. These are located on specific transferable genetic 
elements known as pathogenicity islands which may be as large as 170 kb and can 
increase the size of the pathogen genome by about 20% over a commensal strain 
(Wiles et al, 2008, Oelschlaeger  2002). Virulence factors of UPEC may be broadly 
divided into two groups according to whether they are involved in bacterial adhesion 
or not.  
1.3.1. Adhesive Virulence Factors 
The presentation of cell surface adhesive organelles (adhesins) by UPEC is one of the 
most significant determinants of pathogenicity. UPEC may express several adhesins 
that allow it to attach to urinary tract tissues (Mulvey, 2002). UPEC adhesins can 
contribute to virulence in different ways which include: directly triggering host and 
bacterial cell signalling pathways, facilitating the delivery of other bacterial products to 
host tissues, and promoting bacterial invasion (Mulvey, 2002).  The best characterised 
type of adhesin is the fimbriae.  
Type 1 fimbriae 
Type 1 fimbriae are the most commonly expressed fimbriae on E. coli and are 
composed of a helical rod with repeating FimA subunits that are bound to a distal tip 
structure containing the FimH adhesin (Jones et al. 1995). Classically these fimbriae 
(also called type 1 pili) were shown to mediate hemagglutination of guinea pig 
erythrocytes (Duguid et al, 1979) and the reaction could be inhibited by the addition of 
mannose, hence the term mannose-sensitive hemagglutination (MSHA) (Svenson et al, 
1983; Reid and Sobel, 1987). 
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However, while type 1 fimbriae have been shown to function as virulence factors in 
animal models of urinary tract infection where they facilitate bacterial colonisation, 
their function in human infection remains less clear (Hultgren et al, 1985; Connell et al, 
1996; Mulvey et al, 2002; Emödy et al, 2003; Bergsten et al, 2007). The key difficulty 
with understanding their role lies in the observation that type 1 fimbriae are expressed 
in both pathogenic and commensal strains (Duguid et al, 1979; Hagberg et al, 1981), 
and furthermore there is no significant difference in Fim gene frequency between 
more or less virulent strains in the urinary tract (Plos et al, 1991). In the murine model, 
type 1 fimbriae bind to the urothelial mannosylated glycoproteins Uroplakin Ia (UPIa) 
and IIb (UP1b)  via the adhesin subunit FimH, located at the fimbrial tip (UP1b) (Wu et 
al, 1996). Uroplakins are membrane proteins that are found on umbrella cells, which 
line the luminal surface of the urinary bladder. The interaction between FimH and the 
Uroplakins stimulates signalling pathways involved in invasion and apoptosis, and may 
also contribute to mucosal inflammation (Connell et al, 1996; Martinez et al, 2000; 
Schembri et al, 2001;  Oelschlaeger et al, 2002; Thumbikat et al, 2009). In humans, the 
main evidence for the role of type 1 fimbriae has been obtained from the analysis of 
urinary bacterial isolates from patients with UTIs, which were found to express 
mannose-sensitive adhesins (Ljungh and Wadstrom, 1983).  
Murine studies show that after binding to the urothelial surface, bacteria with FimH 
adhesins are quickly internalised as a result of localised actin rearrangement and 
engulfment of the bound bacterium by changes in the cell membrane around the 
bacteria (Martinez and Hultgren, 2002). Within the superficial urothelium, UPEC is able 
to establish a new niche that functions as a mechanism to avoid the host innate 
immune response (Anderson et al, 2004). Within the cell, UPEC proliferates in the 
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cytosol to form clusters known as intracellular bacterial communities (IBCs) (Anderson 
et al. 2004). After six to eight hours, the morphology of the bacteria changes to an 
engulfing ‘biofilm’ phenotype that further protects the uropathogen from host’s 
immune response (Justice et al. 2004)  
The switch to a biofilm phenotyope is marked by a significant decrease in the rate of 
bacterial growth allowing the formation of a ‘biofilm matrix’. This matrix is able to 
prevent the host’s neutrophils from penetrating its surface and engulf the bacteria, 
and is also effective at preventing both host antimicrobials and external antibiotics 
from gaining access to the bacteria. Animal models also suggest that bacteria at the 
edge of IBCs are able to detach and become motile again to re-enter the urine and 
then re-adhere to the superficial urothelium, and reinvade cells to form further IBCs 
(Mulvey et al, 2001). Ultimately, after a few days, possibly as a result of ongoing 
immune activity, the invasive bacteria enter quiescent state but persist in a dormant 
state in IBCs before re-emerging at a later to cause recurrent infection (Anderson et al, 
2004). 
P fimbriae 
The next most common UPEC virulence factor are the P fimbriae which mediate 
hemagglutination of human erythrocytes that is not altered by mannose and is thus 
termed mannose-resistant hemagglutination (MRHA).  These fimbriae are believed to 
play a key role in ascending UTI and pyelonephritis (Leffer et al, 1981, Vaisanen et al, 
1981). P fimbriae are heteropolymeric fibres made up of various peptides encoded by 
the papA-K gene (Hull et al, 1981). The adhesin PapG, at the tip of these fimbriae 
recognise kidney glycosphingolipids carrying the Gal α (Kaper et al, 2004, Wiles et al, 
2008) Gal determinant on renal epithelia (Kaper et al, 2004). The attachment of P 
 8 
 
fimbriae, leads to the release of ceramide, which acts as an agonist of Toll-like receptor 
4 (TLR4), a receptor involved in activation of the innate immune response including 
cytokines and antimicrobial peptides (Fischer et al, 2007). This then activates an 
inflammatory response and the associated pain of UTI (Bergsten et al, 2005).  
P fimbriae may also work synergistically with type 1 fimbriae; with the former 
enhancing early colonisation of the tubular epithelium, while the latter mediates 
colonisation of the centre of the tubule by forming a biofilm. This colony then disrupts 
tubular filtration leading to obstruction of nephron and the symptoms of 
pyelonephritis (Melican et al, 2011). P fimbriae have also been implicated as one of the 
key virulence factors involved in acute kidney dysfunction within renal transplant 
patients (Rice et al, 2006). 
Other adhesins 
S fimbriae and F1C fimbriae have also been shown to play a role in UTI. S fimbriae bind 
to sialic acid residues via the SfaS adhesin, this facilitates bacterial dissemination 
within host tissues and is often associated with E. coli strains that cause sepsis, 
meningitis, and ascending UTIs (Mulvey, 2002). F1C fimbriae bind to glycosphingolipids 
in renal epithelial cells and induce an interleukin-8 inflammatory response (Backhed et 
al, 2002). 
UPEC also expresses a group of afimbrial Afa adhesins, which have been clustered with 
the fimbrial Dr adhesin family due to similarity in structure plus their ability to bind to 
decay-accelerating factor (DAF) and type IV collagen in the kidney. Both fimbrial Dr and 
afimbrial Afa adhesins of E. coli are associated with UTIs, particularly recurrent 
infection and infection during pregnancy (Foxman et al, 1995; Garcia et al, 1996; 
Nowicki et al, 1990; Servin et al, 2005). Murine models have demonstrated that Dr 
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adhesins  display a tropism to the basement membrane of the renal interstitium which 
is critical for the development of chronic pyelonephritis (Goluszko et al, 1997). 
Adhesins of the Afa family also demonstrate a unique renal tissue tropism; 
experimental findings suggest that UPEC strains with Afa adhesins are more likely to 
result in chronic or recurrent infection (Foxman et al, 1995, Bouguenec 2005). 
1.3.2. Non-adhesive Virulence Factors 
While much attention is focussed on the adhesive virulence factors as many are 
relatively specific to UPEC, like other gram negative bacteria, UPEC has cell wall 
modifications, motility enhancements and secreted toxins that further enhance its 
pathogenicity. 
Polysaccharides 
Both the bacterial capsule and the lipopolysaccharide (LPS) can also act as virulence 
factors. The capsule is a polysaccharide covering for the bacteria, which protects it 
from the host immune system in particular phagocytic engulfment and complement-
mediated attack. Certain capsular types such as K1 and K5, mimic components of host 
tissue and can thus prevent an effective humoral response (Johnson et al, 1991).  
LPS is a core component of the cell wall of Gram-negative bacteria; the LPS of UPEC is 
important in activation of a proinflammatory response in UTIs via the induction of 
nitric oxide as well as antimicrobial peptide and cytokine production (Bäckhed et al, 
2001). However, the systemic immune response evoked by UPEC LPS may also have 
detrimental effects by causing acute kidney injury particularly in renal transplant 
patients with UTI (Wolfs et al, 2002, Samuelsson et al, 2004). Animal experiments 
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suggest that this systemic response and the consequential kidney injury are 
independent of the TLR4 LPS receptor mediated response (Cunningham et al, 2004). 
Flagellum 
The flagellum is a macromolecular organelle complex that protrudes from the exterior 
of the bacterial outer membrane up to 15μM long and is responsible for bacterial 
motility (Macnab et al, 2003). Its activity is linked to chemotactic receptors that sense 
environmental, chemical and physical information and stimulate motility when 
required for growth or survival (Berg et al, 2003). Structurally, it consists of a protein 
called flagellin and its shape is helical consisting of 3-parts: the motor, hook, and 
filament. The motor, also known as the body, is embedded in the cell envelope 
spanning both the inner and outer membranes. Its rotation is powered by the diffusion 
of protons from the periplasm into the cytoplasm (Sowa et al, 2008). The hook consists 
of a flexible curved helical structure 55 nm long made up of multiple copies of the FlgE 
flagellin protein which are formed into helical protofilaments (DePamphilis et al, 1971). 
The hook couples the motor to the filament which consists of a single flagellin protein, 
FliC, made into a rigid protofilaments, 10 to 15 μm long that function as a propeller 
(Berg et al, 2003). An E. coli cell typically has between 4 and 10 flagella which are 
configured in a Peritrichous configuration i.e. they come together to form a bundle at 
the posterior pole when swimming. A change of direction in the bacterium can be 
achieved by one of more motors reversing direction and breaking from the bundle, 
causing the bacterium to re-orientate (Darnton et al, 2007).  
Animal models of UPEC infection have indicated a significant role for flagellum in both 
lower and upper urinary tract infection. In upper tract infection flagella may allow 
bacteria to ascend from the bladder and cause pyelonephritis. These UPEC strains may 
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invade renal collecting duct cells through flagellin, with flagellin acting as an invasin in 
this process (Pichon et al, 2009).  Other work in the murine model has suggested that 
mice deficient in TLR5 (the flagellin receptor) are more susceptible to UPEC infection in 
both the bladder and the kidney suggesting that flagellin may be involved in the 
original ascent into the bladder (Andersen-Nissen et al. 2007). 
1.3.3. Secreted factors 
Like other gram negative bacteria, toxins secreted by UPECs often contribute to or are 
responsible for inflammatory responses and symptoms. The most significant of these 
secreted toxins is a lipoprotein called α-haemolysin (HlyA), which is frequently 
associated with pyelonephritis and renal scarring (Mobley et al, 1990). Alpha-
haemolysin is a pore-forming toxin of the RTX (repeats in toxin) family that are 
common amongst gram-negative pathogens (Bhakdi et al, 1986; Eberspacher et al, 
1989). At high concentrations it lyses erythrocytes and host cells, enabling UPECs to 
cross epithelial barriers, damage immune cells, and gain access to host iron stores 
(Cavalieri et al, 1984; Keane et al, 1987; Johnson et al, 1991). At low concentrations, it 
can induce apoptosis of host immune cells and promote the exfoliation of bladder 
epithelial cells (Russo et al, 2005; Chen et al, 2006; Smith et al, 2006) It can also affect 
intracellular calcium levels in renal epithelial cells, with consequent increases in IL-6 
and IL-8 production (Uhlén et al, 2000).  
Another secreted protein involved in ascending infections is cytotoxic necrotising 
factor 1 (CNF1), which is produced by around one-third of all pyelonephritis strains 
(Landraud et al, 2000, De Rycke et al, 1999). Experimental data suggests that CNF1 has 
effects on the epithelial cell membrane which enhance the ability UPEC to invade cells 
(Bower et al, 2005). In addition the protein has been shown to interfere with 
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polymorphonuclear phagocytosis and cause the death of bladder epithelial cells by 
apoptosis, which in turn increases bladder exfoliation and the exposure of underlying 
cells. (Mills et al, 2000; Fiorentini et al, 1997). 
Other secreted proteins include secreted autotransporter toxin (SAT) and   
Toll/interleukin (IL-1) receptor (TIR) domain-containing protein (Tcp). In vitro, SAT has 
toxic activity against bladder and kidney cells suggesting a role in early pathogenesis of 
UTI (Guyer et al, 2002). Tcp is a more recently discovered type of virulence factors, 
which is able to subvert epithelial toll like receptor (TLR) signalling preventing early 
initiation of the innate immune response thereby facilitating bacterial survival and 
continuing infection (Cirl et al, 2008). 
1.4. Host Defences against UPEC Colonisation  
The normal urinary tract has a number of physiological and immunological defences 
geared towards preventing bacterial colonisation. First and foremost is the ‘washing’ 
effect of the flow of urine. Both the flow through the urinary tract and the ‘bulk 
disposal’ at the time of micturition helps rinse away loosely adherent or non-attached 
pathogens from the epithelial surface (Sobel et al, 1997). Adherence is further limited 
by the secretion of glucosamines by the urothelium which forms a mucous-type layer. 
In addition, the high concentrations of urea, salts and low pH due to organic acids 
make it difficult for poorly-adapted bacteria to survive.  
Within the urine there are also a number of larger proteins which have been identified 
as important in the innate defence of the urinary tract. Of these, perhaps the most 
well-known is Tamm-Horsfall protein (THP), which is a glycoprotein secreted by 
epithelia lining the loop of Henlé and is present at high concentrations in the urine.  
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THP acts as an anti-adhesive urinary factor by binding to UPEC expressing type 1 
fimbriae and forming the complex, which is then cleared by voiding (Serafini-Cessi, 
2003).  THP knockout mice have been shown to clear E. coli less rapidly than wild-type 
mice and go on to develop chronic bladder wall inflammation suggestive of persistent 
infection (Bates, 2004).  The epithelial proteins lactoferrin and lipocalin also show 
antimicrobial activity through the sequestering of iron.  Lipocalin knockout mice were 
more susceptible to systemic infection from E. coli (Berger et al, 2006).  Lactoferrin is 
expressed in the distal collecting tubules and deposited on the luminal surface. It 
inhibits bacterial growth both by chelation of iron and membrane damage but does 
not appear to be induced by active infection (Abrink et al, 2000). Antimicrobial 
peptides are also secreted by urothelium in response to pathogens (Ali et al, 2009). 
These peptides work in a non-specific manner by attachment to the anionic 
phospholipids on the cell wall of pathogens and disruption of their cell membrane 
function, increasing cell permeability and causing cell death (Ganz, 2003). This non-
specific action makes them a powerful first line defence against new pathogens and 
the have antimicrobial action against bacteria, fungi, and some encapsulated viruses 
(Ganz, 2003).  
1.4.1. Antimicrobial peptides  
 Classification 
Antimicrobial peptides (AMPs) are a ubiquitous component of innate immune defence 
and are expressed by neutrophils or epithelial cells either constitutively or induced by 
exposure to pathogen.  They consist of 15–45 amino acid residues and most have an 
overall positive charge.  This cationic state is a key functional attribute common to 
most AMPs and results from numerous arginine and lysine residues. There are, 
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however, a small number of AMPs that are rich in glutamic and aspartic acids and 
consequently have a negative charge. 
AMPs can be categorized into 4 groups according to amino acid composition, structure 
and size using nuclear magnetic resonance (NMR) with over 100 different entities 
described throughout the animal kingdom (Table 1.1).   
Table 1.1 Classes of antimicrobial peptides 
Group Examples Structure Amino acid content Human forms 
Linear cationic α-
helical 
Cecropins 
Magainins 
Cathelicidin 
Linear helical No cysteine residues LL37 
Cationic peptides 
enriched for specific 
amino acids 
Apidaecins 
Drosocins  
Indolicidin 
 PR-39 
Histatin 
Linear extended helical 
Rich in certain amino 
acids e.g. proline, 
arginine or typtophan 
but  no cysteine 
residues 
Histatin 
Cationic peptides 
enriched for specific 
amino acids 
Defensins 
Protegrins 
β-sheet structures 
which are stabilized by 
2 or 3 intramolecular 
disulfide bonds 
Cysteine residues  and  defensins 
Anionic peptides 
Maximin 
Dermicidin 
small peptides with 
one intramolecular 
disulfide bond, 
characteristically near 
the C-terminus 
Rich in glutamic and 
aspartic acids 
Dermcidin 
 
Evidence for antimicrobial activity 
Both in vitro and in vivo models have provided compelling evidence that AMPs protect 
against a range of micro-organisms including bacteria, enveloped viruses, fungi and 
some protozoa (Zaiou, 2007).  Much of the evidence relates to lower order animals 
which lack adaptive immunity and hence are totally reliant on innate mechanisms such 
as AMP expression for survival.  Translation to human physiology can be difficult since 
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genome location, structure and activation from pro-peptides differ from other species, 
even within the mammalian kingdom such as rodents.   
Mechanisms of action 
Although the exact way in which AMPs kill microrganisms is not fully understood, it is 
known that their distinct structure containing both a charged, hydrophilic and a non-
charged, lipophilic segment facilitates cell membrane disruption. Predilection for 
microbial rather than native cell membranes may relate to differing arrangements of 
charged and non-ionic lipid components of the membrane bi-layer (Tytler et al, 1995. 
Ludtke et al, 1996). Bacterial membranes tend to be rich in negatively charged lipids 
with phospholipid head groups such as phosphatidylglycerol on the outer surface, 
encouraging attachment of cationic peptides.  Mammalian membranes in contrast 
have mainly neutral lipids such as phosphatidylcholine and also contain cholesterol, 
both tending to discourage cationic peptide attack (Shai, 1999).  Many studies have 
demonstrated that the bacteriocidal activity of AMPs relates to their secondary 
structure, charge and hydrophobic nature which govern interaction with cell 
membranes (Mor, 2000; Wiepricht et al, 1997). A number of models of this interaction 
have been proposed.  The barrel and stave model suggests that α-helical peptides can 
form channels by boring through the bacterial cell membrane using the hydrophobic 
domain and then bind together like the vertical staves of a barrel with their hydrophilic 
domains orientated to the cell interior.  Increasing polymerization enlarges the size 
and number of membrane pores resulting in cell lysis (Matsuzaki et al, 1998).  The 
carpet model holds that the peptides coat the outer bacterial cell membrane in a 
carpet-like fashion and interaction between the hydrophobic domains and the lipid 
bilayer causes it to deform and disintegrate (Mor, 2000; Dagan et al, 2002). Another 
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possible mechanism of cell lysis is the toroidal pore model.  Here AMPs encourage 
membrane permeabilisation by acting as bridges between the exterior and cytoplasmic 
membrane layers.  Interaction between the membrane lipids and the peptide forms a 
channel through which ions can escape upsetting homeostasis and eventually leading 
to cell lysis (Matsuzaki et al, 1997). Other mechanisms for AMP activity under 
investigation include activation of autolysis as suggested in studies on bovine seminal 
plasmin, (Shai, 1999) together with non-lytic mechanisms such as inhibition of protein 
synthesis, degradation of proteins required for DNA replication and interference with 
the transport and energy metabolism of bacterial cells (Tossi et al, 2000; Sochacki et al, 
2011). 
It is perhaps not surprising that a number of resistance mechanisms have been 
developed by certain bacteria to protect against AMPs including altered cell surface 
charge, active efflux and peptide inactivation by trapping or protease digestion 
(PescheI, 2006). Consideration of these potential inactivating mechanisms will be an 
important part of harnessing the therapeutic potential of AMPs.  
Antimicrobial peptides in the urinary tract 
To date, four groups of AMPs have been identified within the genito-urinary tract. The 
evidence for these AMPs is discussed below. 
Alpha defensins  
Defensins, characterized by a 15-20 amino acid sequence including 6 cysteine residues, 
have received most attention in terms of human AMP research. The -defensins, HNP1 
to HNP4 (Human Neutrophil Peptides) are primarily found in neutrophils where they 
provide non-oxidative antimicrobial activity. A clinical study found an 8-fold increase in 
urinary concentration of HNP-1 in patients with chronic pyelonephritis compared to 
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both normal controls and patients with glomerulonephritis. The rise in HNP-1 
correlated with similar changes in urinary levels of the cytokine, interleukin-8 (IL-8) 
together with the leukocyte count (Tikhonov et al, 1997).  No microbiological 
information was provided in this study however. The concentration of HNP1-3 has 
been shown to be elevated in vaginal washings from women during episodes of 
vaginitis/cervicitis compared to healthy controls (Bevins et al, 2006).  In this study HNP 
content was two-fold higher for mixed or group B Streptoccal infections whilst levels in 
women with chlamydial infection did not differ from control.   
The expression and function of epithelial human -defensins, HD5 and HD6, has been 
most characterized in the small intestine where they are secreted by Paneth cells into 
the intestinal crypts. Research findings indicate a key role in maintaining the numerical 
and species balance of intestinal flora together with a protective function in 
maintaining stem cell activity (Wiechula et al, 2007). HD5 has also been demonstrated 
in the female urogenital tract with highest concentrations identified in the vaginal 
epithelium and associated secretions.  Here it is thought to form an intrinsic 
component of the innate immune defence system against infection by Chlamydia with 
its expression modulated by hormonal and pro-inflammatory factors (Quayle et al, 
1998). More recently, Spencer et al (2012) demonstrated that HD5 is expressed in the 
urothelium of the lower urinary tract and the kidneys with evidence of induction in the 
kidney during pyelonephritis.  
In addition to the antibacterial effects of HD5, interesting findings have also been 
made in relation to its antiviral action against BK virus, a polyoma virus that establishes 
a lifelong persistence in most humans and is a major problem in immunocompromised 
patients with kidney transplants. Dugan et al (2008) demonstrated that HD5 inhibited 
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BK virus by interacting with it directly and inducing aggregation of virions. The authors 
speculate that HD5 may also help clear BKV infection in urinary tract tissue during 
reactivation. 
Beta defensins 
Beta-defensins are widely expressed throughout human epithelia. Whilst over 30 gene 
loci are believed to exist (Schutte et al, 2002), predominantly clustered on 
chromosome 8p23, only a few human -defensins; HBD1 to HBD4, have been studied 
in depth. Expression of a variety of HBDs has been demonstrated throughout the 
urinary tract by protein and RNA molecular identification techniques but their 
functional roles remain uncertain.  Apart from their characterized antimicrobial activity 
-defensins have also been implicated in iron metabolism and tumour surveillance 
(Leong et al, 2004). In the kidney, HBD1 has been shown to be constitutively expressed 
by epithelial cells lining the loop of Henlé, distal tubule and collecting duct (Valore et 
al, 1998).  Despite this, urine levels of HBD1 are insufficient to lyse invading bacteria. It 
is probable that there is a significantly higher concentration of HBD1 at the luminal 
surface of the tubular epithelium which, in conjunction with other antimicrobials, 
provides a fast-acting antimicrobial coating, destroying microbes that manage to gain 
attachment and thus preventing invasion.  One could describe this layer as an 
‘antimicrobial paint’ protecting the epithelial surface beneath. In contrast, expression 
of HBD2 is not found in normal kidney, but is induced by chronic renal infection 
suggesting that it is involved as a second line defence perhaps in co-operation with 
other induced mediators such as cytokines (Lehmann et al, 2002). The most convincing 
evidence that defensins play a direct role in the defence of the kidney against infection 
is provided by studies using knock-out mouse models. In one study, animals with 
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deletion of the murine HBD1 gene (Defb1 -/-) showed a 30% increase in bacteriuria 
compared to wild-type mice (Defb1 +/+) (Morrison et al, 2002). 
The same group that demonstrated HBD1 secretion in the kidney also showed 
expression in the female urogenital tract (endocervix, ectocervix, vagina) and isolated 
peptides from vaginal lavage (Valore et al, 1998). More recently expression of HBD1-4 
mRNA has been detected in endometrium and it has been shown that each defensin 
has a unique temporal expression profile (Fleming et al, 2003; King et al, 2003). HBD1 
and 3 are expressed at highest levels during the secretory phase. This is similar to the 
pattern of expression described above for the alpha defensin, HD5 (PescheI, 2006). In 
contrast, HBD2 mRNA expression shows a dramatic peak during menstruation while 
HBD4 is expressed mainly in the proliferative phase.  
It has been noted that within the HBD gene locus there are significant copy number 
polymorphisms (CNP) and that mRNA concentration correlates with copy number. This 
contention is supported by findings in patients with Crohn’s disease affecting the colon 
where the gene copy number of HBD2 is lower than normal (Fellerman et al, 2006.) In 
addition to copy number, intragenic single nucleotide polymorphisms (SNP) have been 
reported. It is therefore possible that variations in amino acid content and structure of 
expressed peptide could affect host antimicrobial defence capability and may increase 
susceptibility to disease such as UTI 
Cathelicidin 
The human cathelicidin, LL37 is an alpha-helical AMP expressed on all epithelial 
surfaces and by circulating neutrophils (Agerberth et al, 2000).  Its transcription is 
determined by a single gene – CAMP, situated at 3p21 and its expression in most 
epithelial sites is induced by local injury or infection. There is limited but reasonably 
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convincing evidence that it has a role in human urinary defence against bacterial 
invasion.  An investigation into the expression of cathelicidin in the human kidney 
suggested that it was induced to high levels when a microbial presence is detected in 
the urinary tract (Chromek et al, 2006).  In support of this the normally low urinary 
levels of LL-37 were increased in children with UTI. The cathelicidin found in urine was 
thought to be of epithelial origin as levels did not correlate with urinary leucocyte 
count. This is supported by localization studies on renal biopsies which showed 
continuous synthesis of LL-37 by tubular epithelium with subsequent release into the 
lumen.  The inducibility of LL-37 gene expression was demonstrated by exposure of 
renal tissue to UPEC.  In these experiments cathelicidin mRNA rose to maximum levels 
within 5 minutes and continued at supra-normal levels for up to 2 hours, accompanied 
by a surge in peptide secretion.  These findings suggest that the cathelicidin defence 
mechanism is designed to facilitate both an immediate and sustained response to 
bacterial threat. 
The same study provided further evidence for the role of cathelicidin using a mouse 
model to investigate the activity of the murine cathelicidin homologue, CRAMP. In 
these experiments, a large inoculum of UPEC was used to overwhelm the defences of 
the lower urinary tract and induce severe pyelonephritis.  The results showed that in 
early infection cathelicidin was secreted by renal tubular epithelium whilst in more 
advanced stages this was supplemented by release from leukocytes – suggesting a dual 
source for urinary cathelicidin in the mouse. Deletion of the CRAMP gene in knockout 
mice resulted in a greater and more rapid bladder colonisation and invasion together 
with higher rates of ascending infection.   Although these results require confirmation 
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by others they do provide a powerful rationale for the possible therapeutic 
exploitation of LL-37 in the treatment or prophylaxis of UTI.  
1.4.2. Toll like receptors 
The ability of epithelium of the urogenital tract to mount a response to invading 
pathogens is highly dependent on the presence of immune surveillance molecules. In 
common with other epithelial surfaces, the lining of the urinary tract contains 
receptors capable of pathogen recognition via a set of specific pathogen associated 
molecular patterns (PAMPS), these receptors are known as the Toll-like receptor (TLR) 
family (Samuelsson et al, 2004; Adersen-Nissen et al, 2007). TLRs are type I trans-
membrane proteins which structurally contain large, leucine rich, repeat domains in 
the extracellular region and a Toll/IL-1 receptor homology (TIR) domain in the 
cytoplasmic region. Each TLR shows responsiveness to a different microbial component 
and activation leads to production of innate immune effectors such as cytokines and 
AMPs. Other cellular responses are also induced, most particularly of chemotaxis of 
innate immune cells involved in regulating inflammation and adaptive immunity 
(Beutler et al, 2003). The primary receptors expressed on human urothelium are TLR 2, 
4 and 5. TLR 2 is activated by peptidoglycan or lipotechoic acid, part of the cell wall of 
bacteria. TLR 4 and its co-receptors (CD14 and MD2) recognise bacterial LPS and TLR 5 
is activated by flagellin.  
Signalling 
Activation of TLRs by PAMPs triggers conformational changes in the receptor to allow 
recruitment adaptor molecules to the TIR Toll/interleukin-1 receptor (TIR)-domain of 
the TLR. Several adapter molecules are recognised but the most significant are MyD88 
and TIR-domain-containing adaptor protein-inducing interferon (IFN)-β (TRIF) (Akira et 
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al, 2006). The differential immune responses mediated by distinct TLR ligands are 
partly dependent on selective usage of these adaptor molecules in that MyD88 and 
TRIF activate distinct signalling pathways. The MyD88 pathway causes early activation 
of NF-κB (via several adaptor molecules) which then translocates into the nucleus and 
initiates expression of cytokine and AMPs (see Figure 1.1) whereas the MyD88-
independent, TRIF-dependent pathway initiates expression of type I interferons and 
late activation of NF-κB (Akira et al, 2006). 
Figure 1.1  TLR simplified intracellular signalling pathway 
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Toll-like receptor 4 (TLR4)  
TLR4 is the most studied of the TLRs and is well expressed on epithelial cells of the 
kidney and bladder (Samuelsson et al, 2004). TLR 4 and its co-receptors (CD14 and 
Activation of cell surface TLR recruits cytoplasmic adaptor molecules to propagate signal.  
These proteins, identified as MyD88, Tirap(Mal), Trif and TramMyD88, interact with TLR through 
Toll/IL-1receptor domain and in turn engage serine-threonine kinase(IRAK) through a death 
domain. Signal transduction factors such as TRAF6 carry signals through series of phosphorylations 
until NFB is ultimately released to enter nucleus where it can activate transcription of 
appropriate immune response genes resulting in production of AMPs and cytokines. 
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MD2) recognise bacterial LPS. In the mouse urinary tract, its activation has been shown 
to promote a florid innate immune response against Gram negative bacteria but when 
the gene is knocked out, (TLR4-/-) mice develop an asymptomatic carrier state (Schilling 
et al, 2001). As well as the conventional cytokine and AMP responses, a more novel 
function of TLR4 has was recognised by Soman Abraham’s group in North Carolina who 
demonstrated a cAMP regulated mechanism by which TLR4 is able to expel UPEC from 
infected bladder epithelial cells (Bishop et al, 2007).  
The significance of TLR4 has been further highlighted by the effect of gene 
polymorphisms. In mice, polymorphisms of the TLR4 gene are associated with reduced 
sensitivity to LPS, absence of neutrophil recruitment, and delayed clearance of bacteria 
from the urinary tract (Haraoka et al, 1999). A role for polymorphisms in the TLR4 gene 
has also been suggested in human where a TLR4 polymorphism has been shown to 
increase susceptibility to septic shock and Gram-negative bacteraemia (Lorenz et al, 
2002). Other studies have suggested that reduced TLR4 expression may play a role in 
promoting a clinically beneficial tolerance state in asymptomatic bacteriuria rather 
than a more harmful situation of severe disease (Ragnarsdottir et al, 2010). 
Nonetheless, there is still some uncertainty regarding the nature of expression of TLR4 
in the human bladder as work by Jenny Southgate’s group in York, UK demonstrated 
that finite cultured normal human urothelium NHU cells neither bound nor responded 
to LPS (Smith et al, 2011). Within the vagina also, there are also differing reports in 
relation to TLR4 expression. Fazeli et al (2005) investigated TLR expression in tissue 
samples from the uterine tubes, endometrium, endocervix, ectocervix and vagina of 
nine patients and found no expression of TLR4 in the vagina. In contrast, Pivarsci et al 
(2005) demonstrated the presence of TLR4 in both vaginal tissue and the PK vaginal 
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cell-line, and more recently, Dusio et al (2011) demonstrated the presence of TLR4 at 
protein and RNA level in the VK2 vaginal cell-line too. 
Toll-like receptor 5 (TLR5)  
TLR5 is the specific receptor for the bacterial flagellin (Hayashi et al. 2001). Its potential 
importance was first recognised in studies on TLR5 knockout mice (TLR5-/-). These 
mice, when challenged with the CFT073 UPEC strain, initially showed decreased 
inflammation compared to controls as an early response after challenge but 
subsequently demonstrated reduced bacterial clearance and a delayed inflammatory 
response (Andersen-Nissen et al, 2007). In the same year Lane et al (2007) 
demonstrated that while wild-type UPEC were able to establish infection in both the 
bladder and kidney by 6 hours post-inoculation, flagellin-mutant bacteria were only 
able to effectively colonise the bladder with limited presence and activity in the kidney 
at that early time point. Subsequently, by 48 hours post-inoculation, flagellin-mutant 
bacteria were attenuated in both the bladder and kidneys while wild type still 
demonstrated high numbers at both sites. The authors suggested that these data 
provided compelling evidence that flagellin was a key factor in the ability of UPEC to 
cause infection.  The two studies together suggest a critical role in the innate immune 
response to UPEC. 
TLR5 has also been of specific interest from genetic association studies in humans. In 
these studies, a common single nucleotide polymporhism (SNP) causing a premature 
stop codon (TLR5392STOP) has been identified which causes loss of the trans-membrane 
domain of TLR5 protein and the entire signalling cytoplasmic tail (Hawn et al. 2003). 
Population studies have demonstrated that this SNP is linked to susceptibility to 
Legionnaire’s disease, a type of pneumonia caused by the flagellated bacterium 
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Legionella pneumophila (Hawn et al. 2003) and recurrent cystitis (Hawn et al. 2009). 
However, population studies have also shown that the SNP confers resistance to two 
autoimmune disorders: Crohn’s disease (Gewirtz et al, 2006) and Systemic Lupus 
Erythematosus (SLE) (Hawn et al, 2005).  
TLR5392STOP has been shown to cause a loss of function of TLR5 in an autosomal-
dominant fashion and is found in geographically different populations at frequencies 
between 5% and 10% (Hawn et al. 2003, 2005; Gewirtz et al. 2006). This is a 
surprisingly high population frequency for a potentially detrimental SNP and indeed 
there is evidence that the SNP is actually being positively selected (Wlasiuk et al, 
2009). One proposed explanation is that there may be some as yet unrecognised 
evolutionary advantage associated with defective TLR5-mediated signalling (Hawn et 
al, 2005). Irrespective of any potential advantage, the presence of this common SNP 
makes TLR5 particularly interesting from a UTI point of view. 
Toll-like receptor 2 (TLR2) 
TLR2 recognizes cell-wall components such as peptidoglycan, lipoteichoic acid and 
lipoprotein from Gram-positive bacteria. As well as TLR4, TLR2 expressed in tubular 
cells may also play a role in defending the upper urinary tract against UPEC. 
Stimulation of renal tubular cells in vitro by TLR2 ligands results in the secretion of 
inflammatory mediators and chemokines (Tsuboi et al, 2002). It has been suggested 
that TLR2 and TLR4 may work in a synergistic manner to produce a stronger response 
in the presence of ligands for both TLRs,  particularly where the ligand for TLR2 is from 
a Gram positive bacteria and the ligand for TLR4 from a Gram negative (Amdekar et al, 
2011). This synergy may provide a rationale for the use of probiotics (Amdekar et al, 
2011) or other agonist agents that help enhance the TLR4 response. In the vagina, 
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Dusio et al (2011) demonstrated the use of low molecular weight hyaluronic acid 
(LMW-HA) as a non-bacterial agent to induce higher levels of antimicrobial secretion 
and enhanced wound repair through stimulation via TLR2 and TLR4. 
Toll-like receptor 11 (TLR11)  
TLR11 has been described in the urinary tract of mice where it seems to play a role in 
preventing UTI (Zhang et al, 2004). Mice lacking TLR11 are highly susceptible to 
pyelonephritis  induced by UPEC indicating a potentially important role in preventing 
ascending infection. However, in humans, the gene for TLR11 contains a premature 
stop codon resulting in a non-functional peptide and therefore is unlikely to play a 
significant role. 
1.4.3. Activated Responses 
If a microbe evades first line innate defences, contact with the urothelium results in 
the activation of further host immune defence mechanisms, which include the 
exfoliation of bladder cells and induction of an inflammatory response. 
Exfoliation of Infected Cells 
One of the most notable observations of the host response during a UTI is the 
disruption of the epithelial barrier by exfoliation of infected cells (Fukushi et al, 1979, 
Mysorekar et al, 2002). In the absence of infection the urothelium is relatively 
quiescent and the umbrella cell layer is renewed every few months. However, the 
normally repressed proliferation and differentiation cascades are rapidly activated by 
the FimH component of fimbrae that results in an exfoliation mechanism, which 
involves activation of caspases and cysteine proteases in a pathway that is similar to 
apoptosis (Mulvey et al, 1998, Klumpp et al, 2001). Following activation of this 
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pathway, there is potential for the umbrella cell layer to regenerate within 24 hours of 
the exfoliation process. 
The significance of this response has been highlighted by experiments in which the 
exfoliation mechanism has been dampened using a pan-caspase inhibitor. The effect is 
to greatly reduce bacterial expulsion from the bladder in early infection, which in turn 
allows bacteria to escape from dying superficial cells and go onto infect other cells 
(Mulvey 2001). The net effect is to enhance dissemination of the bacteria but 
potentially also allows access to underlying cells where bacteria can persist in long 
term reservoir colonies. In mouse studies, a mild exfoliation process in response to 
UPEC was more likely to result in a biofilm-producing state allowing bacteria to migrate 
into deeper layers (Anderson et al. 2004b). Consequently, it is clear that exfoliation is a 
key mechanism in the eradication of both attached and internalised bacteria from 
urothelium. 
Inflammatory Response 
In addition to triggering exfoliation, bacterial adherence to urothelium or the detection 
of bacterial products also induces a variety of other innate immune responses. Such 
responses are characterised by the production of a number of proinflammatory 
mediators, including cytokines and chemokines (Agace et al, 1993; Schilling et al, 2001; 
Schilling et al, 2003). Bladder and kidney epithelial cells appear to be a major source of 
interleukin-6 (IL-6) and interleukin-8 (IL-8) after infection with UPEC, which are 
important in the development of local tissue damage (Hedges et al, 1991; Agace et al, 
1993; Otto et al, 1999; Jantausch et al, 2000; Gabay 2006). IL-6 possesses a variety of 
proinflammatory functions, including activation of signals involved in neutrophil 
recruitment and production of acute phase proteins (Gabay 2006). IL-8 is also a potent 
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neutrophil chemotactic molecule. In humans, the induction of IL-8 after infection with 
UPEC correlates with appearance of neutrophils in the urine (Agace et al, 1993). 
Neutrophil recruitment to the site of infection has been shown to be critical for 
bacterial clearance from both the bladder and kidney, and the presence of neutrophils 
in the urine is a hallmark of UTIs. Other immune cells such as macrophages, 
eosinophils and natural killer cells are also recruited and granulocytes synthesise nitric 
oxide which has a toxic effect on the invading bacteria (Poljakovic et al. 2001; 
Poljakovic and Persson 2003;).  
Neutrophils play a key role in the early inflammatory response as they migrate towards 
the site of infection. This process is initiated by specific bacterial components which 
activate pathogen-associated molecular pattern receptors (PAMPs) such as the Toll-
like receptors (Albiger et al, 2007; Song and Abraham, 2008). As discussed above, 
activation of these receptors triggers a signalling pathway which initiates inflammatory 
and antimicrobial response from the immune system.  
Antibody Response 
Due to the relatively short duration and adaptability of pathogens, the mainstay of the 
immune response to UTI is the innate response. However, in ascending infections of 
longer duration, the adaptive immune response is activated with the production of 
high affinity antibodies by B and T lymphocytes. In pyelonephritis there is 
immunoglobulin synthesis within the serum and kidney with antibodies targeting type 
1 and P fimbriae detectable in serum as well as IgG and IgA antibodies in the urine 
(Rene et al. 1982). Local synthesis of these antibodies enhances opsonisation and 
reduces adherence of E. coli (de Ree and van den Bosch 1987).  The presence of these 
antibody responses has led to attempts to create vaccines against fimbrial components 
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of the bacteria in an attempt to reduce colonisation and ascending infections in 
susceptible female patients (Uehling et al, 1994).  
1.5. Implications for Recurrent UTI 
The therapeutic potential of AMPs in preventing or treating infection has been clear 
since the discovery of their bactericidal properties, but development has been given 
added impetus by the realisation of increasing adverse effects and short-term 
usefulness of traditional exogenous antibiotics. One area where it is hoped that a 
better understanding of AMPs may provide new therapeutic options is in the 
troublesome area of recurrent urinary tract infection (rUTI).  Recurrent UTI represents 
a common, debilitating and difficult-to-treat problem affecting 5% of women and 
increasing in prevalence with age (Wild et al, 2005). Current treatment consists of 
preventive behavioural advice and intermittent or long-term use of antibiotics (Franco, 
2005). This gives limited symptom benefit and encourages emergence of resistant 
strains of the main pathogen, E. coli so there is consequently a real need for 
alternative therapies (Stapleton, 1999). It is possible that an increased understanding 
of the role and activity of AMPs in the urinary tract could result in therapeutic 
strategies to reinforce innate defences and condition the vaginal, urethral or bladder 
mucosa to hinder migration of bacteria and subsequent infection. 
Note 
Some sections of this chapter have formed part of a published review article: 
Maintaining a sterile urinary tract: the role of Antimicrobial Peptides. AS Ali, CL 
Townes, J Hall and RS Pickard. Journal of Urology 2009; 182: 21-8. 
Other sections have formed part of a textbook chapter written by Ased Ali for: “The 
Oxford Textbook of Urological Surgery”, edited by Professor Freddie Hamdy and Mr 
Ian Eardley, Oxford University Press, for publication in 2014. 
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2. Recurrent Urinary Tract Infection 
Lower urinary Tract Infection (UTI) or cystitis is generally regarded as having recurred if 
a second symptomatic infection follows clinical resolution of an earlier infection, 
although there is not a universally accepted definition. A practical working 
categorisation is the occurrence of at least two episodes of acute uncomplicated 
cystitis within a 6-month period, or at least three episodes in a 12-month period, or at 
least two episodes per year for 2-years (Franco, 2005; Schoof and Hill 2005; Hooton 
and Stamm 2006). 
Recurrent cystitis is very common among young healthy women and is rarely 
associated with any anatomical or functional abnormality of the uro-genital tract. In 
the 1970s, Mabeck found that almost one-half of the women whose initial 
uncomplicated UTIs resolved spontaneously developed a recurrent UTI within the first 
year (Mabeck 1972). In a Finnish study of women aged 17–82 years who had 
Escherichia coli cystitis, there was an overall recurrence rate of 44% within 1 year with 
rates of 53% in women older than 55 years and 36% in younger women (Ikaheimo et al 
1996). It should be noted that to date no large population based studies have been 
performed to determine what proportion of women with cystitis develop a pattern of 
repeated frequent recurrences over longer periods. 
2.1. Aetiology 
Recurrent cystitis occurs in one of two situations: 
 Bacterial persistence i.e. infecting bacteria re-emerge from a reservoir within 
the uro-genital tract 
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 Re-infection i.e. new infection from bacteria outside the urinary tract (bowel or 
skin flora). 
Bacterial persistence is typically characterised by infection with the same organism 
recurring at very short intervals by. In contrast, re-infections usually occur at more 
varied longer intervals which can be up to several months and may not necessarily be 
caused by the same organism. It is important to distinguish between these two 
categories since identification and removal of reservoirs of infection may resolve the 
problem. Re-infection, while more common in women than bacterial persistence, is a 
more complex situation where a single remediable abnormality is much less likely to 
be found. In men, recurrent UTI is less common and more likely to be associated with 
underlying abnormality such as bladder outlet obstruction. 
2.2. Bacterial Persistence  
2.2.1. Diagnosis 
Once acute cystitis has resolved and there is no further microbiological evidence of 
bacteriuria, it is possible under certain circumstances for the organism to ‘hide’ within 
a part of the urinary tract or vagina which was exposed to less high concentrations of 
antimicrobial chemotherapy. The specific abnormalities that can result in this situation 
are outlined in Table 2.1.   
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Table 2.1  Urinary Tract Abnormalities Causing Bacterial Persistence 
Anywhere in urinary tract Stones 
 Foreign bodies 
Renal Infected atrophic kidney 
 Medullary sponge kidney 
 Papillary necrosis 
 Infected renal calyceal cyst 
Ureter Ureteral duplication 
 Ectopic ureter 
 Non-refluxing,  infected ureteral stump 
Bladder Infected urachal cysts 
 Perivesical / pelvic  abscess 
Prostate Chronic bacterial prostatitis 
Urethra Urethral diverticula  
 
 
Urinary culture is useful in the detection of Proteus mirabilis, the commonest organism 
linked with the presence of infection stones (although most patients with P. mirabilis 
cystitis do not go on to form infection stones). P. mirabilis can cause significant 
alkalinisation of the urine with precipitation of calcium, magnesium, ammonium, and 
phosphate salts and the subsequent formation of branched struvite (triple phosphate) 
renal stones. This has serious consequences as bacteria can persist inside struvite 
stones even when the urine shows no growth. Consequently, struvite infection stones 
are a possible cause of bacterial persistence in women. 
Many of the other abnormalities can be identified by a combination of imaging and 
endoscopic evaluation of the urinary tract. Although conventional intravenous 
urography may still be used, CT KUB (non-contrast) and CT urography (late phase 
contrast-enhanced) and cystoscopy provide the most sensitive investigation 
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(particularly as Struvite stones are often relatively radiolucent), retrograde urography 
and ureteroscopy are also useful in some situations.  
 
2.2.2. Treatment 
Where a reservoir for persistent infection is identified, the standard treatment is to 
remove the foreign body or correct the anatomical abnormality. Most of the 
abnormalities listed in Table 2.1 will require surgical intervention to facilitate removal 
and eradication of the source of bacterial persistence. For struvite infection stones, 
complete removal of the calculus either by percutaneous nephrolithotomy, 
ureteroscopic lithortripsy, extracorporeal shockwave lithotripsy, or rarely open 
removal, is needed for bacteriological cure and to prevent renal damage due to 
obstruction (Silverman and Stamey 1983). However, management with continuous 
antibiotic prophylaxis and acidification of the urine provides some symptomatic relief 
and may slow deterioration in renal function. Chronic bacterial prostatitis is usually 
treated initially with penetrative long course antibiotic therapies but transurethral 
resection may be helpful in some cases (Barnes et al 1982).  
Where the reservoir of infection cannot be removed, long-term, low-dose antibiotic 
treatment may be the only option to supress bacterial growth and prevent symptoms. 
Agents typically recommended for this use are nitrofurantoin and trimethoprim.  Other 
drugs such as cefalexin, and the fluoroquinolones are effective but their use is avoided 
where possible due to higher risk of ecological bacterial change. 
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2.3. Re-infection  
2.3.1. Diagnosis 
Recurrent infections occurring at longer intervals or involving different species/type of 
bacteria are the hallmarks of re-infection and the diagnosis is therefore typically made 
on the basis of history, examination and urine culture. This pattern is more commonly 
seen in females of all ages and is usually secondary to infection by ascending bowel 
flora particularly coliforms. Though the ascending route is by far the most common 
route, fistulas (enterovesical or vesiovaginal) or other structural abnormalities are still 
important possibilities to consider particularly where other risk factors are present 
such as diverticulitis, and previous surgery or radiotherapy. In men, re-infection is 
more frequently associated with structural or functional abnormality impeding bladder 
emptying. 
As in the case of bacterial persistence, it is important to identify and correct urinary 
tract structural and functional abnormalities where they exist. Any abnormality which 
either reduces the formation of urine or disrupts its orderly progress through the 
urinary tract can increase the risk of re-infection and limit the effectiveness of 
antibiotic therapy. Imaging typically by ultrasound is useful to demonstrate the 
anatomy of the urinary tract and indirectly indicate the emptying ability of kidneys, 
ureter and bladder. Cystoscopy should also be performed if symptoms are suggestive 
of persistent mucosal irritation (stones or cancer), obstruction (urethral stricture), 
bladder dysfunction (diverticula), and fistula. 
2.3.2. Treatment 
Initial management should be directed towards identifying and where possible 
modifying any of the reversible risk factors shown in Table 2.2. Consequently, in 
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patients with diabetes, glycaemic control should be optimised. In women using 
spermicides, a diaphragm or depot hormonal contraception, alternative forms of birth 
control should be explored.  Where an indwelling catheter or intermittent 
catheterisation is used, catheter management should be reviewed. In postmenopausal 
women, the local effects of reduced oestrogen should be examined and local 
replacement considered. In elderly patients, perineal hygiene, general hydration, and 
both faecal and urinary incontinence should be managed.  
Table 2.2  Risk Factors for Cystitis 
Sexual activity – increased inoculation  
Urinary incontinence – increased inoculation 
Faecal incontinence or constipation– increased inoculation 
Spermicide – increased binding  
Oestrogen depletion – increased binding  
Antimicrobial agents – decreased commensal ‘healthy’ flora  
Inadequate fluid uptake (dehydration) – decreased urine flow 
Diabetes – enhanced medium for growth 
 
General advice in terms of increased fluid intake, use of sanitary towels instead of 
tampons, post-coital micturition, and avoiding the use of soaps in the vaginal area is 
also often given, though evidence of benefit is weak (Remis et al 1987; Strom et al 
1987; Foxman and Chi 1990). 
When an infection occurs it should be treated with a full (three or seven-day) course of 
an appropriate antibiotic (as in the case of acute uncomplicated cystitis). After the 
resolution of an acute episode, there are several evidence-based antibiotic strategies 
which may be employed to prevent recurrences: long-term prophylaxis, post-coital 
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prophylaxis, and patient-initiated therapy as well as some alternate, non-antibiotic 
based strategies with weaker evidence of effectiveness.  
Antibiotic Strategies 
Low-Dose Continuous Prophylaxis  
Long term prophylaxis usually requires a single daily dose of antibiotic (typically taken 
at bedtime). The success of prophylaxis is dependent on the ability of an antimicrobial 
agent to eliminate or suppress proliferation of pathogenic bacteria from the uro-
genital tract prior to excitement of a host response and without causing the 
development of significant resistance or change to the ecology of bowel or vaginal 
commensal flora. Evidence of efficacy exists for the following antimicrobials: 
trimethroprim, trimethroprim / sulphamethoxazole, nitrofurantoin, cefelexin and 
fluorquinolones (Kodner and Gupton, 2010; Dason et al, 2011). It should be noted that 
the use of fluorquinolones for this purpose is discouraged by most guidelines due to 
their broad spectrum. 
Long-term prophylaxis typically involves continuing the daily antibiotics for 6–12 
months, although this can be extended to several years. It is possible that breaks of 1-2 
months every 6 months or the use of alternating agents may reduce the risk of 
changing resistance patterns although good evidence of effectiveness is lacking.  If 
symptomatic re-infection occurs during prophylactic treatment, then urine should be 
sent for culture and full therapeutic dosage of another antimicrobial should be used 
for treatment. Prophylaxis may then be resumed once the infection has resolved 
provided the culture results do not show the presence of resistance to the prophylactic 
agent. Long term prophylaxis is effective at preventing recurrences in 95% of patients 
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whilst they are on prophylaxis. Unfortunately, once prophylaxis is discontinued, 
around 50% of patients will have a further UTI within 3 months (Nicolle 2002).   
As an alternative to these conventional antibiotics described earlier, weak evidence for 
the use of methanamine hippurate also exists. Methanamine decomposes at an acid 
pH to formaldehyde and ammonia, and the formaldehyde is bactericidal. Urinary 
acidity can be ensured by co-administering vitamin C (ascorbic acid) or ammonium 
chloride. Methanamine is particularly useful for long-term prophylaxis as bacteria do 
not develop resistance to formaldehyde. However, it should not be used in the 
presence of renal impairment.  
Patient-Initiated Intermittent Therapy.  
Patient-initiated intermittent or self-start therapy is a useful alternative to long term 
prophylaxis. The key aim is to empower the patient to initiate a 3-day course of 
empirical antibiotic treatment at the first onset of their symptoms or at an ‘early 
warning sign’ which is consistent with development of previous episodes of cystitis 
(Schaeffer and Stuppy 1999; Gupta et al 2001).  As an adjunct, the patient can be given 
reagent strips and instructed to also occasionally submit urine for culture when 
symptoms of infection occur with a subsequent culture a week after treatment to 
check for microbiological efficacy and changing resistance patterns. 
As the antimicrobial agent selected for patient-initiated therapy will be largely used on 
an empirical basis, it should have a reasonably broad spectrum of activity and achieve 
high urinary levels to minimise development of resistance while having as little effect 
as possible on the bowel flora. Nitrofurantoin and trimethorpim are recommended in 
the UK whilst trimethoprm-sulphamithoxasol is also available in other countries.  
Agents such as tetracycline, amoxicillin, cefalexin and fluroquinolones in full doses 
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should be avoided because they can give rise to resistant bacteria and ecological 
bacterial change (Wong et al 1985). Overall, there is much to commend patient-
initiated therapy both from a bacterial point of view as the use of a short full dose 
course is less likely to result in resistant strains and from a patient point of view where 
it is gives patients with less frequent infections the ability to play an active role in their 
diagnosis and management. 
Post-intercourse Prophylaxis.  
In women where sexual intercourse has been identified as ‘triggering event’ in the 
history, post-intercourse prophylaxis is a useful option (Nicolle 2002).   Taking a 
reduced dose of an antimicrobial agent such as nitrofurantoin 50 mg or trimethoprim 
100 mg immediately after voiding post-intercourse can be very effective at reducing 
the rate of re-infection (Pfau et al 1983). Furthermore, studies have shown the efficacy 
to be comparable to daily prophylaxis with the advantage of fewer side effects as on 
average only a third of the total dosage of antibiotic is used (Melekos et al 1997). 
 
Estrogen Therapy 
Postmenopausal women are recognised as group more prone to frequent re-infections 
(Raz and Stamm, 1993; Raz et al, 2000). While in some cases, pelvic organ prolapse 
contributes to residual urine after voiding; in others, the lack of estrogen causes 
marked changes in the vaginal commensal microflora and vaginal pH which leads to 
reduced Lactobacilli sp. and increased colonization by E. coli (Melekos et al 1997). 
Estrogen replacement therapy is believed to partially restore the normal vaginal 
environment which allows re-colonisation with lactobacilli, reduces uropathogenic 
bacterial colonisation and hence occurrence of UTI (Raz et al, 1993). However, the 
mechanism of action is not typical of a classical endocrine effect. Local oestrogen 
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reduces UTI occurrence whilst systemic therapy does not (Perrottta et al 2008). The 
vaginal response is also rapid in onset but short-lived, lasting only for the duration of 
the therapy. The beneficial effects of local oestrogen therapy in recurrent UTI are also 
seen in younger women using the oral contraceptive without evidence of oestrogen 
deficiency (Pinggera et al 2005). Despite the unclear mechanism, the use of vaginal 
oestrogen in post-menopausal women is supported by evidence from a meta-analysis 
performed as part of a Cochrane systematic review and there may also be a role in pre-
menopausal women (Perrotta et al, 2008). 
Other Strategies 
For women with a persistent post-void residual urine (> 100 mL) and evidence of 
reduced urethra calibre, a single dilation of the urethra under a general anaesthetic to 
improve bladder emptying may be appropriate. There is no evidence, however, that 
repeated urethral dilation is beneficial in the routine management of women with 
recurrent UTI. 
Cranberry extract has been a popular preventive method for many years. It is believed 
to work partly by acidifying the urine, and partly by reducing bacterial adhesion and 
bacteriuria. Cranberry extract contains proanthocyanidins which has demonstrable in-
vitro to both competitively inhibit the E. coli fimbrial subunit from binding to the 
uroepithelial cells, and prevent the expression of normal fimbrial subunits (Patel and 
Daniels 2000). From the clinical viewpoint, in 1994, Avorn et al studied 153 women and 
showed that 300 mL/day of cranberry juice reduces bacteriuria and pyuria by 42% and 
persistent bacteriuria and pyuria by 72% (Avorn et al 1994). However, the proportion 
of cranberry extract in commercial juices and tablets is highly variable therefore effects 
are unpredictable. Furthermore, subsequent randomised controlled trials of cranberry 
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products have not shown benefit and the latest Cochrane systematic review has shown 
no evidence that they are effective for management of UTI (Jepson et al 1998). 
  
Note 
Some sections of this chapter have formed part of a textbook chapter written by 
Ased Ali for: “The Oxford Textbook of Clinical Nephrology (OTCN), Fourth Edition”, 
edited by Neil Turner, David Goldsmith, Christopher Winearls, Norbert Lameire, 
Jonathan Himmelfarb, Christoph Wanner, Guiseppe Remuzzi, Oxford University 
Press, for publication in 2014. 
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2.4. Aims of the Study 
It is evident from review of the literature that while considerable strides have been 
made in the scientific understanding of UTI, treatment options for recurrent UTI still 
largely consist of preventive behavioural advice and intermittent or long-term use of 
antibiotics (Franco, 2005). These give limited symptomatic benefit and given the 
plasticity and adaptability of E. coli, encourage the emergence of resistant strains 
(Stapleton, 1999), potentially making the condition worse in the long term for both the 
individual patient and the wider community.  
The host aspect of aetiology of rUTI is unclear with genetic, hormonal and behavioural 
factors all thought to play a part (Stapleton, 1999). The route of infection, however, 
does seem clear with increased colonisation of vaginal and periurethral mucosa by 
bowel and skin commensals, leading to migration up the urethra and attachment to 
the bladder mucosa (Handley et al, 2002). Despite this, much of the existing research 
outlined has focussed on either immune defence of the kidney from ascending 
infection (Zasloff, 2007), or pathogenic mechanisms of E. coli persistence within the 
bladder once an infection has been established (Andersson et al, 2004). There has 
been comparatively less research into which of the normal innate defence mechanisms 
have been breached to allow lower urinary tract infection to take hold in the first 
place. In particular, given the route of infection, it would seem appropriate that in 
addition to urothelium, the vaginal epithelium should also be considered as part of the 
first line of bladder defence. Studies in other tissues have suggested that epithelial 
production of cationic peptides such as cathelicidins and defensins are an important 
aspect of host anti-microbial defence (Boman, 2003) and an improved of 
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understanding of how these mechanisms protect and in rUTI, fail to protect, may give 
insights in how to prevent rUTI. 
The overall aim of this doctoral research study was therefore to compare differences in 
antimicrobial peptide (AMP) expression and secretion between women with recurrent 
urinary tract infection (rUTI) and those without focussing on human beta defensin 2 
(BD2). It was hypothesised that,  
“Women suffering from recurrent urinary tract infection (rUTI) have altered 
tolerance to infecting bacteria related to differences in expression of endogenous 
antimicrobial peptides (AMPs) and that identification of this deficiency represents a 
potentially useful opportunity for design of preventive or adjunctive treatment.” 
Within this overall aim, the study sought to: 
 Determine the pattern of constitutive and inducible expression and activity of 
selected AMPs in bladder and vaginal epithelium using cultured cell lines. AMPs 
for analysis were selected on the basis of those already described in the 
literature and those found on analysis of human tissue samples in the present 
study 
 Evaluate differences in expression and secretion of AMPs in urine and vaginal 
washings from 2 groups of women recruited to the study (rUTI/no UTI).   
 Determine if any clinically identifiable factors influenced differences in AMP 
expression and secretion. 
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3. Laboratory Materials and Methods 
3.1. Tissue Culture 
All tissue culture experiments were carried out in the sterile environment of a class ІІ 
laminar flow cabinet (S@feflow 1.2, BIOAIR, Italy) using aseptic techniques to avoid 
contamination. A sterile environment was maintained by daily irradiation with UV light 
and regular spraying with 70% ethanol and TriGene (Starlab, UK). All medium was 
stored at 4ºC and warmed to 37ºC prior to use. 
3.1.1. RT4 Cells 
The immortalised RT4 cell line was derived from a non-invasive papillary transitional 
cell carcinoma of the bladder at the Medical Research Council Biochemical Genetics 
Unit, London, UK (Master et al. 1986). The cell line was chosen as it is commercially 
available (ATCC HTB-2) and  has been used by our research group previously as it has 
an antimicrobial peptide expression profile comparable to normal human urothelium 
(Townes et al. 2010). 
The RT4 urothelial cell line was maintained without antibiotics in HEPES (4-[2-
hydroxyethyl]-1-piperazineethanesulfonic acid) modified RPMI (Roswell Park Memorial 
Institute) 1640 medium with 2 mM glutamine and 10% foetal calf serum (Sigma, 
Dorset, UK).   
Cells were grown in 75cm2 flasks (Corning, Tewksbury, Massachusetts, USA) at 37ºC in 
5% CO2 in air until confluent at approximately four days (determined by light 
microscopy). After confluence, they were sub-cultured and re-seeded at a density of 
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1x106 cells per flask. Cells from passage 10 to 30 were used for experiments beyond 
which a new culture was initiated from frozen stocks. 
3.1.2. VK2 E6/E7 Cells 
The VK2 E6/E7 cell line was developed from vaginal mucosal tissue obtained from a 32-
yr-old woman following anterior-posterior vaginal repair surgery and laboratory 
immortalised using HPV 16 E6/E7 transduction at the Harvard Medical School, Boston, 
Massachusetts, USA (Fichorova et al, 1997). This cell line was chosen as it is the only 
commercially available vaginal cell line (ATCC CRL-2616).  
The VK2 vaginal epithelial cell line was maintained without antibiotics in Keratinocyte 
Serum-free medium (GIBCO, Paisley, UK) containing 0.4mM calcium with 0.1 ng/ml 
human recombinant Epidermal Growth Factor (EGF) and 0.05 mg/ml bovine pituitary 
extract supplements. 
Cells were grown in 75cm2 flasks (Corning, Tewksbury, Massachusetts, USA) at 37ºC in 
5% CO2 in air until confluent at approximately seven days (determined by light 
microscopy). After confluence, they were sub-cultured and re-seeded at a density of 
5x106 cells per flask. Growth medium was replaced every three to four days. Cells from 
passage 5 to 25 were used for experiments beyond which a new culture was initiated 
from frozen stocks. 
3.1.3. Primary tissue 
Primary tissue culture was carried out on my behalf by Claire Varley from Jenny 
Southgate’s group at the University of York. The technique is described in detail in 
publications by Jenny Southgate’s group (Southgate et al. 2002 and Smith et al. 2011). 
However, briefly, human ureter tissue removed during routine nephrectomy and 
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surplus to diagnostic requirements obtained was collected (with informed consent and 
ethical approval). Ureter used was from patients with no history of urothelial 
neoplasms and confirmed normal histology. Tissue was transferred from the hospital 
to the laboratory in transport medium consisted of HBSS (Hank’s Buffered Saline 
Solution) without Ca2+ and Mg2+ (HCMF) with 0.01 M HEPES buffer pH 7.6 and 0.04 
KIU/mL (Kallikrein Inhibitor Unit per mL) aprotinin. 
In the laboratory, serosa, fat and debris were removed from the specimen, which was 
cut into 1-2 cm2 pieces. Urothelium was isolated by leaving the pieces incubated 
overnight at 4ºC with 15ml stripping solution that consisted of the transport medium 
supplemented with 0.1% EDTA (ethylene diaminetetraacetic acid, disodium salt). The 
tissue was transfered to a Petri dish and, using two pairs of sterile jeweler's forceps, 
the urothelium was gently separated from the underlying stroma. The urothelium 
detaches easily as intact sheets of cells. The pieces of stroma were picked out with a 
wide-tipped sterile plastic Pasteur pipette and the sheets of urothelium transferred 
into a 10ml centrifuge tube. 
The urothelial cell sheets are collected by centrifugation at 250g for 4 min. The 
supernatant was aspirated and the tube flicked to resuspend the pellet in the residual 
volume. 2 ml collagenase (200 units of collagenase type 4 in HBSS with 10 mM sterile 
HEPES at pH 7.6) was added and the cells incubate at 37°C for 20 min. After incubation, 
3ml of KSFMc [Keratinocyte Serum Free Medium (GIBCO, Paisley, UK) complete with 
5ng/mL Epithelial Growth Factor (EGF) and 50ng/mL Bovine Pituitary Extract (BPE)] 
was added and the cell sheets disaggregated by gentle pipetting. The cells were once 
again pelleted by centrifugation and resuspended in a further 5 ml of KSFMc. 
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A hemocytometer was used to estimate the number of urothelial cells in the 
suspension, which contained a mixture of single cells and clumps of urothelial cells, 
erythrocytes, and leukocytes. Detached normal human urothelium (NHU) was cultured 
in flasks containing KSFMc growth medium at a minimum seeding density of 4x104 
urothelial cells per cm2 for primary cell culture and maintained at 37ºC in a humidified 
atmosphere of 5% (v/v) CO2 in air. Medium was replaced after 24-hours and 
subsequently on alternate days.  
Cells were sub-cultured by removing the medium from the flask and incubating the cell 
monolayer in 0.2 ml/cm2 of PBS with 0.1% EDTA solution for 5 minutes at 37ºC until 
the cells separated. The solution was then aspirated and sufficient Trypsin-EDTA 
(HCMF with 0.025% Trypsin and 0.02% EDTA) to cover the monolayer and incubated 
again at 37ºC for around 2-minutes for the cells to detach. 5ml of KSFM with 2.5mg of 
trypsin inhibitor is added to the cells which were then centrifuged and resuspended in 
KSFMc re-seeded at around 5x105 cells in a T25 culture flask. Cell were used for 
experimentation between passages 3 and 5. Cytodifferentiation was induced using 5% 
adult bovine serum and 2mM calcium chloride and verified by qualitative RT-PCR for 
uroplakin-2 expression. 
3.2. Bacterial Culture 
3.2.1. Strains 
To model the induction of AMPs in a state of urinary tract infection, both RT4 and VK2 
cells were initially challenged with three strains of Uropathogenic E. coli for varying 
times up to 24-hours. The strains used were: 
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 NU14 – a laboratory strain of UPEC with multiple virulence factors derived from 
a clinical isolate of E. coli originally obtained from the urine of a patient with 
cystitis in 1986 (Hultgren et al. 1986).  
 NU14-1 – a non-functioning fimH mutant of NU14.  
 NCTC 10418 (ATCC 10536) – A long established National Collection of Type 
Cultures (NCTC) E. coli strain used for testing antimicrobial and disinfectant 
agents originally isolated in 1947 (Personal communication from HPA Cultures) 
 K12 – a long established gut strain originally isolated in 1922 (Bachmann, 1972) 
and regarded as a standard strain for use in microbiology experiments but 
lacking many virulence characteristics. 
 CFT073 – a laboratory strain of UPEC with multiple virulence factors derived 
from a clinical isolate of E. coli originally obtained from the urine of a patient 
with pyelonephritis in 1990.  
3.2.2. Luria Bertani Broth and Agar Plates 
Luria Bertani broth (LB) was prepared with 10% (w/v) Bacto-tryptone (10g), 10% (w/v) 
sodium chloride (10g), 5% (w/v) Bacto-yeast (5g) and 1L of deionised water with pH 
adjusted to 7.4 using 5M NaOH. The LB broth was sterilized at 121°C for 20 minutes at 
a pressure of 15 pounds per square inch (PSI). 2% (w/v) agar plates were prepared 
using LB broth and agar, and re-sterilised in the same manner as the original broth.  
20-25ml of autoclaved agar was poured into each petri dish, allowed to solidify and 
dried at 37°C.   
3.2.3. Storage and culture of E. coli strains 
Glycerol stocks of bacterial strains were prepared by inoculating 10ml of LB broth with 
a loopful of bacteria and incubating aerobically at 37°C overnight culture 
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(approximately 16-hours).  An aliquot of this culture (0.5ml) was placed into a 1.5ml 
cryovial containing 0.5ml 50% (v/v) glycerol and stored at -80°C.  
When required for experimentation, bacteria were taken simply by dipping a sterile 
10μl pipette tip into the glycerol stocks and then inoculating 10ml of LB broth for 
overnight culture. 
3.2.4. Challenge Experiments 
For challenge experiments, both RT4 and VK2 E6/E7 cells were seeded onto 30 mm, six 
well plates (Corning, Tewksbury, Massachusetts, USA) at 104 cells/well and cultured at 
37ºC and 5% CO2 until confluent.  Prior to challenge, cells were washed in PBS and 
incubated for 24-hours in 1ml of new medium.  
For bacterial challenges, bacteria from overnight culture were used to inoculate 5ml of 
LB medium for 1-hour then 50μl of this solution was grown in a further 5ml of LB 
medium for 3-hours (synchronisation by stationary phase method). Growth 
characteristics of the four E. coli strains have been previously characterised by our 
research group using serial optical density measurement and confirmed to be in log-
phase using this method. 20μl of the 3-hour culture was re-suspended in 980μl PBS to 
give a working solution. 10μl of the working solution was serially diluted, plated in 
quadrants on agar plates and incubated overnight to confirm that 20μl was 
approximately 5x105 colony forming units (CFU). Dead bacteria were produced by 
incubating live bacterial stock solution for 30 minutes at 65ºC and death confirmed by 
overnight agar plating. Each well of eukaryote cells was inoculated with either 20μl of 
live or dead bacteria for the time required.  
For bacterial component challenges, each well of eukaryote cells was inoculated with 
20μL of LPS (0.25 – 1mg/mL), S. typhimurium flagellin (100 – 250ng/mL), Peptidoglycan 
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(5 – 10μg/mL) (Invivogen, San Diego, California, USA) and E. coli Flagellin (250 ng/mL) 
(gift from Marcelo Lanz, Newcastle University, UK). 
When the appropriate time point in a challenge was reached, the medium from the 
well was removed, stored at -20ºC and the cells prepared for RNA extraction as 
described in section 3.3.1. 
3.2.5. Time kill antimicrobial assay 
Time kill antimicrobial assays using the laboratory uropathogenic E. coli (UPEC) strain 
NU14 were adapted from the technique described previously by our research group 
(Townes et al. 2010).  A 20μL aliquot a 3-hour NU14 bacterial culture (described in 
section 3.2.4) was diluted to 2 mL in PBS. 50μL samples of eukaryote cell culture 
medium taken from either challenge or control experiments or synthetic defensin 
peptide were added to 50μL of the diluted bacterial culture, vortexed, and incubated 
for one hour at 37°C. Suspensions (taken at 0 hr and 1 hr time-points) were 
sequentially diluted to 1:104 in PBS, and each dilution was plated onto LB agar. All 
plates were incubated overnight at 37°C and the colonies counted.  
3.2.6. Motility Assay 
The E .coli motility assay was carried out by Dr Chris Birchall and Dr Phil Aldridge on my 
behalf. Swarm plates were prepared one day prior to use with 25 ml of LB medium 
fortified with 0.3% Bacto agar, 1% tryptone and 0.5% Sodium chloride. To minimize 
water on the agar surface, plates were dried 20 min prior to inoculation. For 
qualitative swarm assays, plates were centrally inoculated with cells from a freshly 
grown overnight colony using a sterile stick. Plates were incubated at 37°C for 8-hours 
and pictures taken. 
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3.3. RNA Extraction 
3.3.1. TRIzol® RNA Isolation 
Tissue samples were initially homogenized at room temperature in 1ml of TRIzol® 
reagent (Invitrogen, Paisley, UK) with a rotor-stator style homogenizer (TissueRuptor, 
Qiagen, Crawley, UK) ensuring that the homogenizer was cleaned thoroughly between 
samples to prevent cross-contamination. 
For cells cultured during challenge experiments in 30 mm, six well plates, the culture 
medium was removed and the cells washed in 2ml of PBS. 1ml of TRIzol® reagent was 
then added to the well and left to lyse the cells for five minutes with the cell lysate 
passed several times through a pipette to facilitate the process. 
Once the homogenised and lysed cells had been incubated at room temperature for 
five minutes, 200µl of chloroform was added to the lysate, gently mixed and left for a 
further three minute incubation period at room temperature.  The samples were then 
centrifuged for 15 minutes at 12000g and 4°C, the clear supernatant removed, mixed 
with 700µL of Isopropanol and the solution re-centrifuged.    The clear pellet was 
washed with 1ml of 70% ethanol, and after centrifugation the RNA pellet resuspended 
in 20µL of molecular grade water. To aid preservation of RNA, 1µl of RNAsinTM RNAse 
inhibitor (Promega, Southampton, UK), was added to all samples.  Samples were 
stored at -80°C. 
3.3.2. Analyses of RNA concentration, purity and integrity 
The concentrations of RNA extracted from the tissue samples and cells were 
determined spectrophotometrically.  Essentially, RNA samples were diluted 1:10 or 
1:100 in nuclease-free water and the absorption of RNA measured at 260nm.  The 
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conversion factor 40µg/ml per 1 unit OD260nm was used to calculate RNA 
concentration.  For initial calibration of the spectrophotometer nuclease-free water 
was used.  Absorbance was also measured at 280nm and 230nm to check for 
contamination of the sample with protein (A260/A280) and guanidine isothiocyanate 
(A260/A230).  In both cases ratios of 1.8-2.2 indicated that the sample was within an 
acceptable purity range and was free from protein and /or chemical contamination. 
Random samples of extracted RNA were checked using a Bioanalyzer 2100 (Agilent 
Technologies, Berkshire, UK) to ensure quality of the nucleic acid. A minimum RIN-
number of 8.0 was maintained for quantitative real time PCR (RT-qPCR)  analyses of  
the  in vitro samples and a minimum of 7.0 for biopsy samples.  
3.4.  Reverse Transcription  
3.4.1. DNase treatment of RNA 
Following quantification of RNA, all samples were treated with DNAse (DNAse kit, 
Promega, Southampton, UK) to remove any genomic DNA contamination. In a 
microfuge tube approximately 4.5µg of RNA was mixed with 2µl of DNase buffer 
(400mM Tris-HCL, pH 8.0, 100mM MgSO4, 10mM CaCl2) and 4.5µl of DNase.  To this 
molecular grade water was added to give  a total reaction volume of 20µl.  Where 
samples had a poor RNA yield, water was omitted from the sample and instead a larger 
volume of RNA was added.  The tube was briefly vortexed, incubated at 37°C for 30 
min and the reaction terminated by the addition of 4µl of DNA stop solution (20mM 
EDTA, pH8). The reaction was heat treated at 65°C for a further 10 min.  Samples were 
used for reverse transcription or stored at -20°C. 
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3.4.2. Complementary DNA Preparation 
Total RNA was reverse transcribed into complementary DNA (cDNA) for use in end-
point and real-time qPCR analyses.  For these reactions, 5µl of DNAse treated RNA was 
set up in a microfuge tube reaction with an Applied Biosystems PCR set consisting of 
2µl 10xPCR buffer, 1.6µl Magnesium Chloride,  8μl of 10mM dNTPs (dATP, dGTP, dCTP, 
dTTP) and 0.5 μl of muLV reverse transcriptase (Life Sciences, Paisley, UK). To this, 1μl 
of 15mM oligoDTs, 0.5μl of 40u/μl Human Placental RNAse inhibitor, and 1.4µl 
nuclease-free water were added (Promega, Southampton, UK). These were mixed and 
the solution placed in a thermal cycler (Hybaid PCR express, Sprint ™, Hybaid, 
Middlesex, UK) and treated for 1 hour at 42°C, 95°C for 5 min and 5°C for 5 min.  All 
cDNA was stored at 4°C prior to PCR amplification.  In addition to samples, ‘no 
template’ and ‘no reverse transcriptase enzyme’ controls were also used.   
3.5. End-point polymerase chain reaction 
3.5.1. Primers 
Primers for cDNA amplification were designed using NCBI Blast sequences of targeted 
genes and designed to amplify across at least two exon containing regions. The primer 
sets have been extensively used in our research group with validation and optimisation 
outlined by Stephanie Bell in her PhD thesis (Bell, 2008) and by Marcelo Lanz in his 
MRes (Lanz 2010). Primers were produced by Invitrogen (Life Sciences, Paisley, UK), 
supplied laboratory ready as a stock solution of 100µM. Working solutions of 10µM in 
RNAse and DNAse free deionised water were prepared from the stock solutions. 
Ambion 18S primer pair was used as a positive control (Life Sciences, Paisley, UK).  All 
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primers were used at an annealing temperature of 58°C, the sequences and their size 
are outlined in Table 3.1. 
Table 3.1 Primer sequences for End-point RT-PCR 
Gene Forward Primer Reverse Primer Product size (bp) 
HBD1 CCATGAGAACTTCCTACCTTC GTCACTCCCAGCTCACTTG 221 
HBD2 GTGAAGCTCCCAGCCATCAG GATTGCGTATCTTTGGACACC 325 
HD5 GCCATCCTTGCTGCCATTC GATTTCACACACCCCGGAGA 240 
LL37 CATGAAGACCCAAAGGGATG CACACTAGGACTCTGTC 518 
TLR4 TGCAATGGATCAAGGACCAGAGGC GTGCTGGGACACCACAACAATCACC 449 
TLR5 CCTCATGACCATCCTCACAGTCAC GGCTTCAAGGCACCAGCCATCTC 355 
Er GGATACGAAAAGACCGAAGAG GTCTGGTAGGATCATACTCGG 246 
Er TAGTGGTCCATCGCCAGTTATCAC GCACTTCTCTGTCTCCGCACAA 439 
18S Ambion commercial primer Ambion commercial primer 344 
 
3.5.2. Amplification 
Polymerase chain reaction (PCR) was used to amplify cDNA exponentially using a hot-
start Taq (Thermus aquaticus) polymerase. PCR reactions were set up using Biolinekit 
reagents consisting of 0.8μl Magnesium Chloride [25 mM], 4μl of 10 x PCR Buffer and 
0.5μl Taq Polymerase (Bioline Reagents, London, UK) to which was added 4μl of Primer 
pair (2μl of forward [10µM] and 2μl reverse primer [10µM]) and 10μl of cDNA from the 
respective reverse transcription reaction. The reaction volume was made up to 20μl 
with deionised water. 
The mixed solution was placed in a thermal cycler (Hybaid PCR express, Sprint ™, 
Hybaid, Middlesex, UK) for amplification consisting of a 5-minute denaturation step at 
95°C; then 35 cycles of the following sequence: 30 seconds at 95°C, 30 seconds at 58°C 
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(annealing temperature) and 30 seconds at 72°C, and a final extension step at 72°C for 
12 min.  A final5-minute cooling step lowered  the reaction temperature to 4°C. 
3.5.3. Agarose gel electrophoresis 
PCR products were electrophoresed on 1.5% w/v TBE-agarose gels.  Molecular grade 
agarose was dissolved in 1 X TBE buffer (0.089M Tris-borate, 2mM EDTA, pH8.3) with 
5µg/ml ethidium bromide added before pouring into an electrophoresis tank. The 
solidified gel was submerged in TBE buffer and samples added. To 8µl of PCR product, 
2µl of gel loading dye was added (50mM Tris, pH8.5, 5mM EDTA, 50% glycerol and 
0.1% bromophenol blue).  Each gel was also loaded with 4µl of Hyperladder IV DNA 
ladder (Bioline Reagents, London, UK).  Electrophoresis was performed at a voltage of 
70V for 45 to 60 minutes.  Gels were visualized and photographed under ultraviolet 
illumination. 
3.6. Real-Time Polymerase Chain Reaction 
3.6.1. Primers 
Primers for qPCR were designed in a similar manner as described for end-point PCR 
(section 3.5.1) and had also been previously validated and optimised by our research 
group for defensins (Bell, 2008) and Toll like receptors (Lanz, 2010). This validation 
included coefficient of variation (CV) calculations consistent with MIQE guidelines for 
each assay to ensure reproducibility using the first and second clone dilutions from 
standard curves.  
Two types of primer were used: Probes Master, an oligonucleotide probe based 
detection system or the SYBR Green I Master intercalating DNA-dye based system 
(Roche Products, Welwyn Garden City, UK). Probes Master primers are produced by 
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Roche whereas SYBR Green primers were produced by Invitrogen (Life Sciences, 
Paisley, UK). Pre-designed primer pairs for ‘house-keeping’ reference genes were 
produced by Primer Design (Southampton, UK)  
The primer type, sequence and annealing temperature (Tm) are shown in Table 3.2. 
Table 3.2: Primer sequences for RT-qPCR 
Gene Primer Sequence Primer Type Tm (ºC) 
BD1 
Reverse: cgccGGTAGGAAGTTCTCATGGcG 
Forward: GTCAGCTCAGCCTCCAAAGGA 
Probes Master 60 
BD2 
Forward: GTGAAGCTCCCAGCCATCAG 
Reverse: GATTGCGTATCTTTGGACACC 
SYBR Green I Master 58 
HD5 
Forward: GCCATCCTTGCTGCCATTC 
Reverse: GATTTCACACACCCCGGAGA 
SYBR Green I Master 58 
LL37 
Forward: cgctGACGGGCTGGTGAAGcG 
Reverse: CCCAGCAGGGCAAATCTCTT 
Probes Master 55 
TLR4 
Forward: GAATTTAGAAGAAGGGGTGCC 
Reverse: CCTTCATGGATGATGTTGGC 
SYBR Green I Master 58 
TLR5 
Forward: CAGAGACTGGTGTTCAAGGAC 
Reverse: GTGTCCAGGTGTTTGAGCA 
SYBR Green I Master 54 
GAPDH 
Primer Design commercial primer 
(House-keeping reference gene) 
SYBR Green I Master 60 
ATP5B 
Primer Design commercial primer 
(House-keeping reference gene) 
SYBR Green I Master 60 
3.6.2. Amplification 
Polymerase Quantitative PCR (qPCR) was carried out on a Roche LightCycler 480 using 
LightCycler 480 SYBR-green Master Mix (Roche, UK).  
For amplification of genes of interest the protocol was as follows: 95 ºC for 10 minutes, 
45 cycles of 95ºC (10 seconds), TmºC (20 seconds) and 72ºC (10 seconds), followed by 
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melt curve analysis (cooling to 65ºC followed by heating to 97 ºC during which a 
continuous fluorescent reading is recorded) and a cooling step.  
For house-keeping reference genes, the manufacturer’s protocol was followed: 95ºC 
for 10 minutes, 45 cycles of 95ºC (15 seconds), 60 ºC (30 seconds) and 72ºC (10 
seconds), followed by melt curve analysis and a cooling step.  
All data was normalised to a geometric mean derived from the two appropriate 
reference genes.  
3.6.3. GENORM Analysis and Choice of Reference Genes  
Utilising cDNA samples taken from several passages of each cell line (RT4 urothelial 
and VK2 vaginal) in challenged and unchallenged states, twelve house-keeping 
reference genes for use in data normalisation were analysed. Analyses utilised a 
Genorm kit with pre-designed primer mixes and software (PrimerDesign, 
Southampton, UK), which quantifies the stability of each potential gene relative to the 
others. Of the twelve, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and 
ATP5B (ATP synthase) were selected as the two most suitable genes. 
3.6.4. Relative quantification and Data Analysis 
For qPCR analysis, two types of quantification, absolute and relative, are commonly 
used. For absolute quantification a standard with a known copy number is required 
and assays must have highly reproducible amplification efficiencies between plates to 
allow extrapolation of an exact copy number value for a given sample. Relative 
quantification instead assigns relative values to individual samples allowing 
comparison between them. These values typically consist of either crossing point (CP) 
value (the number of cycles required for fluorescence to a reach a pre-determined 
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level that is significantly increased from background) or by using a ‘standard curve’ to 
extrapolate relative expression in arbitrary units (Fleige et al. 2006, Larionov et al. 
2005). For exploratory work such as that carried out in this study, relative 
quantification provides sufficient information to allow comparison of gene expression 
between samples without the need for the more rigorous control of interpolate 
variation required for absolute quantification. Relative quantification was therefore 
chosen as the quantification method in this study. Standard curves were formed using 
serial dilutions of plasmids previously created during validation of the qPCR assays (Bell 
2008, Lanz 2010). 
3.7. Sandwich ELISA 
BD1 and BD2 peptides were measured in clinical and cell culture samples using Human 
BD2 and Human BD1 ELISA Development Kits (Leinco Technologies, St Louis, Missouri, 
USA) as indicated by the manufacturer.  Briefly, 100μL of 0.25 μg/mL defensin capture 
antibody (purified rabbit anti- human BD1 or purified goat anti- human BD2) was 
added to each ELISA Nunc Maxisorp microplate well (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA). The plate was sealed and incubated overnight at room 
temperature to allow coating. After incubation, capture antibody was removed from 
each well and the plate washed four times with 300μL of wash buffer (0.05% Tween-20 
in PBS) per well then blotted on paper towels. Block buffer (1% BSA in PBS) was 
applied for a minimum of two-hours at room temperature. The plate was again 
washed four times with wash buffer. 
Standards, 500 pg/ml to 2 pg/mL, were prepared in diluent (0.05% Tween-20, 0.1% 
BSA in PBS).  Samples and standards were added in duplicate to the coated 
 58 
 
microplates, 100μl to each well, and incubated for two hours at room temperature. 
After incubation, a further four washes were carried out, 100μl of 0.5 μg/mL detection 
antibody (purified biotinylated rabbit anti-human BD1 or purified biotinylated goat anti 
human BD2) was added to each well and left to incubate  for two-hours at room 
temperature. The plates were again washed four times, 100μl of Avidin HRP conjugate 
concentrate (diluted in diluent to a 1:200) was added, and left to incubate for 30 
minutes at room temperature. After washing  a further 4 times, TMB substrate was 
added to start the colour reaction, and the plates were incubated in a dark room for 
five to ten minutes. The colour reaction was stopped by adding 50μl of 1M Sulphuric 
acid as a stop solution. The plates were read at 450nm using a micro plate reader with 
wavelength correction set at 650 nm.  
3.8. Immunohistochemistry 
Tissue specimens were stored embedded in paraffin. Cut sections (4 μm) were 
mounted on SuperFrost Plus microscope slides (VWR International, Lutterworth, UK) 
and allowed to dry at 56°C. The sections were dewaxed in xylene, rehydrated, and 
incubated for 5 minutes in 3% hydrogen peroxide. Blocking was carried out for 5 
minutes with goat serum diluted 1:10 with Tris-buffered saline (TBS).  This was 
followed by overnight incubation with anti-defensin antibody at a dilution of 1:100 at 
4°C (Abcam, Cambridge, UK). Primary antibody binding was detected using Vectastrain 
Elite biotinylated goat anti-mouse antibody (Vectorlabs, Peterborough, UK) for 30-
minutes at room temperature then visualised with NOVA red peroxidase agent 
incubated for 10-minutes  at room temperature. Finally counterstaining was 
performed with haematoxylin for 30-second.  Slides were washed three times with TBS 
at pH 7.6 slides between each step.   
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3.9. Single Nucleotide Polymorphism (SNP) Analysis  
3.9.1. DNA extraction from blood 
The GeneCatcher™ gDNA 3–10 mL Blood Kit (Invitrogen, Paisley, UK) was used for the 
extraction of gDNA (genomic DNA) from frozen whole blood. Purification was achieved 
using a magnetic bead based purification procedure in which cells were lysed using the 
GeneCatcher lysis Buffer and the lysate mixed with GeneCatcher Magnetic Beads for 
subsequent DNA binding to the beads. The DNA-bound magnetic beads were 
separated from the lysate using a magnetic separation rack. Any residual proteins were 
digested with the Protease (25 mg/mL in 50 mM Tris-HCl, pH 8.5, 5 mM CaCl2, 50% 
glycerol). The beads were thoroughly washed with the GeneCatcher buffers to remove 
contaminants. The genomic DNA was recovered in elution Buffer (10 mM Tris-HCl, pH 
8.5). 
3.9.2. PCR Amplification of SNP Region 
PCR amplification of the TLR5392Stop containing region of the TLR5 gene was carried out 
in a similar manner to the end point PCR described in section 3.5.2 but with some 
important differences. Instead of Taq polymerase, a high fidelity, proof reading Kod 
(Thermococcus kodakaraensis) DNA polymerase was used – Novagen Kod Host start 
DNA Polymerase (Merck Millipore, Darmstadt, Germany). This enzyme has a very low 
incidence of mispriming events which is important in SNP analysis.  
PCR reactions were set up using the kit supplied with the enzyme: 2μl Magnesium 
sulphate [25 mM], 5μl of 10 x PCR Buffer, 5μl of dNTPs, 1μl Kod Polymerase to which 
was then added 3μl of Primer pair (1.5μl of forward primer, GGTAGCCTACATTGATTTGC 
[10µM] and 1.5μl reverse primer, GAGAATCTGGAGATGAGGTACCCG [10µM]) and 
100ng of gDNA. The reaction volume was brought up to 50μl with deionised water. 
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The mixed solution was placed in a thermal cycler (Hybaid PCR express, Sprint ™, 
Hybaid, Middlesex, UK) for amplification consisting of a 2-minute denaturation step at 
95°C; 30 cycles of the following sequence: 20 seconds at 95°C, 10 seconds at 60.3°C 
(annealing temperature) and 10 seconds at 70°C, and a final extension step at 70°C for 
10 min.  A final 5-minute cooling step returned the reaction temperature to 4°C. A 
10μL aliquot of the 461 bp product was used for sequencing. 
3.9.3. Sequencing 
Prior to sequencing, all samples had their OD (optical density) values checked with a 
spectrophotometer at 260 nm and 280 nm to ensure that 260/280 ratio was between 
1.7 and 1.9. DNA quality check, clean-up and DNA sequencing were performed by 
Genevision (Newcastle upon Tyne, UK) the latter employing an Applied Biosystems 
3730xl DNA Analyzer. 
3.9.4. Software Analysis 
Sequencing data was provided in AB1 data format and data analysis was carried out on 
the freeware FinchTV trace viewing software (Geospiza, Seattle, USA) – 
http://www.geospiza.com/Products/finchtv.shtml. 
3.10. NF-kB Reporter Gene Transfection 
3.10.1. Stable Transfection 
The stably transfected RT4 NFB reporter cell line was produced by Marcelo Lanz – the 
methodology and validation of this engineered cell line is described in his MRes 
dissertation (Lanz, 2010). Briefly, RT4 cells were seeded onto 30mm diameter, six well 
plates at a density of 105cells/well and cultured in 2ml growth medium at 37ºC and 5% 
CO2 until 90% confluent. Plasmids for pBlue-NFκB and negative control pBlue-TATA 
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promoter were diluted in Optimem medium (GIBCO, Paisley, UK). The cells were 
washed twice in PBS, incubated for four hours with the appropriate plasmid and 
lipofectamine 2000 transfection mixture (Life Sciences, Paisley, UK) and then with 
normal growth medium. After 24 hours, the media was changed to include G418 
Geneticin aminoglycoside antibiotic (Sigma, Dorset, UK) at 0.5mg/ml for positive 
selection. The selection medium was changed every 72-hours and after six weeks, 
stably transfected colonies were trypsinised, pooled and passaged in flasks as for non-
transfected RT4 cells.   
3.10.2. Transient Transfection 
A procedure for developing a transient VK2 E6/E7 NFB reporter cell line was achieved 
using the Attractene fast-forward transfection protocol (Qiagen, Hilden, Germany) by 
Bea Suarez M-Falero during her summer studentship working with our research group. 
Briefly, in this procedure 5×104 VK2 cells were seeded in 100µl of medium in a Costar 
96-well plate (Corning, Tewksbury, Massachusetts, USA). To this medium, 50uL of TE 
buffer containing 0.2 µl of either NFκB-GFP, CMV promoter or negative control TATA 
promoter plasmid (Qiagen, Hilden, Germany) and 0.75µl of Attractene transfection 
reagent were added. Cells were cultured for 24-hours, washed with PBS and medium 
changed to normal medium prior to challenge experiments. To account for 
transfection efficiency, GFP fluorescence results were calculated relative to 
fluorescence by the CMV promoter. 
3.11. Statistical Analyses 
All statistical analyses were carried out using the Prism 5 Software package (GraphPad 
Software Inc, La Jolla, California, USA) 
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Two tailed Student’s t-test was used for all in vitro experiments to compare a given 
challenge against the control. Unless otherwise indicated, analysis was always carried 
out at the time point where maximum difference between challenge and control was 
apparent. Significance level was set at the 5% level. 
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4. Clinical Study Material and Methods 
 
The aim of the clinical study was to compare the types and amounts of antimicrobial 
peptides (AMPs) expressed by urogenital epithelium in women with recurrent cystitis 
against those found in age−matched women without cystitis (controls) and determine 
whether any patient or clinical characteristic influenced AMP response.  It was 
anticipated that the results would indicate the importance of AMP innate immune 
mechanisms in protecting against cystitis and suggest how this might be enhanced 
therapeutically in the future.  
4.1. Study Design 
At the inception of the study it was decided that a group of women with recurrent 
cystitis and a group of age−matched women without a history of symptomatic urinary 
infection would be identified and recruited. Each participant would be requested to 
provide demographic and clinical data together with specimens of blood, urine, vaginal 
washings, bladder epithelium and vaginal epithelium. These samples would then be 
analysed in a blinded manner in the laboratory for mRNA expression and where 
appropriate peptide secretion of relevant AMPs (as directed by in vitro findings). The 
results would be analysed and compared statistically to determine whether there were 
any significant differences between the affected and control groups of subjects. 
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4.1.1. Funding 
The study including salaries, materials and other direct costs were all met by a Clinical 
Research Training Fellowship awarded to the author by the Wellcome Trust 
(WT085040MA) on the 15th of July 2008 (letter in appendix B ). 
4.1.2. Ethical & NHS approval 
The County Durham & Tees Valley 1 Research Ethics Committee reviewed and 
approved the study (09/H0905/15) on the 26th February 2009 (letter in appendix B). 
Newcastle upon Tyne Hospitals NHS trust gave research and development (ID 4841) 
approval on the 15th May 2009 (letter in appendix B).  
The National Institute for Health Research (NIHR) adopted the study (ID 7018) into the 
Clinical Research Network (CRN) Portfolio on the 19th June 2009 (letter in appendix B). 
4.1.3. Development of ‘One-Stop’ Clinic for Women with Recurrent 
UTI 
To enhance the delivery of care for women with recurrent urinary tract infection (rUTI) 
and facilitate the recruitment of patients into this research study and future research 
studies, a new ‘one-stop’ rUTI clinic was developed. The concept was based on a 
similar idea to the prevalent ‘one-stop’ haematuria diagnostic clinic with the purpose 
to ensure that: 
 All patients had their clinical history and symptomatology recorded in a 
uniform and consistent manner. Previously, patients had attended a variety of 
general urology out-patient clinics with varying degrees of details of their 
clinical history recorded. 
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 All patients had the appropriate investigations performed on the same day as 
their clinical consultation. These investigations included haematological (full 
blood count) and biochemical (urea and electrolytes) blood tests, a renal tract 
ultrasound scan and a flexible cystoscopy to inspect the urethra and bladder 
epithelial surface. Previously patients would attend an out-patient consultation 
then subsequently attend on a minimum of three further occasions – one visit 
for an ultrasound scan, one for a flexible cystoscopy and a further consultation 
with all the results. The number of visits was therefore reduced from up to four 
to one.  
 All patients were managed according to an agreed treatment protocol based on 
guidelines from the European Association of Urology (current version of 
guidelines: Grabe et al, 2013) and a simple treatment algorithm adapted from 
the Canadian Urology Association guidelines (current version of guidelines: 
Dason et al, 2011) – Figure 4.1 . 
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Figure 4.1 UTI Treatment Flowchart 
 
Choice of antibiotic was determined by past microbial sensitivity, potential drug 
interaction and patient tolerance and/or preference. Typically however, this would be 
(in order of preference): 
1. Trimethoprim 
2. Nitrofurantoin 
3. Cefalexin ( only if 1 and 2 poorly tolerated or resistance previously 
encountered) 
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All patients were booked for routine out-patient follow-up in 6-months to assess 
benefit. 
4.1.4. Patient Recruitment 
Control and affected women with structurally normal urinary tracts willing to provide 
biopsies, samples of urine and vaginal washings were recruited from the Urology and 
Urogynaecology departments of Newcastle upon Tyne Hospitals NHS Foundation Trust 
from the 14th July 2009 to February 24th 2011. The cohort of women with recurrent 
cystitis (rUTI) and the control group of unaffected women were stratified according to 
menopausal status to create 4−groups:  
 Pre-menopausal controls 
 Pre-menopausal cases (rUTI sufferers) 
 Post-menopausal controls 
 Post-menopausal cases (rUTI sufferers) 
Prior to the start of the study, sample size calculations based on urinary LL−37 urinary 
concentration suggested that 18 women in each group will give an 80% chance of 
detecting a difference at the 5% significance level. A recruitment target of 80 was set 
with an aim to recruit 20 in each group but a minimum target of 18.  
Inclusion and exclusion criteria 
The main inclusion criterion was women who have been referred for assessment of 
recurrent UTI and who had suffered at least 2 episodes per year for 2 years or 3 
episodes in the last year. Controls were recruited from women scheduled to attend the 
'one−stop' clinic for investigation of haematuria or other non-infection related 
urogynaecological assessment. Women with a history of symptomatic urinary infection 
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or who had previous microbiological evidence of urinary infection in the past 2-years 
were not recruited as controls.  
Other inclusion criteria were: 
 Age > 18 years 
 Pre-menopausal or at least 6−months post−menopause. 
 Good general health [American Society of Anaesthesiologists (ASA) grade < 3] 
 Both cases and controls could not have had antibiotic therapy within 4 weeks 
of their recruitment. 
Exclusion criteria were: 
 Structurally abnormal urinary tract. 
 Inability to give informed consent. 
 Severe impairment of renal function [estimated glomerular filtration rate 
(eGFR) < 30 ml/min] because this could lead to reduced renal secretion of 
AMPs and confound results. 
 Inability to complete trial tasks. 
4.2. Clinic protocol 
Patients were informed about the study via an information sheet (see appendix A) sent 
out in the post with their clinic appointment. This sheet described the study and 
explained the need for urine and tissue samples. On the day of the patient’s clinic 
appointment, the research nurse confirmed that the patient had received the 
information pack and discussed the study further, answering any questions. 
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Agreement to take part was then confirmed by written informed consent taken by a 
research nurse before the clinic.  
At the out-patient appointment itself, in the consultation room, relevant demographic 
and clinical data were collected on a pro−forma, and a blood sample was taken (at the 
same time as routine blood tests) by a nurse practitioner. The patient was then 
requested to give a mid-stream sample of urine (MSSU) for culture. An ultrasound scan 
(USS) of the urinary tract was also performed by a sonographer.   
The UTI Symptoms Assessment (UTISA) questionnaire and the EuroQol 5-domain (EQ-
5D) general health status questionnaire were filled in by the patient herself in the 
waiting room before entering the endoscopy room.  
In the endoscopy room, the clinical history was briefly reviewed by the author and a 
clinical examination plus cystoscopy performed. Biopsies from the posterior bladder 
wall were taken during cystoscopy. Following cystoscopy, the first vaginal douche was 
collected. Then a vaginal biopsy from the first 2-3 cm of the vagina was obtained using 
the flexible cystoscope to carry out a vaginoscopy during the vaginal examination. 
After the consultation, each subject was given the necessary instructions and 
containers to collect an overnight urine specimen (approximately 600-800 ml) and a 
further vaginal douche 6-8 weeks later. They were given instructions to collect the 
douche (at approximately the mid−point of their menstrual cycle for pre−menopausal 
women) and bring the specimens to a designated collection point at Freeman Hospital 
or Newcastle University on the morning of the next day.  
Figure 4.2 shows a summary of the steps involved in the protocol. 
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Figure 4.2 Clinical study  summary flowchart 
 
 
  
Summary Flow Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Women with rUTI 
(Cases) 
Women without rUTI 
(Controls) 
UTI Clinic 
Routine clinical work-up:  
 History,  
 Exam,  
 MSSU, routine blood tests 
 USS 
 Cystoscopy (+/- biopsy) 
Haematuria Clinic 
Routine clinical work-up: 
 History,  
 Exam,  
 MSSU, routine blood tests 
 USS 
 Cystoscopy (+/- biopsy) 
  
 
At home 
 Overnight urine collection within 
7-days of clinic appointment 
 Cervico-vaginal washings 
(douche) 6-8 weeks later 
 
 
Within clinic 
 Questionnaire 
 Cystoscopic biopsies 
 Full urine biochemistry 
 Blood sample for research 
 
Step 2 
 
Step 1 
 
Step 3 
 
Within clinic 
 Questionnaire 
 Cystoscopic biopsies 
 Full urine biochemistry 
 Blood sample for research 
At home 
 Overnight urine collection within 
7-days of clinic appointment 
 Cervico-vaginal washings 
(douche) 6-8 weeks later 
Pre-menopausal and post-
menopausal women with rUTI. 
 
(Recruited from female patients 
referred to UTI clinic) 
Pre-menopausal and post-
menopausal women 
 
(Recruited from female patients 
referred to haematuria clinic with 
non-visible haematuria) 
Routine 
care 
Additional 
steps for 
research 
volunteers 
Abbreviations 
MSSU  Mid-stream sample of urine for microbiological culture 
rUTI Recurrent urinary tract infection 
USS Ultrasound scan of urinary tract to look for abnormalities 
UTI Urinary tract infection 
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4.3. Clinical Details 
4.3.1. Medical history 
The following details were recorded for each rUTI subject: 
 Presenting complaint and urinary symptoms 
 Predominant type of UTI symptoms 
 Length of history of proven rUTI 
 How many treatment courses of antibiotic for UTI had been taken in the last 
year? 
 Relationship of UTI to sexual activity 
The following details were recorded for every patient (rUTI and control) 
 Menopausal status (pre-, peri- or post- menopausal) 
 Presence of vaginal symptoms 
 Use of vaginal estrogen (currently or previously) 
 Use of vitamin tablets 
 Use of cranberry products 
 Use of oral contraceptive 
 Use of systemic hormone replacement therapy (HRT) 
 Previous sexually transmitted infection (STI) 
 Previous gynaecological or urological history 
 Number of pregnancies 
 Other medical conditions and treatment 
 Smoking history 
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A clinical examination including vaginal examination was performed for all patients. 
Ultrasound and cystoscopy results were also recorded. 
4.3.2. Symptom and Quality of life score 
All recruits were requested to fill in the UTISA symptoms questionnaire (see appendix 
A). This questionnaire rates severity and bother of the following eight symptoms: 
1. Frequency of urination (going to the toilet very often) 
2. Urge of urination (a strong & uncontrollable urge to pass urine) 
3. Pain or burning when passing urine 
4. Not being able to empty bladder completely/passing only small amounts of 
urine 
5. Feeling feverish or shivers 
6. Pain or uncomfortable pressure in the lower abdomen/pelvic area caused by 
your urinary tract infection 
7. Low back pain caused by your urinary tract infection 
8. Blood in your urine 
For each of the eight symptoms, recruits are asked to give a rating from 0-3 relating to 
the severity of the symptom and the degree of bother it causes thus:  
 Please indicate whether you have had the following symptoms during a urine 
infection by circling one number for each symptom.  
0. Did not have 
1. Mild  
2. Moderate  
3. Severe 
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 If you experienced these symptoms during a urine infection please indicate 
how much they troubled you by circling one number for each symptom. 
0. Not at all 
1. A little 
2. Moderately 
3. A lot 
The recruits were also requested to fill in a general health status questionnaire, the 
EQ-5D (see appendix A). This asked participants to rate the degree of problems they 
have on a 3-point scale (0 – No problems, 1 – Some problems, and 2 – Unable to carry 
out) in relation to the following five domains: 
1. Mobility 
2. Self-care 
3. Usual activities (e.g. work, study, housework, family or leisure activities) 
4. Pain / discomfort 
5. Anxiety / depression 
4.4. Clinical samples 
4.4.1. Blood 
Blood for DNA analysis was collected in a 4 ml  container with EDTA bottle using the 
Vacutainer System (BD Diagnostics, Oxford, UK). Samples were stored temporarily in a 
-20ºC freezer in the hospital prior to long-term storage in the University. 
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4.4.2. Urine 
A conventional mid-stream sample of urine (MSSU) was collected in a 30 ml universal 
container (Sterilin, Newport, UK) in the clinic and sent for culture and sensitivity to the 
hospital microbiology lab. Overnight urine collection was taken in a 1-litre 24-hour 
collection container (Sterilin, Newport, UK) and stored in a -20ºC freezer in the hospital 
prior to transfer for long-term storage in the University. 
4.4.3. Vaginal douche 
Vaginal douches were carried out using the ‘Summer’s Eve Cleansing Douche’ (Fleet 
Laboratories, Lynchburg, Virginia, USA) according to the manufacturer’s instructions 
and collected in a 100ml container (BD Diagnostics, Oxford, UK). 
4.4.4. Biopsies 
Biopsies were taken during cystoscopy using an Olympus rigid or flexible cystoscope 
with a standard 1.8mm flexible biopsy forceps.  
Biopsy samples for RNA extraction were immediately immersed in 1.5ml of RNAlater 
solution (Life Technologies, Paisley, UK) in a 1.7ml centrifuge tube (Eppendorf AG, 
Hamburg, Germany). Tubes were then stored overnight at -4°C to allow the RNA later 
to penetrate through the tissue and then put into the -20ºC freezer in the hospital 
prior to transfer for long-term storage in the University at -80ºC in a secure freezer. 
Samples for immunohistochemistry were fixed in formalin overnight in an appropriate 
container before being transferred to 10ml Falcon tube (BD Diagnostics, Oxford, UK) 
containing 2-3 ml of 70% ethanol for long term storage. 
 75  
 
4.5. Sample Anonymisation and Data Handling 
Demographic, clinical and questionnaire data were transferred from paper collection 
sheets (kept in the participants’ medical record) onto an electronic spread sheet stored 
on the hospital network drive. An anonymised version was created for transfer to the 
university network drive for analysis. Caldicott and Data Protection approval 
(reference 676) was granted on the 9th February 2009 (see appendix B). 
All samples had patient identification labels removed and were pseudo-anonymised 
using a standard coding system with patient identification held at the hospital. 
Samples were transferred on ice to the laboratory for storage and further processing.  
4.6. Statistical Analysis 
All statistical analyses were carried out using the Prism 5 Software package (GraphPad 
Software Inc, La Jolla, California, USA) with significance level set at 5%. 
4.6.1. Demographics and Clinical History 
For demographic details, the age of the control and recurrent UTI groups were 
compared according to menopausal status to make sure that there was no significant 
difference in the age distribution of cases and controls. Given the expected continuous 
parametric distribution, a Student’s t-test carried out between control and rUTI 
subjects.  
For all other comparisons on clinical history criterion between control and recurrent 
UTI groups, Fisher’s exact test was used. 
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4.6.2. SNP Analysis 
The relative prevalence of TLR5392Stop SNP was compared between the control and rUTI 
groups using Fisher’s exact test. 
4.6.3. Symptom and quality of life scores 
Symptom and health status scores between control and rUTI groups were rated on an 
interval ordinal scale and were not necessarily normally distributed therefore 
comparisons were carried out using the non-parametric, Mann-Whitney U test. 
When comparing matched scores relating to severity and bother, a Wicoxon matched 
paired test was used. 
The EQ-5D scores were analysed according to the descriptive system looking at each 
category separately which is regarded as the most appropriate method for clinical 
observational studies (Krabbe and Weijnen, 2003) with a Student’s t-test carried out 
between control and rUTI subjects.  
4.6.4. Biopsy, urine and douche analyses 
For biopsies, urine and douche analyses, two-tailed Student’s t-test (with Welch’s 
correction to correct for unequal variance) was used to compare control and rUTI 
subjects. For analyses of the 12-patients that had infection (which involved comparison 
with the TLR5392Stop subjects), a one-tailed t-test was used as this was a smaller sub-
group and from the in vitro data there was a reasonable expectation that differences in 
expression or secretion would be in the negative direction potentially making a two-
tail test arguably unnecessary. However, for the sake of completion, data is included 
for both types of analyses. 
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For comparison of the first and second douche, a paired two-tail test was used as each 
measurement was taken from the same individual. 
Data for gene mRNA expression is presented on a log scale in line with the nature of 
PCR based amplification. Peptide data is presented on a linear scale as the ELISA 
technique is not based on an amplification protocol. 
The significance level for all these analyses was set at 5%. However, the p-value has 
been also been indicated on each graph to allow the reader to appreciate the exact 
probability that any given result is due to chance. It is my opinion that unlike the in 
vitro data, since clinical data contains great variability, confounding factors plus many 
sub-groups and can therefore never be repeated exactly in the same way, then it is 
beneficial for the reader to have the opportunity to make their own judgement also on 
the significance of any given result. 
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5. In-Vitro Model of Cystitis 
5.1 Introduction 
Innate immunological mechanisms are important in protection of the lower urinary 
tract against bacterial colonisation. These mechanisms are remarkably effective in 
maintaining a bacteria free bladder. When infection does occur it begins with 
increased colonisation of vaginal and periurethral mucosa by bowel and skin 
commensals with subsequent migration up the urethra and attachment to the bladder 
mucosa.  A key component of the innate defence is the synthesis of cationic 
antimicrobial peptides (AMP) following activation of epithelial cell surface Toll-like 
receptors (TLR) by bacterial components. Existing research suggests that epithelial 
production of cationic antimicrobial peptides (AMPs) such as cathelicidins and 
defensins are an important aspect of host anti-microbial defence. Several AMPs have 
been previously identified in the urogenital tract: beta-defensin 1 (BD1), beta-defensin 
2 (BD2), alpha-defensin 5 (HD5) and cathelicidin (LL37). However, the roles and nature 
of these peptides in the lower urogenital tract has not been fully delineated (Zasloff 
2007). 
The aims of the in vitro experiments outlined in this chapter were to: 
 Delineate which AMPs were involved in the normal innate immune response of 
the bladder and vagina against E. coli infection. 
 Determine the nature of the AMP response induced by E. coli in terms of 
contrasting the effects of laboratory E. coli strains and their cell wall 
components alone. 
 Determine what effect if any estrogen had on the AMP response. 
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5.2 Basal expression of AMPs 
To examine the basal expression of AMPs in human urogenital tissues, five samples 
each of kidney, ureter, bladder, and vagina were analysed. The end-point PCR gel 
pictures in Figure 5.1 gives a representative example of each tissue type (Bladder, 
Ureter, Kidney and Vagina) tested. BD1 was expressed in all tissues with level of 
expression highest in the kidney. HD5 show highest levels of expression in the ureter 
with lower levels in the bladder and vagina and only a very faint band for the kidney. 
No BD2 expression was seen. LL37 expression was only seen in the kidney tissue. 18S 
expression was qualitatively similar for all tissues. 
Figure 5.1: End-point PCR of One Representative Sample of each Tissue 
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The RT4 Urothelial cell line was chosen as a suitable in vitro immortalised cell line 
modelling AMP response in the bladder as this had been previously used by both our 
own group and others for examining AMP expression (Townes et al. 2010). Other 
possibilities considered included the alternative immortalised commercially available 
cell lines UROtsa (Rossi et al, 2001) and J82 (Xu et al, 1994) but basal AMP expression 
in RT4 was more consistent with that of normal bladder urothelium. Figure 5.2 shows 
basal expression of AMPs in RT4 cells. 
For the selection of the vaginal cell line, there were fewer options available, with only 
two immortalised cell lines described in the literature, VK2 E6/E7 (Fichorova et al, 
1997) and PK2 E6/E7 (Rajan et al, 2000). Of these, the VK2 cell line was more widely 
used in the literature and this was also the only commercially available vaginal cell line 
(from ATCC), although the PK2 cell line is available from the Antony Schaeffer and 
David Klumpp’s group at North West University, Chicago. Figure 5.3 shows basal 
expression of AMPs in the VK2 cell line. 
Figure 5.2: AMP expression in RT4 Cells 
 
 
 
 
Figure 5.3: AMP Expression in VK2 Cells 
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5.3 Urothelial Cells 
In this series of experiments show the RT4 Urothelial cell line is used as in vitro model 
for analysis of AMP expression following challenge by bacteria and bacterial 
components. 
5.3.1 Bacterial challenge 
5.3.1.1 Live bacteria 
Initial challenges were attempted with 3 strains of uropathogenic E.coli for varying 
duration of exposure:: 15 minutes, 60 minutes 120 minutes. Challenge exposure to live 
bacteria continued beyond this time resulted in visibly significant cell death with up to 
50% of cells having lost adhesion by 4 hours. 
The three E. coli strains used were: 
 NU14 – a laboratory strain of UPEC with multiple virulence factors derived from 
a clinical isolate of E. coli originally obtained from the urine of a patient with 
cystitis.  
 NU14-1 – This is the corresponding non-functioning fimH mutant. 
 NCTC 10418 (ATCC® 10536) – A long established National Collection of Type 
Cultures (NCTC) E.coli strain used for testing antimicrobial and disinfectant 
agents.  
Legend for Figure 5.2 and Figure 5.3 
BD1 =  Beta defensin 1   HD5 =  Human alpha defensin 5 
BD2 =  Beta defensin 2   LL37 =  Cathelicidin 
18S =  PCR Positive Control   M = Base pair size marker  
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For each time point a phosphate buffered saline (PBS) control was also used. 
RT-qPCR analyses were carried out for the four AMPs: BD1, BD2, HD5 and LL37. With 
live bacterial challenges, no significant change in expression was seen at any of the 
time points for HD5 and LL37. LL37 showed no expression and HD5 was only 
detectable at very low levels, and not affected by infection. However, significant, 
reproducible differences were seen at 2-hours for BD1 as shown in Figure 5.4. 
Figure 5.4: BD1 mRNA Expression in RT4 cells challenged with live E. coli for 2-hours 
 
 
 
0
0.5
1
1.5
2
2.5
3
PBS T=0 PBS NU14 NU14-1 NCTC 10418
Ex
p
re
ss
io
n
 (
A
U
) 
Agents Used in Challenge 
BD1 mRNA Expression in RT4 Challenged with  
Live Bacteria at 2 Hrs 
* 
* 
* 
*Significant difference from PBS control (p<0.05 Student’s t-test) 
 
Measurements made by qRT-PCR with GAPDH and ATP5B house-keeping gene and shown relative 
to PBS control at time 0. 
 
AU = Arbitrary Units 
N =9  (3 experiments with 3 replicates) 
Error bar shows standard error of the mean 
 
 83  
 
Figure 5.4 shows a modest but statistically significant increase in the expression of 
BD1.  
The pattern for BD2 expression was however quite different. There was almost no 
constitutive expression and no significant difference was seen following challenge with 
the NU14 strain. However exposure to NCTC 10418, resulted in a significant increase in 
BD2 expression, which was observed at 2-hours after challenge and shown in Figure 
5.5. 
Figure 5.5: BD2 mRNA Expression in RT4 cells challenged with live E. coli for 2-hours 
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5.3.1.2 Dead Bacteria 
Rapid epithelial cell death following cellular damage during challenge with live bacteria 
made it difficult to carry out experiments with reliable and reproducible results beyond 
2-hours. While this gave a very early snap-shot of the AMP response during bacteria 
challenge, it was too early to fully understand how the response develops over an 
extended time period and when peptide secretion begins. Consequently, to model 
over a longer period, a decision was made to use dead bacteria. The rationale for this 
being that cell surface ligands known to be involved in TLR-mediated AMP induction 
(such as LPS and flagellin) would still be present after bacterial killing. 
Bacteria were killed as described in the methods section and challenges carried out for 
24-hours. Although there was the suggestion of an increase in BD1 expression when 
the cells were challenged with both E. coli strains this was not statistically significant 
(see Figure 5.6). In contrast a rapid and significant rise (p<0.05) was detected in the 
expression of BD2 in NCTC 10418 challenged cells as can be seen in Figure 5.7. 
Figure 5.6: BD1 mRNA Expression in RT4 cells challenged with dead E. coli for 24-hours 
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Figure 5.7: BD2 mRNA Expression in RT4 cells challenged with dead E. coli for 24-hours 
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such response to NU14 challenge with levels of BD2 expression comparable to the PBS 
control. 
To confirm that these findings were not purely at a transcription level, further 
experiments were carried to check for peptide synthesis using the BD2 sandwich ELISA 
described in Methods. In Figure 5.8, it can be seen that peptide levels increased from 
baseline following challenge with NCTC 10418. The maximal rate of increase was 
detected between 8 and 16 hours which corresponded to the period following the 
maximal mRNA expression seen at 8 hours. By 24-hours, peptide levels had increased 
from a baseline 52 pg/mL to 158 pg/mL, while the control showed no change. In 
contrast, RT4 challenged with NU14 showed no peptide response and comparable to 
the basal level. 
Figure 5.8: BD2 Peptide Secretion in RT4 cells challenged with dead E. coli for 24-hours 
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To further explore the BD2 epithelial response to E. coli, BD2 peptide secretion was 
analysed following challenge by two other E. coli strains: K12, a commensal 
(asymptomatic bacteriuria) type strain and CFT073, a UPEC strain associated with 
pyelonephritis. The results are shown in Figure 5.9. 
Figure 5.9: BD2 Peptide Secretion in RT4 cells challenged with four different strains of dead 
E. coli for 24-hours 
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A clear range of magnitude in BD2 responses evoked in RT4 by the different strains of 
E. coli was demonstrated with highest response induced by NCTC 10418 and the 
lowest response by NU14.  
*Significant difference from PBS control (p<0.05 Student’s t-test) 
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Error bar shows standard error of the mean 
 
*Significant difference from PBS control (p<0.05 Student’s t-test) 
 
N =6  (3 experiments with 2 replicates) 
Error bar shows standard error of the mean 
 
 88  
 
Concurrently with these experiments, my research colleague, Marcelo Lanz carried out 
bacterial challenge experiments in RT4 using the same protocol as my experiments in 
his MRes but using a luciferase based NFκB reporter gene as the outcome measure. 
Where the previously described experiments had examined the link between cell 
surface receptor activation and expression/secretion of immune effector, his 
experiments examined the intermediary signalling molecule NFκB response using 
luciferase luminescence measurements as illustrated in Figure 5.10. 
Figure 5.10: Induction of NF-κB then AMPs by PAMPs acting through TLRs 
  
Figure 5.11 (reproduced with permission) demonstrates the NFκB response in RT4 cells 
challenged with dead E. coli strains over 8 hours using the NF-κB reporter assay. 
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Figure 5.11: NFκB response by luciferase luminescence in RT4 cells challenged with dead E. 
coli for 8-hours 
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Figure 5.12: E. coli Motility assay over 8-hours (data from Chris Birchall) 
 
 
This motility assay demonstrated bacterial movement using time capture over 8-hours. 
The differences in strain motility reflected by the size of each halo led us to frame the 
hypothesis that BD2 secretion may be activated by the presence of the E. coli cell wall 
component, flagellin. Consequently to investigate this further experiment were carried 
out using specific components of E. coli. 
5.3.2 Bacterial component challenge 
5.3.2.1 LPS 
RT4 cells were challenged with commercially sourced E. coli LPS from both E. coli 
0111:B4 and K12 (Invivogen, California, USA) at varying concentrations up to a 
maximum of 1 mg/ml based on manufacturer’s guidelines and published literature 
(Song et al, 2007). LPS is a recognised TLR4 agonist. A small but significant increase was 
seen in BD1 expression, which increased slowly over the 24-hour challenge period. The 
effect was best demonstrated with the 0.5 mg/mL LPS challenge and shown for E. coli 
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0111:B4 in Figure 5.13. The pattern seen broadly conformed with that seen with the 
dead bacterial challenge with a slow rise in BD1 expression in challenged cells, levelling 
out by 24-hours to approximately 2.4 AU vs 1.1 AU for unchallenged cells. 
Figure 5.13: BD1 mRNA Expression in RT4 cells challenged with E. coli 0111:B4 LPS for 
24-hours 
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Figure 5.14: BD1 Peptide Secretion in RT4 cells challenged with E. coli LPS for 2-hours 
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Figure 5.15: BD1 Peptide Secretion in RT4 cells challenged with E. coli LPS for 72-hours 
 
 
In contrast to BD1, no induction of BD2 mRNA was seen, as demonstrated in Figure 
5.16. These data suggested that LPS is not involved in the induction of BD2 in RT4 cells. 
Figure 5.16: BD2 mRNA Expression in RT4 cells challenged with E. coli LPS for 24-hours 
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5.3.2.2 Peptidoglycan 
RT4 was also challenged with commercially sourced peptidoglycan, a TLR2 agonist, 
from both E. coli 0111:B4 and K12 (Invivogen, California, USA). No significant change in 
BD1 or BD2 was seen between challenged RT4 cells and controls at a range of 
concentrations up to 48 hours – data not shown. 
5.3.2.3 Flagellin 
For challenges using flagellin, commercially sourced S. typhimurium flagellin 
(Invivogen, California, USA) and E. coli NCTC 10418 flagellin produced in our own 
laboratory (by Marcelo Lanz) were used. The results for 250 ng challenge are shown in 
Figure 5.17. 
Measurements made by qRT-PCR with GAPDH and ATP5B house-keeping gene and shown relative 
to PBS control at time 0. 
 
AU = Arbitrary Units 
N =9  (3 experiments with 3 replicates) 
Error bar shows standard error of the mean 
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Figure 5.17: BD2 mRNA Expression in RT4 cells challenged with E. coli & S. typhimurium 
flagellin for 24-hours 
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that two different flagellin preparations evoked a BD2 response, coupled with the 
observations on motility provides strong evidence that TLR-5 is the PAMP linked to the 
induction of BD2. To delineate the response further, sandwich ELISA was used to 
examine BD2 peptide concentrations within the medium of the RT4 cells and the 
results are shown in Figure 5.18. 
Figure 5.18: BD2 Peptide Secretion in RT4 cells challenged with E. coli Flagellin for 48-hours 
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pattern but at lower BD2 concentrations was observed using Salmonella typhimuirum 
flagellin, where BD2 values of approximately 120 pg/mL were measured at 48 hours. 
To validate these data further, additional experiments were carried out using 
differentated norman human urothelium (NHU) cells grown from primary tissue taken 
during urological surgery. These experiments were carried out in conjunction with Dr 
Claire Varley and Professor Jenny Southgate, York University. The NHU cells  were 
established in York as described in methods, challenged with flagellin and the peptide 
levels in the medium assayed using the same ELISA technique as for the RT4 medium. 
The results from these experiments are shown in Figure 5.19. 
Figure 5.19: BD2 Peptide Secretion in NHU cells challenged with E. coli & S. typhimurium 
Flagellin for 24-hours 
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E. coli and Salmonella typhimuirum flagellin. Although the absolute concentrations 
measured were different reflecting the different nature of the two cell models, the 
trend and relative changes were similar.  
5.3.2.4 Reporter Assay Response to Flagellin 
In parallel to the experiments measuring AMP effector output following PAMP 
treatments Bea Suarez-Falero (an undergraduate project student working under my 
supervision) examined the NFκB response to the same PAMPs i.e. LPS, Peptidoglycan 
and Flagellin using an NF-κB luciferase reporter luminescence assay. The data from 
these experiments is shown in Figure 5.20: 
Figure 5.20: NFκB response by luciferase luminescence in RT4 cells challenged with E. coli 
PAMPs for 4-hours  
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The data from the NFκB luciferase reporter assay supported the findings of increased 
BD2 expression and secretion following challenge by flagellin. Increased NFκB 
activation was seen following challenge with E.coli flagellin while no significant 
increase was detected using either TLR-4 or TLR-2 activators. Coupling these data, with 
the mRNA expression and peptide secretion data discussed earlier, and the knowledge 
that flagellin works through TLR5, a signalling pathway similar to that presented in 
Figure 5.21 can be suggested. 
Figure 5.21: Flagellin Induced Secretion of Beta Defensin 2 (BD2) 
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be inhibited by blocking of the TLR5 receptor.. To investigate this further, the 
expression of the TLR5 receptor was demonstrated in RT4 cells using endpoint PCR 
(see Figure 5.22) and DNA sequencing. 
Figure 5.22: PCR Confirmation of TLR5 Expression in RT4 cells 
 
Having confirmed expression, TLR5 was then blocked in the RT4 cell model with an 
anti-TLR5 antibody (Invivogen, California, USA) using varying dilutions to establish a 
concentration-dependent response. The results are shown in Figure 5.23. 
Figure 5.23: Anti-TLR5 Antibody inhibition of BD2 peptide secretion in RT4 challenged with 
flagellin 
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These data showed that with increasing concentrations of antibody, there was a 
progressive reduction in the assayed concentration of BD2 peptide with control BD2 
levels measured at an antibody concentration of 5.0 μg/mL. This provided further 
evidence to suggest that flagellin, acting through TLR5 was inducing secretion of BD2 
peptide. To confirm that a similar effect was seen in the signalling pathway, the same 
concentration of anti-TLR5 antibody was used in the luciferase NFκB reporter assay by 
Bea Suarez Falero and similar results found (data not shown). 
5.3.2.6 Effect of Estrogen on RT4 Cells 
As discussed previously, the risk of UTI is higher for women with relative estrogen 
deficiency and the epithelium of at least some parts of the bladder are thought to 
express estrogen receptors (Wolf et al, 1991). Furthermore, from bioinformatics 
analysis using PROMO (Messeguer et al, 2002), the BD2 gene is predicted to have 
several alpha estrogen (ER-alpha) binding sites within the promoter region as shown in 
Figure 5.24. 
N =6  (3 experiments with 2 replicates) 
Error bar shows standard error of the mean 
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Figure 5.24: Beta Defensin 2 Gene Promoter Region Transcription Binding Sites 
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Figure 5.25: Estrogen receptor expression in RT4 cells 
 
It can be seen that both receptors are expressed in RT4, however, qualitatively ER 
band seems fainter than ER.  
Despite the presence of both estrogen receptors, when RT4 cells were grown in 
varying concentrations of estrogen ranging from 2nM to 16nM, no significant 
difference was seen in either basal BD2 AMP gene expression or basal expression of 
any of the other AMPs studied (BD1, HD5 and LL37) – data not shown. 
5.3.3 Antimicrobial Effects 
Having established that flagellin from E. coli elicits a significant AMP response in RT4 
cells through TLR-5 activation and NFκB activation resulting in BD2 mRNA expression 
and peptide secretion, the potency of BD2 as an antimicrobial against E. coli was 
investigated. The importance of BD2 antimicrobial activity against gram negative 
bacteria on skin is well recognised (Schröder and Harder, 1999), however, the activity 
in urothelium has not been described previously.  
The antimicrobial activity was investigated in two ways. Firstly, as shown in Figure 
5.26, medium from RT4 challenged with PBS and flagellin was used in a 1-hour E. coli 
NU14 time-kill antimicrobial assay. 
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Figure 5.26: Antimicrobial activity of RT4 medium following challenge with flagellin 
 
 
The results from this experiment showed that the antimicrobial activity of the medium 
bathing the flagellin challenged cells was increased. Indeed the medium bathing the 
unchallenged cells showed only a small degree of antibacterial activity with NU14 
survival at approximately 86%; in contrast there was considerably enhanced killing 
activity in the medium from the flagellin challenged cells with bacterial survival 
reduced  to 38%. It is likely that this antimicrobial activity was due to a number of 
factors in the medium in addition to BD2, and probably explains why the medium of 
the unchallenged cells showed antimicrobial activity. It is also worth noting that this 
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difference could only be demonstrated in a short time-kill assay as in a longer assay, 
any antimicrobial activity was depleted as there is no mechanism to replenish the 
antimicrobial agents. 
To determine what contribution BD2 was making to the total antimicrobial activity, a 
further time-kill assay was performed using fresh media with synthetic BD2 added at a 
concentration similar to that measured previously via ELISA in the challenge assays 
(see Figure 5.18) i.e. 200 pg/mL. The results of this time-kill assay, shown in Figure 5.27 
demonstrated reduced bacterial survival in BD2 supplemented media to a mean ± SEM 
of 52 ± 15% compared to 100 ± 3% in the non-supplemented control (P< 0.05). 
Figure 5.27: Antimicrobial activity of synthetic BD2 at concentration comparable to challenge 
with flagellin 
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5.3.4 Summary of RT4 Data 
To summarise, a number of important positive and negative findings have been made 
in the RT4 experiments outlined: 
 Of the AMPs examined, the main ones expressed in vitro were BD1 and BD2. 
BD1 was mainly expressed constitutively with a small inducible component in 
response to E. coli LPS challenge. BD2 was not expressed constitutively but RT4 
cells showed a rapid and significant rise in BD2 expression when challenged 
with dead samples of motile E. coli and flagellin. LL37 and HD5 showed very low 
levels of expression and no induction on bacterial challenge. 
 Of the PAMPs examined, the response to flagellin was the most marked 
stimulator of the AMP effector response and the increase in BD2 expression 
seen at the mRNA level was also found at peptide level by ELISA for both motile 
E. coli and flagellin. The BD2 response to flagellin was inhibited by blocking 
TLR5, the archetypal receptor for flagellin.  
 Challenge with flagellin also resulted in induction of NFκB, which could be 
inhibited by anti-TLR5 antibody suggesting that the intracellular pathway from 
TLR5 to BD2 secretion is NFκB mediated. 
  Estrogen had no effect on AMP responses in RT4 cells despite the presence of 
estrogen receptors. 
 The increased levels of BD2 secreted during flagellin a challenge considerably 
enhanced antimicrobial activity with bacterial survival reduced to a mean of 
52% compared to control. 
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5.4 Vaginal Cells 
The vagina provides a primary site of defence against bacterial ascent into the female 
urinary tract. As described in the introductory chapters, preliminary vaginal 
colonisation by potential E. coli pathogens has been hypothesised to occur prior to 
symptomatic UTI. 
5.4.1 Bacterial challenge 
5.4.1.1 Live bacteria 
Live bacterial challenges to vaginal cells showed no significant change in AMP 
expression by 2 hours. At later time points more than 50% of cells lost their adhesion 
to the well indicating significant cell damage. As a consequence, a decision was made 
to concentrate analyses on the responses elicited by dead bacteria similar to RT4 
urothelial experiments. 
5.4.1.2 Dead Bacteria 
Bacteria were killed as described in methods and challenges were carried out for up to 
24 hours. Very low basal levels of expression were seen for both HD5 and LL37 with no 
induction on challenging with dead bacteria. Higher basal levels of expression were 
seen with BD1 but no change was seen on challenge (Figure 5.28) 
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Figure 5.28: BD1 mRNA Expression in RT4 cells challenged with dead E. coli for 24-hours 
 
 
In contrast, a significant and rapid rise was seen in the expression of BD2 following 
challenge by NCTC 10418 (Figure 5.29). BD2 was expressed at very low levels although 
detectable and bacterial challenge leads to a rapid rise. Of note, the maximum rise in 
expression occurred at a similar time, 8-hours, to that seen in RT4, but the gradient of 
increase was lower (see Figure 5.7) although the increase remained significantly higher 
(P<0.05) than control. Furthermore, BD2 expression returned to baseline more rapidly 
in VK2 cells and was equivalent to baseline at 24 hours. This suggests a more 
‘measured’ response to NCTC 10418 in the vaginal cells with a less elevated response 
and more rapid reduction than was seen in the urothelium. 
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Figure 5.29: BD2 mRNA Expression in VK2 cells challenged with dead E. coli for 24-hours 
 
 
The pattern seen in peptide secretion confirmed that the rise in BD2 expression was 
translated to protein with BD2 significantly higher in the 24 hour challenged cells than 
the PBS control (Figure 5.30 below). Interestingly, despite little basal BD2 mRNA 
expression, high levels of BD2 peptide were detected in unchallenged cells indicating 
considerably higher basal secretion. On challenge, a gradual rise was observed with an 
absolute increase of 48 pg/mL (239 pg/mL to 287 pg/mL) compared to the rise of 106 
pg/mL that was seen in RT4 (Figure 5.8).  
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Figure 5.30: BD2 Peptide Secretion in VK2 cells challenged with dead E. coli for 24-hours 
 
 
As with RT4, it was possible to compare the BD2 peptide response seen with other 
uropathogenic E. coli strains of varying motility (Figure 5.31). As with RT4, there 
appeared to be a relationship with motility i.e. NCTC 10418, the most motile, eliciting 
the highest response and the non-flagellated and least motile NU14 causing little if any 
BD2 secretory response. 
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Figure 5.31: BD2 Peptide Secretion in RT4 cells challenged with four different strains of dead 
E. coli for 24-hours 
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Having examined the effect of dead bacteria and seen similar trends to that of RT4, it 
was decided to examine the role of the individual bacterial components and this is 
outlined in the next section. 
5.4.2 Bacterial component challenge 
5.4.2.1 LPS  
Similar to RT4, VK2 cells were challenged with commercially sourced E. coli LPS from 
both E. coli 0111:B4 and K12 (Invivogen, California, USA) at varying concentrations up 
to a maximum of 1mg/ml. No AMP expression response was seen with any of the 
challenges and representative graphs for BD1 and BD2 are shown Figure 5.32 and 
Figure 5.33 respectively.  
*Significant difference from PBS control (p<0.05 Student’s t-test) 
 
N =6  (3 experiments with 2 replicates) 
Error bar shows standard error of the mean 
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Figure 5.32: BD1 mRNA Expression in VK2 cells challenged with E. coli LPS for 24-hours 
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Figure 5.33: BD2 mRNA Expression in VK2 cells challenged with E. coli LPS for 24-hours 
 
 
It can be seen that while both BD1 and BD2 were constitutively expressed (BD2 at only 
very low levels), there was no significant change following LPS  challenge. 
5.4.2.2 Peptidoglycan 
Challenges using peptidoglycan were not specifically carried out during the work for 
this thesis. However, in parallel to this work, my colleague Dr Claire Townes did carry 
out challenges using peptidoglycan did not identify  any significant changes amongst 
the four AMPs (data not shown). 
5.4.2.3 Flagellin  
Given the apparent relationship between motility of the E. coli strains and BD2 
expression, and secretion  in VK2 (and previously in RT4), the effect of E. coli flagellin 
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was also investigated. As reported with RT4 cells, flagellin resulted in increased BD2 
expression in VK2 cells with significantly higher levels by 8 hours (Figure 5.34). 
However, as was observed with the E. coli challenges, the absolute values for increased 
expression were not as high as with RT4 urothelial cells and the decline was again 
much faster reaching baseline at 24 hours. 
Figure 5.34: BD2 mRNA Expression in VK2 cells challenged with E. coli flagellin for 24-hours 
 
 
Peptide analysis via ELISA confirmed a significant rise in BD2 secretion (Figure 5.35). 
The rise was similar to that seen with dead NCTC 10418 (the most motile of the E. coli 
strains). 
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Figure 5.35: BD2 Peptide Secretion in VK2 cells challenged with E. coli Flagellin for 24-hours 
 
 
5.4.2.4 Reporter Assay Response to Flagellin 
In parallel to the measurement of downstream effector molecules, Bea Suarez-Falero 
(the undergraduate student) also examined the response of VK2 cells to E. coli flagellin 
and LPS using a NFκB GFP fluorescence assay (Figure 5.36). Similar to the luciferase 
reporter assay used for RT4 cells, this again demonstrated a rise in NFκB in response to 
the flagellin challenge, again suggesting that the BD2 response seen with flagellin was 
likely to be functioning through the NFκB pathway. 
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Figure 5.36: NFκB response by GFP fluorescence in VK2 cells challenged with E. coli PAMPs 
for 24-hours 
 
 
 
5.4.2.5 Validation of Flagellin Induced BD2 Secretion with Anti-TLR 5 
Antibody in VK2 E6/E7 Cells 
Having found strong evidence that flagellin also induces BD2 expression and secretion 
in VK2 cells, and given that flagellin works through the TLR5 receptor, it was expected 
this response would be inhibited by the use of TLR5 blocking antibody, as was seen 
with RT4. To provide further validation, expression of TLR5 was checked using end-
point PCR (Figure 5.37), and increasing concentrations of TLR5 antibody were used to 
inhibit BD2 secretion in response to flagellin (Figure 5.38). 
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Figure 5.37: PCR Confirmation of TLR5 Expression in VK2 cells 
 
Figure 5.38: Anti-TLR5 Antibody inhibition of BD2 peptide secretion in VK2 challenged with 
Flagellin 
 
 
Figure 5.38 demonstrated that, comparable to what was seen RT4, increasing 
concentration of anti-TLR5 antibody inhibited the BD2 response induced by flagellin. 
Although with VK2, the effect was seen even with more dilute antibody.  A similar 
inhibitory effect with the use of 5μg of anti-TLR5 antibody was seen by my colleague 
Marcelo Lanz using a NFκB GFP fluorescence assay (data not shown).  
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5.4.2.6 Effect of Estrogen on VK2 E6/E7 cells 
It is well recognised that tissues of the genital tract are responsive to estrogen. As 
discussed in the introduction, there are clearly differences in vaginal tissue estrogen 
levels dependent on the pre- or post-menopausal status of women, and application of 
topical vaginal estrogen is recognised as a preventative treatment option for recurrent 
urinary tract infection in women. It has also been reported by Charles Wira’s group 
(Pioli et al, 2006; Fahey et al, 2008) in New Hampshire, USA that estrogen up-regulated 
BD2 expression in uterine cells in culture. Although experiments in RT4 with estrogen 
(section 5.3.2.6) did not yieldepositive results, given that both the uterus and the 
vagina have a shared embryological origin from the Müllerian duct, it was considered 
reasonable to consider that  that estrogen may have a similar effect on vaginal cells. To 
explore this further, VK2 cells were cultured in varying concentrations of estrogen as a 
pre-treatment and then challenged with LPS. Although, as described earlier (section 
5.4.2.1) LPS challenge alone did not result in any increased BD2 expression, the 
adjuvant addition of estrogen changed the response substantially.  Figure 5.39 
illustrates the effect of 4 nM estrogen on the response of VK2 to E. coli LPS and Figure 
5.40 demonstrates the effect of varying concentrations of estrogen in a 24-hour 
challenge. 
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Figure 5.39:  BD2 mRNA Expression in VK2 cells grown with or without 4nM Estrogen and 
challenged with E. coli LPS 
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Figure 5.40: BD2 mRNA Expression in VK2 cells grown in varying concentrations of Estrogen 
and challenged with E. coli LPS 
 
 
It can be seen from Figure 5.39 that a physiological concentration of estrogen has a 
significant potentiating effect on BD2 expression. VK2 cells, which are otherwise 
largely unresponsive to LPS stimulation showed increased BD2 expression when grown 
in estrogen-supplemented medium and then challenged by LPS. By 24 hours the 
increase  in BD2 response to LPS by VK2 in the presence of supplementary estrogen 
was significant (p<0.05). Furthermore, this effect of estrogen appeared to be dose-
dependent reaching maximal effect at 4 nM (Figure 5.40). It is important to note that 
there did appear to be some positive effect on BD2 expression with estrogen alone i.e. 
without any immune stimulation, but this was not statistically significant. No effect 
was seen for BD1, HD5 or LL37 expression. 
Measurements made by qRT-PCR with GAPDH house-keeping gene and shown relative to PBS 
control at time 0. 
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Examining induced peptide secretion following estrogen supplementation, a similar 
overall pattern was observed when assaying for BD2 via ELISA as shown in Figure 5.41. 
There was a significant increase in peptide secretion by 24-hours when compared to 
the control with no increase in peptide secretion detected in either unchallenged cells 
grown in estrogen, or those challenged with LPS but without estrogen 
supplementation. There was a slight upward trend under all the experimental 
conditions most likely due to the accumulation of basally secreted peptide over time. 
Figure 5.41: BD2 Peptide Secretion in VK2 cells grown with or without 4nM Estrogen and 
challenged with E. coli LPS 
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responses reaching approximately 700 pg/mL by 24 hours when VK2 cells were grown 
in estrogen and challenged with flagellin (Figure 5.42). It also demonstrated that even 
where a response is initiated by the PAMP itself as is the case with flagellin, there is 
still potential for further amplification of the response when estrogen is present i.e. in 
VK2 cells flagellin alone does not evoke the maximal BD2 epithelial secretory response. 
 
Figure 5.42: BD2 Peptide Secretion in VK2 cells grown with or without 4nM Estrogen and 
challenged with E. coli Flagellin 
 
 
5.4.3 Summary of VK2 E6/E7 Data 
To summarise, the key finding from the VK2 E6/E7 experiments are as follows: 
 Similar to RT4, the main detectable AMPs in VK2 are BD1 and BD2. BD1 mRNA 
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lowly expressed at baseline but is highly up-regulated in the presence of heat-
killed motile strains of E.coli and flagellin. HD5 and LL37 were not expressed. 
 Challenge with E. coli flagellin evokes a strong BD2 response which is 
detectable at peptide level via ELISA. However, even in the absence of 
challenge, VK2 cells secrete significant amounts of BD2 peptide. The rise seen 
during challenge by flagellin can be inhibited by treatment with TLR5 antibody. 
 Similar to RT4, the response seen with flagellin appears to be transduced 
through the intermediary molecule, NFκB as is demonstrated by the NFκB GFP 
fluorescence assay which shows up-regulation in the presence of flagellin. 
 Unlike RT4, VK2 shows a significantly enhanced innate immune response after 
estrogen treatment. This response is particularly profound as it works by 
potentiating the response to PAMPs. Estrogen alone does not cause any 
significant increase in BD2 expression or secretion, however, when cells are 
challenged with LPS, a response is seen despite the fact that LPS alone also 
results in no response. Stimulation with flagellin in the presence of 
physiological estrogen concentration results in a higher level of BD2 expression 
and secretion. 
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6. Clinical Sample Analysis 
6.1 Introduction 
A key element of this research study was the analysis of samples from patients with 
the target condition; recurrent UTI, and from age-matched female controls. As 
discussed in chapter 4, the aim of the clinical study was to compare the AMP profiles 
of women with recurrent UTI with those without. Given the evidence that AMPs are 
influenced by hormonal changes and that recurrent cystitis tends to present most 
commonly in two periods of a women’s life; during the third and fourth decade, or 
post-menopausal, controls and cases were also categorised into sub-groups according 
to menopausal status. To allow for single nucleotide polymorphism (SNP) analysis, 
blood samples were also collected. 
6.2 Clinical data 
For all subjects a standard clinical history was taken and information recorded on the 
clinical data sheet found in appendix A. All subjects were also asked to fill in symptom 
severity and quality of life questionnaires (sample questionnaires available in appendix 
A). The key data is outlined below. 
6.2.1 Demographics and Clinical History 
Table 6.1 shows the key demographic and clinical history for both the control and rUTI 
subjects.  
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Table 6.1 Summary table of demographics and clinical history  
 Control rUTI 
Pre-menopause Post-menopause Pre-menopause Post-menopause 
Number  
(infection at time of biopsy) 
19 
(0) 
19 
(0) 
31 
(5) 
29 
(7) 
Median Age  
(Range) 
35 a 
(18-46) 
58 b 
(42-76) 
31 a 
(18-41) 
60 b 
(40-75) 
Taking vaginal estrogen 1 (5%) 2 (11%) 0 (0%) 0 (0%) 
Taking vitamins 4 (21%) 3 (16%) 4 (13%) 4 (14%) 
Taking cranberry-juice 5 (26%) 5 (26%) 16 (52%) 15 (52%) 
On oral contraception 6 (32%) 0 (0%) 4 (13%) 0 (0%) 
Had HRT 0 (0%) 4 (21%) 0 (0%) 9 (31%) 
Previous STI 1 (5%) 0 (0%) 3 (10%) 0 (0%) 
Previous urological  or 
gynaecological surgery 
10 (53%) 10 (53%) 16 (52%) 17 (59%) 
Median no of 
pregnancies 
(Range) 
1 
(0-6) 
2 
(0-5) 
1 
(0-3) 
2 
(0-6) 
Smoker 5 (26%) 5 (26%) 9 (29%) 16 (55%) 
a No significant difference between control and rUTI pre-menopausal subjects (t-test) 
b No significant difference between control and rUTI post-menopausal subjects (t-test) 
 
 
6.2.2 TLR5392Stop SNP Status 
As described in methods, blood samples collected from recruits to the study had a 
specific sequence (461bp) of the TLR5 gene amplified by PCR and sequenced by Sanger 
sequencing at Genevision, Newcastle upon Tyne, UK. The sequence was analysed for 
the TLR5392Stop Single Nucleotide Polymorphism (SNP) using the Finch TV software 
(Geospiza, Seattle, USA). Figure 6.1 illustrates the sequence found in a normal subject 
and that from one of the subjects found to have the heterozygous TLR5392Stop SNP. In 
the SNP sequence the two different base pairs can be seen with the normal blue 
cytosine (C) base at half height and a thymine base in the other allele resulting in 
amino acid-coding triplet 392 changing form CGA (Arginine) to TGA (stop codon). 
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Figure 6.1: TLR5 Sequence (A = Normal, B = TLR5392Stop SNP) 
 
In total nine out the 98 subjects recruited were found to have the TLR5392Stop SNP 
giving a frequency of 9.2%. However, all nine subjects carrying the SNP were from the 
recurrent UTI group (60-patients) giving a prevalence within that group of 15% versus 
0% in the control group.  
Of the nine subjects with the TLR5392Stop SNP, four were pre-menopausal and five post-
menopausal. Three had infection at the time of biopsy but six did not. Five were 
treated with estrogen, three with long term antibiotic prophylaxis; one was satisfied 
with general UTI avoidance advice following clinic attendance. 
6.2.3 Symptoms score 
All recruits were requested to fill in the UTISA questionnaire to gauge their symptoms 
at the time of enrolment into the study (see appendix A). The UTISA questionnaire 
tests seven domains; a shortened clinician description of each domain is indicated in 
[brackets]: 
 Frequency of urination (going to the toilet very often) [Frequency] 
B 
A 
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 Urgency of urination (a strong & uncontrollable urge to pass urine) [Urgency] 
 Pain or burning when passing urine [Dysuria] 
 Not being able to empty your bladder completely/passing only small amounts 
of urine [Poor Emptying] 
 A high temperature or shivers [High temp] 
 Pain or uncomfortable pressure in the lower abdomen/pelvic area caused by 
your urinary tract infection [Lower abdo pain] 
 Low back pain caused by your urinary tract infection [Lower back pain] 
 Blood in your urine [Blood in urine] 
Each symptom was scored on a scale of 0-3 for the severity of the symptom i.e.  0 = Did 
not have, 1 = Mild, 2 = Moderate, 3 = Severe. Each symptom was also scored on a scale 
of 0-3 for the amount of bother it caused i.e.  0 = Not at all, 1 = A little, 2 = Moderate, 3 
= A lot. 
Figure 6.2 and Figure 6.3 show the mean score comparison data for severity and 
bother of symptoms in the pre-menopausal group: 
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Figure 6.2: UTISA – Severity of Symptoms in Pre-menopausal control and rUTI subjects 
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Figure 6.3: UTISA – Bother from Symptoms in Pre-menopausal control and rUTI subjects 
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There is a marked, statistically significant difference in both severity of symptoms and 
bother between the control and rUTI groups (p<0.05, Mann Whitney non-parametric 
test) on all domains except lower back pain severity and bother. 
A similar pattern was observed in relation to the post-menopausal patients (Figure 6.4 
and Figure 6.5): 
Figure 6.4: UTISA – Severity of Symptoms in Post-menopausal control and rUTI subjects 
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Figure 6.5: UTISA – Bother from Symptoms in Post-menopausal control and rUTI subjects 
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Again a marked difference in severity of symptoms and bother was observed. 
However, for the post-menopausal group, the difference reached statistical 
significance (p<0.05, Mann Whitney non-parametric test) on all domains except the 
severity and bother of poor bladder emptying. 
When comparing the seeming discrepancy between severity of symptoms vs bother, 
the only domains in which there was a significant difference in the scoring was dysuria 
for pre-menopausal subjects and urgency plus blood in urine for post-menopausal 
subjects (p<0.05, Wilcoxon matched paired non-parametric test). For dysuria in pre-
menopausal patients, the mean bother score was higher than the severity score. For 
urgency and blood in urine in post-menopausal subjects, the mean bother score was 
lower than the severity score. 
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6.2.4 Health State scores 
The EQ-5D quality of life questionnaire (see appendix A) is a well-validated generic 
health status questionnaire that compares health state across five domains: 
 Mobility 
 Self-Care 
 Usual Activities (e.g. work, study, housework, family or leisure activities) 
 Pain/Discomfort 
 Anxiety/Depression 
Each domain has three categories scored from 1-3 depending on the current state of 
health. Figure 6.6 and Figure 6.7 show the average scores in each domain for the pre-
menopausal and post-menopausal subjects respectively. 
 
Figure 6.6: EQ-5D score in Pre-menopausal control and rUTI subjects 
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Figure 6.7: EQ-5D score in Post-menopausal control and rUTI subjects 
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There was no significant difference between controls and rUTI in either the pre- or 
post-menopausal cohorts in any of the health domains tested by EQ-5D. 
6.2.5 Summary of Clinical data 
In summary, the following findings were noted in relation to the clinical data collected: 
 A total of 98 subjects were recruited into the study of which 12 had infection at 
the time of their biopsy and therefore were noted as requiring separate sub-
group analysis. Pre-investigation power calculations had suggested that a 
minimum of 18-patients would be required in each cohort, this was therefore 
exceeded. 
 There was no significant difference in age between the control and rUTI 
subjects recruited to the study. 
 Nine patients were found to have TLR5392Stop SNP, all had recurrent UTI (four 
were  pre-menopausal and five  post-menopausal). 
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 Pre-menopausal rUTI patients were found to have significantly greater severity 
and bother symptoms compared to controls on the UTISA questionnaire in 
terms of frequency, urgency, dysuria, poor bladder emptying, raised 
temperature, lower abdominal pain and blood in the urine. Only lower back 
pain showed no significant difference. The bother score for dysuria was 
significantly greater than the severity in this sub-group. 
 Post-menopausal rUTI patients were found to have significantly greater severity 
and bother symptoms compared to controls on the UTISA questionnaire in 
terms of frequency, urgency, dysuria, poor bladder emptying, raised 
temperature, lower abdominal pain, lower back pain and blood in the urine. 
Only poor bladder emptying showed no significant difference. The bother score 
for urgency and blood in urine was significantly less than the severity in this 
sub-group. 
 No significant difference was found between control and rUTI subject in any of 
the EQ-5D health state domains. 
6.3 Bladder Samples 
A crucial part of the clinical study protocol was that patients with recurrent UTI were 
preferably recruited at a time when they didn’t have infection. Although some subjects 
were ultimately recruited at the time of infection (as it wasn’t known that they had 
infection at the time of recruitment), these patients are analysed separately later and 
have serendipitously given interesting sub-group data.  In vitro studies described in the 
previous chapter showed that in the absence of infection, only BD1 is expressed 
constitutively; BD2 is primarily expressed in response to infection. No urothelial 
 134  
 
expression of LL37 was found in bladder urothelium and HD5 could only be detected at 
very low expression levels. So to examine differences in basal expression in the clinical 
samples, the analysis was focussed initially on BD1. 
6.3.1 Recurrent UTI vs Controls  
To investigate whether there was any ‘basal’ difference in BD1 AMP expression 
between control and rUTI subjects, bladder epithelial biopsies were assayed using qRT-
PCR, and the results are shown in Figure 6.8. 
Figure 6.8: BD1 Gene mRNA expression in bladder biopsies from control and rUTI patients 
with no infection at the time of biopsy 
 
The data presented in Figure 8 shows that there is no statistically significant difference 
between the two groups in terms of BD1 expression with a comparable mean and 
spread of expression between the two populations. From the outset, the study design 
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had sought to separate pre- and post-menopausal women into similar-sized sub-
groups due to the potential differences in the nature of rUTI within these two groups. 
It is therefore possible to look at these groups separately as shown in Figure 6.9.  
Figure 6.9: BD1 Gene mRNA expression in bladder biopsies from pre-Menopausal & post-
Menopausal control and rUTI patients with no infection at the time of biopsy 
 
Even when the different sub-groups were examined separately, there was no 
difference in BD1 expression with similar levels detected across all four sub-groups. 
From the in vitro work, it was apparent that BD2 expression in response to flagellin 
was a particularly important component of the early AMP response. However, as an 
BD1 Gene Expression in Bladder Biopsies
P
re
-M
 C
on
tr
ol
P
re
-M
 r
U
TI
P
os
t-
M
 C
on
tr
ol
P
os
t-
M
 r
U
TI
0.01
0.1
1
10
100
1000
Patient Type
R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
 (
A
U
)
Measurements made by qRT-PCR with GAPDH and ATP5B house-keeping gene. 
 
AU = Arbitrary Units, note vertical access is on logarithmic scale 
N=19 (Pre-menopausal control), N=26 (Pre-menopausal rUTI),  
N = 19 (Post-menopausal control), and N=22 (Post-menopausal rUTI) 
Central bar shows mean with standard error of the mean above and below 
 136  
 
inducible AMP rather than a constitutively expressed AMP like BD1, BD2 was 
essentially undetectable in biopsy samples in the absence of infection. Nonetheless, 
the receptor for flagellin, TLR 5, is constitutively expressed and it’s possible that 
differences in expression of TLR5 could cause variable AMP response in subjects with 
rUTI. TLR 5 expression in the bladder biopsies was therefore analysed (Figure 6.10): 
Figure 6.10: TLR5 Gene mRNA expression in bladder biopsies from control and rUTI patients 
with no infection at the time of biopsy 
 
Again, the data indicated that there was no difference in TLR5 gene expression 
between the two groups and even if further sub-categorised into pre- and post-
menopausal categories (Figure 6.11), the same pattern was maintained: 
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Figure 6.11: TLR5 Gene mRNA expression in bladder biopsies from pre-Menopausal & post-
Menopausal control and rUTI patients with no infection at the time of biopsy 
 
 
The sub-groups showed similar levels of TLR5 expression and if this was compared with 
TLR4 expression in the same samples (as a comparator, independent of TLR5), the 
pattern was comparable, although there was perhaps somewhat less spread in the 
data (Figure 6.12):  
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Figure 6.12: TLR4 Gene mRNA expression in bladder biopsies from pre-Menopausal & post-
Menopausal control and rUTI patients with no infection at the time of biopsy 
 
Overall, there was no evidence supporting a difference in basal AMP expression 
(outside periods of infection) between women in the recurrent UTI and control groups; 
the absence of differences in the activating Toll like receptors demonstrated the lack of 
difference in the afferent arm of the pathway too. The next section therefore examines 
the samples taken from 12 women at the time of infection. 
6.3.2 Non-SNP vs SNP Patients 
The in vitro work outlined in the previous results chapter demonstrated that during E. 
coli urinary infection, a key role for flagellin in induction of BD2 could be demonstrated  
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mediated by the TLR5 receptor and which could be blocked by the use of TLR5 
inhibiting antibody. As described in section 6.2.2, within the total recruited population 
of 98-patients, nine (9.2%) were found to have the TLR5392Stop SNP in heterozygous 
form. All nine were found in the 60 patient rUTI sub-group (15%). Given that the 
TLR5392Stop SNP results in a truncated protein with absent signalling then an interesting 
comparison is possible between those with TLR5392Stop against those without. 
Unfortunately, in the case of the urothelium, as BD2 is only expressed during infection, 
such an analysis is only possible on the twelve patients who happened to be recruited 
at a time when they had infection. Interestingly these patients had negative urine 
dipsticks as otherwise for patient safety reason, patients with active infection would 
not normally have a flexible cystoscopy. It is possible that either human error on the 
part of the clinical staff interpreting the dipstick, or problems with the dipstick itself 
may have allowed this to happen. Nonetheless, it was serendipitous in terms of being 
able to explore this hypothesis, that of those twelve patients, three also had 
TLR5392Stop. Figure 6.13 shows localisation of BD2 in infected bladder epithelium using 
immunohistochemistry (carried out on my behalf by Liz Shiels and Dr Alison Tyson-
Capper). The results for BD2 mRNA analysis are shown in Figure 6.14.  
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Figure 6.13: Immunohistochemistry staining of BD2 peptide secretion in normal infected 
bladder (Inset shows negative control) 
 
Figure 6.14: BD2 Gene mRNA expression in bladder biopsies from non-SNP and SNP rUTI 
patients with infection at the time of biopsy 
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The BD 2 expression data shows that clinically, subjects with TLR5392Stop SNP and active 
infection do have statistically significant lower BD2 expression than non-SNP subjects 
with active infection with a mean of 112.9±59.1 AU for the non-SNP rUTI patients 
compared with 0.08±0.04 AU for the SNP patients.  Given that the expectation was 
that BD2 would be lower i.e. the direction of the change was as expected from the in 
vitro data, it was felt reasonable with these relatively small numbers to carry out a one 
tail t-test (with Welch’s correction for unequal variance) and this gives a p-value of 
0.046 which is significant at the 5% level. However, with a two tail test, the p-value 
would be 0.0927 which would not be significant. 
Peptide analysis of BD2 levels in infected urine samples demonstrates mean levels 
87.4±21.0 pg/mL for the non-SNP rUTI subjects vs 35.6±16.1 pg/mL for the SNP 
subjects (p=0.02) (Figure 6.15): 
Figure 6.15: BD2 Peptide levels in urine from non-SNP and SNP rUTI patients with infection 
at the time  
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Again, there is a statistically significant difference between the two groups at the 0.5% 
significance level in this case with both a 1-tail or 2-tail analysis with lower levels in the 
SNP group as expected. Of course, it is worth bearing in mind that the sample size is 
small and qualitative consideration of the range in peptide measurement for the group 
with no SNP, suggest that there may be 3-groups of patients:   
(i) a group with relatively low level of BD2 around 25 to 75 pg/mL  
(ii) a pair with intermediate levels between 100 and 150 pg/mL 
(iii) a single subject with higher levels at around 180 pg/mL 
In contrast, the SNP group seem to have consistent low levels. The spread in the non-
SNP group may reflect differences in the stage of infection, those with more recent 
infection not yet having fully mounted a BD2 response which may be consistent with 
the narrower range seen in expression of mRNA level. Given that urine can vary 
considerably in concentration between individuals and different times of day within 
the same individual, this could have been a factor that potentially accounted for the 
variability. However, when the results are normalised to urine creatinine, the three 
groups are just as apparent. 
Each ELISA assay was done with three replicates & compared against a standard curve of synthetic 
defensin. 
 
N=8 (No SNP) and N=3 (SNP) – note one non-SNP patient with infection did not provide an 
overnight urine collection 
Central bar shows mean with standard error of the mean above and below 
Statistical analysis by one and two tail Student’s t-test with Welch’s correction (for unequal 
variance) 
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Figure 6.16  BD2 Peptide levels in urine from non-SNP and SNP rUTI patients with infection at 
the time (normalised to urine creatinine) 
 
 
Another variable which could have accounted for some of the spread was the 
menopausal status of the women and indeed if the original peptide data presented in 
Figure 6.15 is re-examined, taking this into account then it can be seen that two of the 
SNP subjects were pre-menopausal and three of the non-SNP patients were pre-
menopausal. These sub-categories are shown in Figure 6.17: 
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Each ELISA assay was done with three replicates & compared against a standard curve of synthetic 
defensin. 
 
N=8 (No SNP) and N=3 (SNP) – note one non-SNP patient with infection did not provide an 
overnight urine collection 
Central bar shows mean with standard error of the mean above and below 
Statistical analysis by one and two tail Student’s t-test with Welch’s correction (for unequal 
variance) 
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Figure 6.17: BD2 Peptide levels in urine from non-SNP and SNP rUTI patients with infection 
at the time categorised by menopausal status 
 
Given the small very numbers in each sub-group, it’s difficult to come to any firm 
conclusion but the figure serves to illustrate how other factors may be affecting 
peptide concentrations and may merit further research. If the BD 2 peptide 
concentrations in the two pre-menopausal women with TLR5392Stop are compared 
statistically with the three without then there is still a significant difference but the 
validity of this comparison in such small numbers is questionable. Such a comparison is 
not even possible with the post-menopausal group as there is only one post-
menopausal subject with TLR5392Stop. Nonetheless, on ELISA, the post-menopausal 
women would appear to demonstrate a trend towards lower BD2 peptide levels than 
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pre-Menopausal women although this is not statistically significant and mRNA 
expression of BD2 seems to show even less support for such a trend (Figure 6.18): 
Figure 6.18: BD2 Gene mRNA expression in bladder biopsies from non-SNP and SNP rUTI 
patients with infection at the time of biopsy categorised by menopausal status 
 
Given that in vitro data indicated that TLR5 activation is key a component of mounting 
a BD2 response, another consideration to explore in the clinical material is the 
expression of TLR5 during infection. Previously, in Figure 6.11, it was demonstrated 
that there was no significant difference in TLR5 expression between rUTI patients and 
controls. However, from Figure 6.19, which shows a comparison of TLR5 expression in 
those patients with rUTI who had an infection at the time of biopsy against rUTI 
patients without active infection and control patients, it is evident that there was an 
increase in TLR5 expression during infection. 
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Figure 6.19: TLR5 Gene mRNA expression in bladder biopsies from uninfected control and 
rUTI patients compared with rUTI patients with infection at the time of biopsy 
 
However, Figure 6.20, indicates that there was no difference in expression of TLR5 
between those with TLR5392Stop and those without during infection with both showing 
higher levels than subjects without infection. This lends support to the notion that the 
differences in downstream response are due to signalling from TLR5 rather than 
expression of the receptor itself. 
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Figure 6.20: TLR5 Gene mRNA expression in bladder biopsies from non-SNP and SNP rUTI 
patients with infection at the time of biopsy  
 
Having identified that TLR5 expression itself was not deficient. The bacteria isolated 
from the patients’ infected urine were used in an ex vivo challenge in RT4 cells to check 
that a  BD2 peptide response could be induced and if this response could be reduced 
by inhibiting TLR5 signalling using antibody. The latter experiment was done to 
attempt to mimic the effects of the TLR5392Stop ex vivo. The results are shown in Figure 
6.21, the response to flagellin is also shown as a positive control. 
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Figure 6.21: RT4 cells challenged for 24 hours with bacteria isolated from SNP patients with 
infection & inhibited with TLR5 antibody 
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From this experiment it is clear that ex vivo in urothelial cells with intact TLR5, the 
bacteria isolated from the patient with SNP who did not appear to mount a BD2 
response in vivo can elicit a BD2 response in the ex-vivo model system. However, this 
response can be progressively inhibited with the use of anti-TLR5 antibody, hence 
mimicking what may be happening in patients with the TLR5392Stop SNP. A similar 
response was also seen at NFB level (data not shown) when examined by my 
colleague Marcelo Lanz as part of other work in our research group.  
Each ELISA assay was done with three replicates & compared against a standard curve of 
synthetic defensin. 
 
N =3 (1 experiment with 3 replicates) 
Error bar shows standard error of the mean  
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6.3.3 Summary of Bladder Sample Analyses 
The key findings from the clinical patient bladder and urine sample analyses were as 
follows: 
 In the absence of infection, differences in the basal expression and secretion of 
BD1 or BD2 were found. Also no difference was found in expression the 
relevant Toll like receptors for LPS and flagellin, TLR4 and TLR5 respectively. 
 Examination of the smaller cohort of women with active infection at the time of 
sampling demonstrated significantly lower BD2 mRNA expression and peptide 
levels in patients with the TLR5392Stop SNP. Hormonal influence may also play 
part but the ‘infection’ cohort is too small to analyse this further 
 Expression of TLR5 was higher in subjects with infection when compared with 
both normal control and rUTI sufferers without infection. 
 Overall expression of TLR 5 was no different in TLR5392Stop SNP patients 
compared to other rUTI patients without the SNP. 
 Bacteria isolated from the infected urine of TLR5392Stop SNP patients with UTI, 
do elicit a BD2 response ex vivo but this can be inhibited by blocking TLR5. This 
adds weight to possibility the lack of response in SNP patients is due to host 
deficiency of functional TLR-5. 
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6.4 Vaginal Samples 
The in vitro work has already demonstrated that the nature of AMP expression in 
vaginal epithelium is different to that of urothelium. In particular, expression of LL37 
and HD5 was very low, and while BD1 was expressed constitutively, there was no 
significant response seen during infection. However, unlike urothelium, a degree of 
basal secretion of BD2 was noted even in the absence of infection which was then 
further elevated during infection. The nature of the vaginal epithelium is such that only 
much smaller biopsies were possible during the study mainly because the epithelium is 
more taut than urothelium (which folds with changes in bladder size). This prevents 
the forceps gaining as much purchase on the epithelium, furthermore the process was 
further confounded by the presence of mucus. Consequently one limitation of the 
vaginal samples is that the volume of vaginal epithelium material obtained from the 
biopsy was much lower than for urothelium, consequently the focus of assays on the 
vaginal samples was on BD2. However, one great advantage of the vaginal samples 
was that the douches (for peptide analysis) were taken at the same time as the biopsy 
potentially allowing greater validation of the mRNA expression data. 
6.4.1 Controls vs Recurrent UTI 
One of the key questions for the clinical arm of this study was whether there was any 
significant difference in the AMP expression between women with and without 
recurrent urinary tract infection. From the in vitro studies, it was clear that of the four 
examined AMPs, BD2 seems to be both the most responsive to E. coli PAMPs within 
the vaginal epithelium and the most active against the bacteria itself. However, as BD2 
in the urothelium is only expressed during infection, an effective comparison cannot 
be made outside of infection. However, in the vaginal epithelium, due to on-going 
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basal secretion of BD2 even in the absence of infection, there was opportunity for 
comparison in both states. Similar to urothelium, BD1 is also present constitutively in 
the vaginal epithelium, consequently this was AMP was also assayed. 
First a broad comparative analysis was made comparing mRNA expression of BD1 and 
BD2 between the two study groups. This data is shown in Figure 6.22 and Figure 6.23 
Figure 6.22: BD1 Gene mRNA expression in vaginal biopsies from all control and rUTI 
patients 
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Figure 6.23: BD2 Gene mRNA expression in vaginal biopsies from all control and rUTI 
patients 
 
 
From this initial broad comparison, it is quite apparent from the graphs that there was 
no significant difference in gene expression between the two groups and this was 
confirmed statistically with a t-test. However, from the clinical details, it is also clear 
that some subjects had infection even at the time of biopsy and in vitro data has 
already demonstrated that infection potentially leads to a rise in defensin expression. 
Since, the state of infection only affects those in the rUTI group, it could act as a 
skewing factor. Indeed, just looking at BD2 expression the rUTI group in Figure 6.23, 
there was  a wider range of expression with considerably reduced levels of expression 
at the lower end of the spectrum – a more prominent ‘tail’. 
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To better focus the analysis and take out this major confounding factor, the twelve 
patients with infection at the time of the biopsy, all of whom were in the rUTI group, 
were separated from this ‘basal’ analysis. The data for BD1 then looks as follows: 
Figure 6.24: BD1 Gene mRNA expression in vaginal biopsies from control and rUTI patients 
with no infection at the time of biopsy 
 
Analysis of the samples with ‘no infection’ at the time of biopsy indicated that there 
was no significant difference in BD1 expression between the control and rUTI group. 
However, for BD2 expression, the difference between the two groups emerges, with 
the basal BD2 mRNA expression in the rUTI group being lower (Figure 6.25). 
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AU = Arbitrary Units, note vertical access is on logarithmic scale 
N=38 (Control) and N=48 (rUTI) 
Central bar shows mean with standard error of the mean above and below 
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Figure 6.25: BD2 Gene mRNA expression in vaginal biopsies from control and rUTI patients 
with no infection at the time of biopsy 
 
 
In Figure 6.25, it is possible to see that the difference between the two groups is 
become clearer with the basal BD2 mRNA expression in the rUTI group being lower. It 
is worth noting these data are presented on a logarithmic scale and that the mean and 
SEM for the control and rUTI groups were 34.8±6.9 and 14.9±4.6 respectively.  A two 
tailed unpaired t-test with Welch’s correction (to allow for different underlying 
variance) demonstrated a significant difference between the two groups at the 5% 
significance level (p = 0.0193). 
This difference was further validated by the peptide concentrations (Figure 6.26). 
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Figure 6.26: BD2 Peptide levels in vaginal douches from control and rUTI patients with no 
infection at the time of the douche 
 
 
Figure 6.26 demonstrates that the levels for BD2 were significantly lower in the rUTI 
group with a mean and SEM of 23.7±3.0 vs 38.9±5.5 for the control group, resulting in 
a significant difference at the 5% level (p = 0.0187). 
From the outset the study was powered to examine pre-menopausal and post-
menopausal subjects. Published data has previously shown that AMPs can be 
influenced by estrogen and the in vitro data has demonstrated that BD2 in particular is 
influenced by estrogen. Examining the data for pre-menopausal and post-menopausal 
subjects yielded the following for BD1 (Figure 6.27). 
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Figure 6.27: BD1 Gene mRNA expression in vaginal biopsies from pre-menopausal & post-
menopausal control and rUTI patients with no infection at the time of biopsy 
 
Thus, sub-categorising by menopausal status for BD1 analysis provided results that 
were not different to that of the overall population with similar BD1 levels expressed 
by all four sub-groups. However, again for BD2 mRNA expression, a very different 
pattern emerged (Figure 6.28): 
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Figure 6.28: BD2 Gene mRNA expression in vaginal biopsies from pre-menopausal & post-
menopausal control and rUTI patients with no infection at the time of biopsy 
 
 
Here it was observed that while subjects with rUTI had lower basal BD2 mRNA 
expression than those without, there was also a difference between the pre-
menopausal and post-menopausal cohorts, with the post-menopausal group showing 
lower BD2 expression. Looking closely, the levels expressed by post-menopausal 
controls were equivalent to those amongst the pre-menopausal group with rUTI. A 
similar pattern was observed at peptide level from the douches (Figure 6.29): 
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Figure 6.29: BD2 Peptide levels in vaginal douches from pre-Menopausal & post-Menopausal 
control and rUTI patients with no infection at the time of biopsy 
 
 
The premenopausal rUTI subjects have a mean level of detectable BD2 21.9 pg/mL 
(42%) lower than control (30.6±4.7 versus 52.5±9.5 pg/mL). In the postmenopausal 
group, those with recurrent UTI have a mean level of detectable BD2 around 9.7 pg/mL 
(37%) lower than control subjects (15.7±2.6 pg/mL versus 25.4±4.0). The effects of 
hormonal status will be analysed more closely in section 6.4.3. 
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6.4.2 Non-SNP vs SNP Patients 
As with the bladder samples, in section 6.3.2, given the nature of BD2 induction via 
flagellin acting through TLR5, BD2 expression and secretion in subjects with the 
TLR5392Stop SNP were compared with subjects without the SNP. However with vaginal 
epithelium, as mentioned previously, there appears to be greater basal secretion even 
in the absence of bacterial challenge. Furthermore, in the clinical situation, the vagina 
is always colonised, this therefore affords an opportunity to compare BD2 levels in the 
TLR5392Stop SNP subjects with others in both an infection and non-infection state. 
Looking first in the infection state, Figure 6.30 shows BD2 expression in rUTI subjects 
who had infection at the time of their biopsy categorised by whether or not they had 
the TLR5392Stop SNP. These results show that those with the SNP had significantly lower 
BD2 expression with a mean of 8.0±2.3 AU vs 115.0 ± 31.1 AU for those without 
(p<0.05). 
Figure 6.30: BD2 Gene expression in vaginal biopsies from non-SNP and SNP rUTI patients 
with infection at the time of biopsy 
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A similar pattern was detected following peptide analysis of the douches for BD2 levels 
with 22.5±7.4 pg/mL for the SNP subjects vs 84.7±13.7 pg/mL for the non-SNP rUTI 
subjects (Figure 6.31): 
Figure 6.31: BD2 Peptide levels in vaginal douches from non-SNP and SNP rUTI patients with 
infection at the time  
 
 
As was done with RT4 in section 6.3.2, the bacteria isolated from the patients infected 
urine were also used in an ex vivo challenge in VK2 cells to check for BD2 peptide 
BD2 Peptide Concentration in Vaginal Washings
of Pts with Infection
No SNP SNP
0
50
100
150
200 p = 0.0015 (1-tail) / p = 0.0031 (2-tail)
Status of TLR5392Stop SNP
P
e
p
ti
d
e
 C
o
n
c
. 
(p
g
/m
L
)
Measurements made by qRT-PCR with GAPDH and ATP5B house-keeping gene. 
 
AU = Arbitrary Units, note vertical access is on logarithmic scale 
N = 9 (No SNP) and N = 3 (SNP) 
Central bar shows mean with standard error of the mean above and below 
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variance) 
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response in vaginal cells and to investigate if this response could be reduced by 
inhibiting TLR5 signalling using antibody. The results are show in Figure 6.32, the 
response to flagellin is also shown as a positive control. 
Figure 6.32: VK2 E6/E7 Cells Challenged for 24 hours with bacteria isolated from SNP patients 
with infection & inhibited with TLR5 antibody 
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As was seen with RT4 urothelial cells, the bacteria isolated from the infected urine can 
elicit a BD2 response in VK2 cells ex vivo but this response again can be inhibited with 
anti-TLR5 antibody mimicking the situation that may be occurring clinically in patients 
with the SNP. A similar response was also seen at NFB level by my colleague, Marcelo 
Lanz (data not shown). 
From the clinical vaginal samples, , as was seen with the bladder biopsy and urine 
analyses, it is clear that in the presence of infection there is greater expression and 
secretion of BD2 from the vaginal tissue of patients with the SNP than those without. 
Each ELISA assay was done with three replicates & compared against a standard curve of synthetic 
defensin. 
 
N =3 
Error bar shows standard error of the mean  
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This is similar to the pattern seen with bladder biopsies and urine analyses. However, 
what is more interesting in the vaginal epithelium is that a similar situation can be seen 
even in the absence of infection. In Figure 6.33, the BD2 mRNA expression of all 
subjects without infection is shown but categorised according to the presence or 
absence of the TLR5392Stop SNP. 
Figure 6.33: BD2 Gene mRNA expression in vaginal biopsies from non-SNP and SNP patients 
without infection at the time of biopsy 
 
 
It is apparent that even in the absence of urinary tract infection, there is significantly 
lower BD2 expression in those subjects with the SNP vs those without (p < 0.0001). A 
similar pattern is seen at peptide level in the douche analysis in Figure 6.34: 
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Figure 6.34: BD2 Peptide levels in vaginal douches from non-SNP and SNP patients without 
infection at the time 
 
 
The mean BD2 peptide level in the no SNP group was 31.3±3.2 pg/mL vs 13.7±2.2 
pg/mL in the TLR5392Stop SNP group. This indicates that even in the absence of infection, 
the mean level of basal BD2 secretion in the non-SNP group is 2.3 fold higher than that 
of the SNP group. It is possible to subdivide these data further and categorise the non-
SNP group into those who had rUTI and those that did not, as shown in Figure 6.35. 
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Figure 6.35: BD2 Gene mRNA expression in vaginal biopsies from non-SNP and SNP patients 
without infection at the time of biopsy further categorised by whether or not they have 
recurrent UTI 
 
 
Figure 6.35 throws further light on the relationship between BD2 expression and 
recurrent UTI. It is evident that those patients with the SNP had lower levels of BD2 
expression (0.8±0.4 AU) than both those with rUTI and no-SNP (16.9±5.2 AU) and the 
normal controls (34.8±6.9 AU). Interestingly, however, subjects with rUTI that did not 
have the SNP also had mean BD2 expression lower than controls (51% reduction). This 
is in line with findings discussed in section 6.4.1 and in relation to Figure 6.25 and 
Figure 6.26 i.e. that those with rUTI do seem to have lower vaginal BD2 expression and 
secretion. It is clear from data presented in Figure 6.35 that the lower BD2 expression 
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in the rUTI group is not just due to the presence of TLR5392Stop SNP subjects within that 
group, but rather that the group as a whole seems to have lower expression with the 
SNP subjects being a particularly affected sub-group.  
Figure 6.36 shows a similar pattern in peptide secretion. Again, mean peptide 
secretion in the SNP group was lowest (13.7±2.2 pg/mL), but the rUTI group without 
the SNP was still lower (25.2±3.3 pg/mL) than the control group (38.9±5.5 pg/mL). It is 
perhaps worth noting that in the rUTI group without the SNP, there were some 
subjects with very low BD2 peptide levels, even lower than those with the SNP. There 
may be various reasons for this including other factors influencing BD2 secretion (e.g. 
hormonal or differences in commensal colonisation) as well as potentially other genes 
encoding signalling pathways. 
Figure 6.36: BD2 Peptide levels in vaginal douches from non-SNP and SNP patients without 
infection at the time further categorised by whether or not they have recurrent UTI 
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6.4.3 Estrogen Effects 
From both the in vitro data and the analyses of clinical samples from the control and 
rUTI groups in Figure 6.28 and Figure 6.29, it seems evident that the presence or 
possible deficiency of estrogen has a significant impact on BD2 expression and 
secretion in response to bacterial challenge. If one first compares all the pre-
menopausal with all the post-menopausal subjects, it is evident that those who are 
post-menopausal have lower BD2 expression. 
Figure 6.37: BD2 Gene mRNA expression in vaginal biopsies from all pre-menopausal and 
post-menopausal recruits 
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This pattern remains significant at the peptide level with mean BD2 levels in the 
premenopausal group being 44.7±5.5 pg/mL vs 25.2±3.1 pg/mL in the post-
menopausal group which gives a difference between the two means of 19.5 pg/mL 
(44% reduction) . This is shown in Figure 6.38 which illustrates the significant 
difference between the two groups (p=0.003). 
 
Figure 6.38: BD2 Peptide levels in vaginal douches from pre-menopausal and post-
menopausal patients  
 
 
BD2 Peptide Levels in Vaginal  Douche
All Pre-M All Post-M
0
25
50
75
100
200
Patient Type
p = 0.0029
P
e
p
ti
d
e
 C
o
n
c
. 
(p
g
/m
L
)
Measurements made by qRT-PCR with GAPDH and ATP5B house-keeping gene. 
 
AU = Arbitrary Units, note vertical access is on logarithmic scale 
N = 50 (Pre-menopausal) and N = 48 (Post-menopausal) 
 
Central bar shows mean with standard error of the mean above and below 
Statistical analysis by Student’s t-test with Welch’s correction (for unequal variance) 
 
 168  
 
 
As noted in section 6.4.1, when analysing differences between control and rUTI 
groups, it is possible that infection may cause artificial skewing of the data and 
confound the analysis (as it is known that BD2 levels rise with infection). Therefore, 
Figure 6.39 compares the two groups with exclusion of subjects who had UTI at the 
time of sampling. The effect is to reduce the mean BD2 level in both groups to 
39.8±5.0 in the pre-menopausal group and 20.2±2.4 pg/mL in the post-menopausal 
group but there is still a difference between the mean secretion of the two groups of 
19.6 pg/mL. 
 
Each ELISA assay was done with two replicates & compared against a standard curve of synthetic 
defensin. 
 
N = 50 (Pre-menopausal) and N = 48 (Post-menopausal) 
 
Central bar shows mean with standard error of the mean above and below 
Statistical analysis by Student’s t-test with Welch’s correction (for unequal variance) 
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Figure 6.39: BD2 Peptide levels in vaginal douches from pre-menopausal and post-
menopausal patients without infection at the time 
 
In addition to the original douche taken at the time of the biopsy, recruits were asked 
to return a second douche approximately 6-8 weeks after the original. In total 38 of 
the recruits returned a second douche of which 31 were part of a pair in which neither 
douche was taken at the time of active infection which forms the dataset for analysis.  
By comparing levels for the paired douches and considering treatment prescribed 
following the first clinical visit, it is potentially possible to examine the effect that 
administration of vaginal estrogen has on BD2 levels. Of the 31 subjects that gave a 
second douche, 9 had been rUTI sufferers and were prescribed vaginal estrogen 
supplementation, 12 had been rUTI sufferers given some other treatment to manage 
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their rUTI symptoms (antibiotic prophylaxis, self-initiated antibiotics, advice, etc.) and 
10 were normal controls. Figure 6.40 shows the result of the analyses of the 3-groups. 
It can be seen that the second douche shows a broadly similar pattern to the data 
discussed in section 6.4.1. Subjects with rUTI treated with agents other than estrogen, 
continue to show significantly lower levels of BD2 than controls (p = 0.049), while 
those treated with estrogen show levels of BD2 comparable with controls and there is 
no statistically significant difference between them (Figure 6.40). 
Figure 6.40: BD2 Peptide levels in second vaginal douche from controls and rUTI subjects 
treated with estrogen or other therapies 
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Comparison of the first and second douche data for the three groups above 
demonstrates the rise in BD2 levels seen in those patients treated with estrogen. 
Individually plotted data shown in Figure 6.41, confirms that there is overall a rise in 
the BD2 levels detected in the second douche of patients treated with estrogen 
(p=0.0008). 
Figure 6.41: BD2 Peptide levels in first and second vaginal douches from rUTI subjects 
treated with estrogen  
 
In contrast, the second douches from both the control and rUTI subjects treated with 
other therapies showed no significant change between the first and second douche 
(Figure 6.42). 
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Figure 6.42 BD2 Peptide levels in first and second vaginal douches from controls and rUTI 
subjects treated other therapies 
 
 
Four of the nine patients that have the TLR5392Stop SNP also had two douches both 
sampled at times when they didn’t have an infection. Three had been prescribed 
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vaginal estrogen as part of their management and one was on long term antibiotic 
prophylaxis. The result of this sub-group’s douche BD2 analyses is shown in Figure 
6.43. Although, there are only a small number of patients, it is evident that those 
carrying the TLR5 SNP conform to the trend seen with the other patients treated with 
estrogen (Figure 6.41). Furthermore, if data analysis is confined to only the three 
estrogen treated SNP patients then using a 1-tail paired t-test the second douches are 
significantly higher than the first (p = 0.0444). Again, it is reasonable in this situation to 
carry out a 1-tail test as our in vitro data gives us a reasonable expectation that 
estrogen cause an increase in BD2, however, it is still worth noting that a two-tail taste 
would not show significant with such small numbers. 
Figure 6.43: BD2 Peptide levels in first and second vaginal douches from treated TLR5392Stop 
SNP rUTI subjects 
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6.4.4 Summary of Vaginal Sample Analyses 
Key findings in the vaginal sample analyses were as follows: 
 Basal vaginal BD2 mRNA expression and douche peptide levels in the absence 
of infection were significantly lower in the rUTI group compared to control. This 
was seen both when comparing the groups as a whole and when 
subcategorising them according to menopausal status. No difference was seen 
in BD1 expression. 
 As was seen in the bladder, during active urinary tract infection, vaginal BD2 
mRNA expression and douche peptide levels were significantly lower in 
TLR5392Stop SNP patients compared to other infected rUTI patients without the 
SNP. This was also the case when comparing basal vaginal mRNA and peptide 
levels between TLR5392Stop SNP subjects and non-SNP patients (control and 
rUTI). 
 The bacteria isolated from the urine of SNP patients with UTI does elicit a BD2 
response from VK2 E6/E7 cells ex vivo, reinforcing the notion that the lack of 
response is due to host deficiency rather than bacterial virulence. 
 Women with rUTI and without the SNP also showed significantly lower basal 
BD2 mRNA expression and peptide levels than normal control subjects but not 
as low as those with the SNP. 
 Pre-menopausal subjects had significantly higher basal BD2 mRNA expression 
and peptide levels than post-menopausal subjects. This suggests that relative 
local estrogen deficiency may reduce BD2 expression and secretion. 
 rUTI subjects treated with vaginal estrogen showed significantly higher BD2 
peptide levels in their second douche compared to those treated with other 
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agents/measures. A significant increase in BD2 was also observed in the second 
douche samples of the three SNP patients treated with estrogen with a 1-tail 
paired t-test. 
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7. Discussion 
The lower urinary tract is continuously exposed to a range of bacteria migrating up the 
urethra, many of which are potentially pathogenic. The ability of the host to detect 
such microbes and mount an appropriate response is critical to preventing on-going 
infection and systemic sepsis. Any delay or deficiency in this response could potentially 
result in increased frequency of infection or increased severity with greater local and 
systemic injury. Recurrent urinary tract infection (rUTI) is a common condition where, 
seemingly, the immune response is insufficient to prevent frequent re-infection with 
an organism (predominantly Escherichia coli) that also persists/exists in the host as a 
commensal. Whether this is due to a primary deficiency in the immune response, 
subversion by bacterial pathogenic mechanisms, host environmental changes 
favouring bacterial invasion, or a mixture of these factors will vary in each individual.  
The focus of this thesis has been on the antimicrobial peptide (AMP) component of the 
innate immune response. The innate immune system provides the first line of defence 
against pathogens and is an important part of the immune system in preventing  initial 
infection. It plays a critical role in the detection and elimination of invading pathogens 
as well instigating secondary and adaptive immune responses. The detection of 
pathogens occurs via a range of receptors on eukaryotic cells, an important set of 
which are the Toll like receptors (TLRs), which can recognise conserved pathogen-
associated molecular patterns (PAMPs) shared by different classes of microbes. 
Activation of the Toll pathway results in the activation of transcription factors such as 
NF-κB and AP-1 that initiate expression of various host immune responses including 
the production of cytokines and AMPs (Akira et al, 2006).  
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AMPs are small, cationic, amphipathic, molecules that function as a form of ‘natural 
antibiotic’ displaying broad spectrum antimicrobial activity against many 
microorganisms including both gram-positive and gram-negative bacteria. The beta 
defensin class is particularly prevalent within human epithelia (Pazgier et al, 2006). 
Their cationic charge and hydrophobic domains gives selectivity for the anionic 
bacterial surface and allows integration within membranes the membrane bilayer 
causing disruption and rapid killing (Mor, 2000). This bactericidal action makes them 
potentially more potent than many therapeutic antibiotics which are bacteriostatic. 
Furthermore, as well as their direct killing role, AMPs are fully integrated into the 
immune system with key roles in mediating inflammation and tissue repair (Takeda 
and Akira, 2005). For this reason, AMPs made a logical target for this investigation in 
relation to the condition of rUTI. 
7.1.   Key Findings from In vitro Model 
The first stage of this study was an in vitro experimentation approach using cell culture 
models that helped guide the analyses performed on the clinical samples. This section 
will discuss the key findings from those experiments. 
7.1.1. Type of AMP 
For urothelial cells, the in vitro cell culture studies demonstrated that of the four 
commonly detected AMPs within urine: (beta defensin 1 [BD1], beta defensin 2 [BD2], 
human alpha defensin 5 [HD5] and cathelicidin [LL37]), only beta defensins 1 and 2 
appear to play a key role in urothelial defence (as opposed to renal defence). The 
former being constitutively expressed without challenge (with some further induction 
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on challenge) and the latter induced only on challenge. A similar pattern was seen for 
vaginal cells, with beta defensin 1 constitutively expressed, beta defensin 2 induced 
following challenge, no detectable expression of LL37 and  only low levels of HD5 
expression. 
These findings are broadly supported by work from other authors. Human BD1 is 
recognised as a constitutive AMP in a number of epithelia including the urinary tract, 
genital tract, skin, and respiratory tract (Zhao et al, 1996; Pazgier et al, 2006), and this 
is consistent with findings from Tom Ganz’s group in their original description of BD1 in 
human urinary tissues (Valore et al, 1998). Interestingly, however, Ganz’s group 
focussed their effort on localising BD1 only in the kidney and female reproductive 
tissues. So while they also found BD1 expression in the vagina, no details were 
published in relation to urothelium. The porcine orthologue of human BD1 was 
reported as expressed in bladder urothelium by Zhang et al in 1998, but the first 
formal report of BD1 in human urothelium was not until 2001, when a Korean group 
carried out end-point RT-PCR for BD1 on a variety of male urogenital tissues including 
the bladder in which they demonstrated expression (Chang et al, 2001). 
LL37 in the urinary tract was first described by Chromek et al in 2006. The authors 
reported that it was a key peptide in protecting the urinary tract. Their research  
described in detail the localisation of LL37 in human kidney from 12 individuals; 
however in relation to urothelium, they focussed on two immortalised cell lines and 
performed bacterial challenge experiments in mouse bladders. No data for LL37 
expression in human samples was shown. Indeed, a later paper published by the same 
group (Hertting et al, 2010) showed very low expression of LL37 in the bladders of the 
control group, which would support the findings of this study. To date, while LL37 has 
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been found to be expressed under certain conditions within the cervical squamous 
epithelium (Nilsson et al, 1999) it has not been reported in vaginal epithelium. This 
may be because the pro-peptide precursor of LL37, hCAP-18 is found in semen and 
processed into a cathelicidin similar to LL37 by the prostate-derived protease gastricsin 
(also found in semen) when incubated at a pH corresponding to vaginal pH (Sørensen 
et al, 2003). At higher concentrations, LL37 has also been demonstrated to be 
cytotoxic against several types of eukaryotic cell (Johansson et al, 1998), which may 
indicate why it’s basal expression and induction is limited only to epithelia where it can 
be cleared rapidly. 
There have been a limited number of studies investigating HD5 within the urinary tract 
with only two papers investigating its expression in urothelium. The first of these was 
from our own group (Townes et al, 2011), which showed very low levels of expression 
in normal ureter and a second study by Spencer et al in 2012, which found that while 
there was low levels of expression in the kidney and lower urinary tract, higher levels 
of expression were seen in the kidney during pyelonephritis. In the vagina, constitutive 
expression of HD5 was first reported by Quayle et al. in 1998, using end-point RT-PCR 
(prior to the availability of RT-qPCR); moreover the cDNA band desnities relating to 
vaginal tissue HD5 expression were comparable to that seen in this study suggesting a 
low level of basal expression. Although, there are studies demonstrating induction of 
HD5 in response to bacterial vaginosis (Fan et al, 2008; Zhang et al, 2009), no 
published literature was found examining the expression of HD5 in response to 
challenge by E. coli or components of E. coli.  
Expression of BD2 has not been previously described in the human bladder or 
urothelium. The Korean group who first described BD1 in the human bladder in 2001, 
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also carried out end-point BD2 RT-PCR on a variety of male urogenital tissues but only 
examined the bladder in a non-infected state and therefore found no expression 
(Chang et al, 2001). This was despite the fact that the authors themselves recognised 
that BD2 was an inducible peptide and demonstrated its expression in n renal samples 
during episodes of pyelonephritis. A more detailed localisation of BD2 in the urinary 
tract by Lehmann et al, 2002 focussed on the distal tubules, loops of Henle and 
collecting ducts of the kidney with no investigation of the urothelium. Nitschke et al. 
also investigated BD2 in renal tubular cells in the same year and demonstrated 
induction with E. coli challenge but also did not look at urothelium. Consequently, BD2 
expression is a novel finding from this study in relation to urothelium.  
In contrast, BD2 expression and secretion in primary vaginal tissue has been described 
in 2010 by Han et al. who, in a contemporary study (carried out at the same time as 
this work), carried out challenge experiments using E. coli lipopolysaccharide (LPS). 
Results in VK2 cells have also been described recently by Christiano Rumio’s group in 
Italy who induced expression following stimulation using low molecular weight 
hyaluronic acid rather than bacterial component challenge (Dusio et al, 2011). 
7.1.2. Response to Flagellin 
BD2 expression and secretion was demonstrated in both RT4 urothelial and VK2 
vaginal cells in response to challenge by flagellin and flagellated bacteria. The results 
for RT4 urothelial cells were also validated in finite cultures of primary cells. The BD2 
response induced in both cell types by this specific bacterial component is a key finding 
of the in vitro studies and to my knowledge, the first time it has been described in the 
urinary or genital tracts. Furthermore, through inhibition experiments (done in 
conjunction with colleagues) it has been possible to delineate the main steps in this 
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process, namely detection via TLR5 and induction of the NFB signal transduction 
pathway.  
While not previously reported in the urogenital system, comparable responses have 
been reported in other epithelial systems. Flagellin was first reported as a potent 
activator of defensin expression in Drosophila (Samakovlis et al, 1992), and its role as a 
potent inducer of the inflammatory response seen in Gram negative sepsis is also well 
recognised (Eaves-Pyles et al, 2001). In 2001, the first report of a specific link with BD2 
was described by Ogushi et al in the Caco-2 colorectal cell line, which when challenged 
with Salmonella enteritidis flagellin showed induction of BD2 via the NFB pathway. In 
the same year the cell surface receptor for flagellin, TLR5 was reported (Hayashi et al, 
2001). Induction of BD2 by E. coli was also first described in Caco-2 cells in response to 
the probiotic E. coli strain, Nissle 1917 (Schlee et al, 2007).  
It is perhaps not surprising that the BD2 response to flagellin has not been described in 
the urothelium as previous studies into BD2 have primarily looked at the kidney. 
However, BD2 expression has been previously described and investigated in vaginal 
cells but in vitro studies have focussed only on responses to LPS (Han et al, 2010) or 
non-bacterial induction agents (Dusio et al, 2011). Herbst-Kralovetz et al reported their 
findings on the stimulation of a variety of TLRs in vaginal epithelial cells in 2008, 
(including TLR5), but they only assayed for the cytokine response, not the defensin 
response. Some clinical studies have described induction of BD2 in response to non-
Escherichia coli related genitourinary infections (Wiechula et al, 2010; Jian et al, 2012), 
but these did not focus specifically on flagellin as the PAMP of interest. 
The relative importance of flagellin in evoking an immune response in the urogenital 
epithelia is an area where understanding is still evolving. Much of the work focussing 
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on the urothelial innate immune response has been performed using immortalised 
urothelial cell-lines and mouse models (particularly by Scott Hultgen’s group in 
Missouri), where experimental evidence has suggested a vital role for TLR4, the LPS 
receptor (Schilling et al, 2001; Schilling et al, 2003). It was also suggested by Soman 
Abraham’s group in North Carolina that TLR4 has a role in bacterial expulsion (Bishop 
et al, 2007). In addition, TLR11 has been shown to have a specific role in detecting 
uropathogenic E. coli in mice (Zhang et al, 2004), but not in humans in whom the 
TLR11 gene contains a stop codon and therefore does not code for a full-length 
protein. However, in recent years, there has been increasing evidence supporting the 
importance of TLR5 in urothelial defence. 
The importance of TLR5 was first noted by Thomas Hawn and the Seattle group in TLR5 
knockout mice, which were more susceptible to urinary tract infection (Andersen-
Nissen et al, 2007) and then subsequently in a population study which demonstrated 
that the TLR5392Stop polymorphism was associated with increased risk of rUTI (Hawn et 
al, 2009). More recently, Walter Hopkin’s group from Wisconsin demonstrated in 
experiments employing offspring of genetic crosses of C3H/HeJ mice with infection 
resistant and susceptible inbred strains, that mice with a normal TLR4 on different 
genetic backgrounds were unable to clear E. coli bladder infections, while animals with 
a defective TLR4 could successfully resolve infections. This suggested the presence of a 
gene other than in TLR4 as an important genetic determinant of infection 
resistance/susceptibility (Suhs et al, 2011). Gene trees of TLR phylogeny have also 
suggested the possibility of gene duplication in a mouse or human progenitor such that 
human TLR5 may perform a similar function to mouse TLR11 (Lauw et al, 2005). This 
theory coupled with afore mentioned observations continue to add to the weight of 
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evidence regarding the potential role of TLR5 and its ligand, flagellin, in UTI while 
simultaneously questioning the traditional understanding of the prime importance of 
TLR4. 
Jenny Southgate’s group from York, UK (with whom I collaborated in this study) 
demonstrated that while immortalised T24 urothelial cells secreted  interleukin 6  (IL6) 
and interleukin 8 (IL8) following challenge with LPS and flagellin, finite cultured normal 
human urothelium (NHU) was only responsive to flagellin (Smith et al, 2011). They also 
noted that only proliferative cells showed an IL6 and IL8 cytokine response while those 
that were induced to differentiate did not. This was despite the fact that they were 
able to demonstrate the presence a 97 kDa protein species on western blot with a 
TLR5 antibody in both proliferative and differentiated cell types. The 97 kDa moiety is 
the expected band for TLR 5 but they hypothesised that another 50 kDa moiety which 
was also detected in western blot by their antibody may be responsible for the 
interleukin response seen only in the proliferative cells. Although interestingly in 
experiments with THP moncytic cell lines, which they used as a positive control, the 
THP cell line demonstrated a dose dependent interleukin response to flagellin in both 
the differentiated and proliferative state despite not having the 50 kDA moiety.  
In the work presented in this thesis, differentiated NHU cultured by Prof Southgate’s 
group and challenged with S. typhimurium and E. coli flagellin demonstrated BD2 
expression and secretion. One explanation for this may be that BD2 expression, unlike 
cytokine expression, is not dependent on the presence of the 50 kDA moiety. Indeed, 
the THP cells described in their study were able to secrete cytokines even in the 
absence of this moiety. An alternative explanation is that there were differences 
between the tissue used for primary culture in the BD2 experiments compared to 
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those used in their original reported experiments. It is well recognised primary culture 
that each sample having been taken form a separate subject can show different 
phenotypic attributes and indeed, in the group’s paper, it is noted that there were 
differences between individual cultures, with some samples showing significant 
differences while other did not. Overall, however, it is my feeling that the NHU data in 
this thesis is in line with expectations from the immortalised cell data particularly since 
the RT4 cells used as a model in this study are regarded as demonstrating a phenotype 
more in keeping with differentiated cells due to their expression of human uroplakins, 
UPIa, UPIb, UPII, and UPIII – a finding itself reported by the Prof Southgate’s group 
(Lobban et al 1998). Nonetheless, this is an area that would be worthy of further 
investigation and is undoubtedly at least partly compromised by the relative small 
number of samples on which the data is based. 
7.1.3. Response to Estrogen 
BD2 expression and secretion in VK2 vaginal cells but not RT4 urothelial cells was 
influenced by estrogen concentration. A role for estrogen in the expression of BD2 was 
suggested by the presence of estrogen receptor binding sites in the promoter region of 
the BD2 (DEF4B) gene. Charles Wira’s group in New Hampshire first demonstrated that 
estrogen could have an influence on BD2 expression in uterine epithelial cells in 2006 
(Pioli et al, 2006; Fahey et al, 2008). Han et al then showed induction of BD2 
expression and secretion in primary cultured vaginal cells in 2010, contemporary to the 
experiments carried out for the present study.  There is therefore a good body of 
evidence to support the effects of estrogen on BD2 in the vaginal cells.  
Although the RT4 urothelial cell-line does express both types of estrogen receptor (ER), 
this is likely to be due to the tumorous origin of the cell-line as ER expression 
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(particularly beta ER) is associated with oncological transformation (Shen et al, 2006). 
There is considerable uncertainty regarding the nature of ER expression in the normal 
bladder with the trigone and bladder neck being the only areas where the ER is 
commonly found (Wolf et al, 1991; Croft et al, 2005). Given this background, it is likely 
that much of the bladder epithelium will not be responsive to estrogen in vivo and the 
specific site of origin of the cell line may determine any effects. In the case of cell-lines 
originating from tumorous tissues, if expression of the ER was part of the 
transformation process, rather than endogenously expressed, then it may not function 
in the expected manner. It is difficult to draw any further conclusion in relation to this 
without further investigation and the use of primary cultures from different regions of 
the human bladder. 
7.1.4. Antimicrobial Activity 
It was demonstrated using antimicrobial assays that the medium from RT4 cells 
collected after challenge with flagellin reduced NU14 UPEC bacterial survival to only 
38% (i.e. 62% killed), suggesting that flagellin evokes a strong soluble antimicrobial 
response. Synthetic BD2 at a similar concentration to endogenous BD2 found in the 
media reduced UPEC bacterial survival to 52% in 1-hour (i.e. 48% killed) suggesting 
that a large portion of the killing seen in response to flagellin is achieved by BD2 
although undoubtedly other effector antimicrobials are also likely to be involved. This 
is consistent with evidence from other studies, which have shown potent action of BD2 
against E. coli (Nitschke et al, 2002). Furthermore, BD2 action may be enhanced 
further in urine where the presence of lysozyme and lactoferrin has a synergistic effect 
(Bals et al, 1998). While minimum inhibitory concentrations (MIC) for BD2 against E. 
coli are reported (Bals et al, 1998), this is probably not the most appropriate measure 
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for an AMP. The reason for this is that AMPs are secreted continuously by epithelial 
cells replacing AMPs used up as microbes are killed. This is in contrast to the action of 
an antibiotic, which is given as a single burst at a fixed concentration. Consequently, 
the measure used in this study and others involving AMP (Nitschke et al, 2002, Townes 
et al, 2007), is based on time kill assays which analyse the amount of killing at a 
specific concentration over a fixed time period. 
7.2. Key Findings from Clinical Study 
The second stage of this study utilised the information gathered from the in vitro 
models to analyse the clinical samples. This section will discuss the key findings. 
7.2.1. Symptoms and Health State 
The difference between symptoms of rUTI patients and controls was as expected with 
significant differences in occurrence of most symptoms commonly associated with UTI. 
In pre-menopausal recruits, the only symptom not significantly different between rUTI 
patients and controls was the presence of back pain – this may possibly be because 
these symptoms are also commonly experienced in premenstrual syndrome 
(Dennerstein et al, 2011) therefore making it a less discriminating symptom in pre-
menopausal women.  
In post-menopausal recruits, the only symptom not significantly different between 
rUTI patients and controls was poor bladder emptying. This was probably because of 
the high prevalence of pelvic organ prolapse in post-menopausal women, which is 
commonly associated with feelings of incomplete emptying (Dain et al, 2010). 
Consequently, in post-menopausal women, this is like to be a less discriminating 
symptom. 
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In terms of health state, no significant difference was found between rUTI sufferers 
and controls. This was somewhat surprising as previous studies have demonstrated 
significantly lower health state scores in UTI sufferers (Ellis and Verma, 2000; 
Abrahamien et al, 2011). While both of these studies used the SF36 questionnaire, the 
scores can be converted to EQ-5D health state values as outlined in a 2012 systematic 
review by Bermingham and Ashe. It was feasible that the lack of a significant difference 
was due to some skewing of the data. This could be explained by either poorer than 
expected health state within the control group (as many were attending hospital 
urological investigation albeit not for UTI) or better than expected health state in the 
rUTI group; the latter possibly due to the fact that the questionnaire was taken at a 
time when they didn’t have an infection or due to optimism regarding their attendance 
and ultimate treatment at the UTI clinic. 
7.2.2. Clinical Samples 
The TLR5392Stop single nucleotide polymorphism (SNP) analysis of the collected blood 
samples showed that out of the total population of 98 subjects recruited 9.2% were 
found to have the SNP, which was within expectations as previously described 
frequencies have ranged from 5 to 10% (Wlasiuk et al, 2009). However, all subjects 
carrying the SNP were from the recurrent UTI group giving a prevalence within that 
group of 15%, which was higher than the 12.2% quoted by Hawn et al in 2003. 
Conversely, the prevalence of 0% in the control group was considerably lower than the 
6.8% found by Hawn et al. One explanation for this difference is that the exclusion 
criterion for control group (such as no history of UTI in the past two years and no 
abnormal urological investigations) is essentially selecting a cohort of ‘super-controls’ 
i.e. a group which is less likely to suffer from rUTI than the general female population. 
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For the clinical tissue samples, the RT-qPCR and ELISA analyses indicate that subjects 
with TLR5392Stop have lower bladder and vaginal BD2 expression, and secretion, than 
other subjects with rUTI during an infection. Furthermore, in the absence of infection 
vaginal BD2 expression and secretion is also lower than both control and other rUTI 
sufferers that do not have TLR5392Stop. This is potentially a key novel finding as it 
provides a potential mechanism by which subjects with TLR5392Stop may have 
compromised immunity against invading E. coli. While there are no comparable studies 
in human urothelium, TLR5392Stop has also been noted to increase susceptibility to 
Legionnaires’ disease, a pneumonia caused by Legionella pneumophila, another 
flagellated bacterium (Hawn et al, 2003). Given that the first description of BD2 was in 
the lung (Bals et al, 1998) and that L. pneumophila has been shown to induce BD2 
(Scharf et al, 2010), one might speculate that reduced BD2 secretion in the lung of 
subjects with TLR5392Stop may also be responsible for susceptibility to this bacterium. 
Also in the lung, it was noted by Singh et al. in 1998, that BD2 was detected in much 
higher concentrations in bronchoalveolar lavage (BAL) fluid of cystic fibrosis (CF) and 
inflammatory lung disease patients compared to normal controls. In a large cohort 
study of adults living with CF, subjects with TLR5392Stop had improved nutritional status 
compared to those without the SNP (Blohmke et al, 2010). Again one might speculate 
that in CF patients, where injury by inflammatory products is a significant part of the 
lung pathology, reduced BD2 secretion as a result of TLR5392Stop may be advantageous 
as local tissue damage may be mitigated. 
As well as the very specific findings in relation to the TLR5392Stop SNP, analysis of the 
clinical samples also revealed BD2 expression and secretion was significantly lower in 
the vaginal epithelium of rUTI subjects even in the absence of infection. This is an 
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important finding as according to the ascending theory of pathogenesis of rUTI, the 
vagina is a key initial site of colonisation by E. coli (Pfau and Sacks, 1977; Fowler and 
Stamey 1977; Larsen and Galask, 1980). Unlike the bladder, the vagina is always 
colonised with commensal bacteria species and therefore there the epithelium is 
continuously under challenge by a mixed flora consisting primarily of diphtheroids, 
streptococci and micrococci while Gram-negative enteric bacteria are relatively rare 
(Pfau and Sacks, 1977). It is possible therefore that BD2 plays a key role in maintaining 
commensal flora but preventing gram negative colonisation, similar to its role in the 
skin (Schröder and Harder, 1999). Consequently, it is possible that in at least some of 
the rUTI patients, low BD2 is responsible for their susceptibility to recurrent infection. 
This could be particularly important in post-menopausal women as BD2 levels in this 
group were observed to be lower in vaginal biopsies and douches regardless of 
whether they had a history of rUTI or not. This, coupled with the in vitro data for 
estrogen, may explain why using topical estrogen as a treatment can help reduce the 
frequency of rUTI (Perrotta et al, 2008) in addition to the previously described 
beneficial effects on vaginal thickness, mucus secretion and pH (Suckling et al, 2006). 
The observation in relation to the second douches after estrogen treatment would 
suggest that estrogen is able to increase BD2 secretion clinically as well as in vitro. The 
direct effects of estrogen on epithelial expression and secretion of BD2 may also help 
explain why local estrogen can be beneficial when utilised by pre-menopausal women 
with rUTI (Pinggera et al, 2005). 
7.3. Strengths and Weaknesses 
A key strength of this study was the planned synergy of in vitro model data and clinical 
samples from the relevant patient group and controls. Starting with in vitro cell culture 
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models of the host–pathogen interaction occurring in the bladder and vaginal 
epithelium, BD1 and BD2 were identified as the key AMPs involved in urogenital 
defence. The study sought to use a hypothesis driven methodology to investigate the 
roles of AMPs in the urothelium, and having established the importance of BD1 and 
BD2, patient samples were collected to investigate the clinical relevance of these AMPs 
with an appropriate power calculation that guided sampling numbers.  
This study also demonstrated one of the first examples of a post-genomics approach to 
investigation of this condition. By taking note of the population-based studies that 
highlighted the TLR5392Stop SNP as a risk factor for rUTI, it was possible to sequence 
patient DNA and identify this particular SNP, and the in vitro studies were focussed 
specifically on flagellin, the ligand for TLR5. The post-genomic translational approach 
that was adopted yielded dividends by producing novel findings from the in vitro 
models and the clinical samples, plus it also provided early indicators as to how the 
findings might be exploited therapeutically. 
However, despite these strengths, there are also a number of weaknesses in the study. 
Perhaps the most significant drawback was in the recruitment of subjects when they 
did not have firm evidence of active infection. There was, however, a clear justification 
for this in that at the start of clinical recruitment, which occurred in parallel to the in 
vitro challenge experiments, it was not known which AMPs would be investigated and 
that BD2 would need to be examined during infection. Furthermore, it would have 
been clinically and ethically more fraught to carry out biopsies at the time of infection 
due to increased risk of patient harm (the few that were obtained during this study 
were done unintentionally). However, this study demonstrated that urine samples and 
vaginal douches could be taken reliably for peptide analysis and gave results in line 
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with the mRNA expression seen in the biopsies. Consequently, a future investigation 
could rely solely on peptide analysis due to the validation provided in this study. 
The next significant weakness, relating to the issue outlined above is that the study 
was never powered for a genetic association study. The TLR5392Stop SNP Is potentially a 
functionally relevant polymorphism and the data acquired in relation to it looks 
promising, but it needs to be recognised that with a population allele frequency of 5-
10% with heterozygous dominant effect, a population of between 300 and 400 would 
need to be examined to find a genotype relative risk of 2 at 5% significance with power 
of 90% (Hall and Blakey 2005). The original population study described by Hawn et al in 
2009 achieves such a figure by looking at 431 rUTI cases and 430 controls. This study 
does not have such numbers and should therefore be considered essentially as pilot 
data. The inferences and conclusions drawn from the sub-analysis of this small group 
should therefore be seen in that context and the evidence needs further confirmation 
in larger studies, similar in size to that described by Hawn et al. and ideally 
incorporating additional sites.  
A third weakness in the study was the lack of any analysis relating to peptide function 
of the clinical samples. This study focussed on quantitative analysis but there was, 
effectively, an assumption that the peptides detected were functional, which may not 
have been the case. Defensin function, particularly BD2 is known to be salt sensitive 
(Bals et al, 1998), plus post-translation modifications resulting in alternate isoforms of 
BD1 and BD2 have been described in the bowel (O’Neil et al, 1999) and urinary tract 
(Valore et al, 1998). The primary reason for the lack of functional data was the lack of a 
reliable technique for separation of the peptides. Attempts were made by Dr Achim 
Treumann at the North East Proteome Analysis Facility (NEPAF) to develop such a 
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technique on our behalf but technical difficulties in peptide isolation could not be 
overcome in the time available for the study. Nonetheless, high performance liquid 
chromatography (HPLC) based separation techniques have been described (Selsted, 
1997), and could potentially be used in functional studies. 
Another element that could potentially be improved is the inclusion criterion for the 
control group. Rather than have recruited subjects that have not had any UTI in the 
past 2-years, a more appropriate control group may have been subjects that have had 
one UTI in the past year but no recurrence. Such an approach may have obviated the 
possibility of recruiting ‘super controls,’ but practically it may have been much more 
difficult to find and recruit such individuals. 
Finally, a more longitudinal approach to sampling with repeat urine samples and 
douches taken over a two-year period would have given more information in relation 
to whether the findings in relation to BD2 were consistent over time or not. The 
comparison with the second douche went some way to achieving this but more 
sequential samples would have given a better picture although practically this is 
unlikely to have been possible.   
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7.4. Conclusions and Implications 
The results of the study support the original hypothesis that: 
“Women suffering from recurrent urinary tract infection (rUTI) have altered 
tolerance to infecting bacteria related to differences in expression of endogenous 
antimicrobial peptides (AMPs) and that identification of this deficiency represents a 
potentially useful opportunity for design of preventive or adjunctive treatment.” 
Furthermore, from the in vitro studies, it can be concluded that: 
 BD1 was constitutively expressed and secreted in urothelial and vaginal cells. 
 E. coli flagellin induced BD2 expression and secretion via TLR5 activation and 
the NFB transduction pathway. 
 BD2 is a potent antimicrobial with significant activity against uropathogenic E. 
coli. 
 BD2 expression and secretion in vaginal cells is positively influenced by 
estrogen. 
From the clinical study, it can be concluded that  
 Women with rUTI have a significantly greater burden of lower urinary tract 
symptoms than control subjects who don’t have rUTI. 
 Women with rUTI had significantly lower basal levels of vaginal BD2 expression 
and secretion than controls.  
 During a UTI, women with the TLR5392Stop SNP showed significantly less BD2 
expression and secretion in the bladder and vagina than other women with 
rUTI but no SNP.  
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 No significant difference was seen in BD1 expression between women with rUTI 
and controls. 
The main implication of this work is the novel identification of the importance of 
flagellin induced BD2 in the urogenital innate immune response, which is reduced in a 
significant proportion of women with rUTI particularly the sub-cohort with the 
TLR5392Stop SNP. The identification of the critical role of this specific peptide potentially 
provides a rational explanation to bring together a number of separate observations 
from both mouse and population studies (Andersen-Nissen et al, 2007; Hawn et al, 
2009). Although the data must be interpreted with caution as the study was not 
powered to specifically look at genetic associations.  
 It also provides a realistic new target for induction or supplementation as the estrogen 
experiments and observation in pre- and post-menopausal women have already 
demonstrated that BD2 expression can be modulated by endogenous factors. 
Furthermore work by others has demonstrated that exogenous factors such as 
hyaluronic acid can have a similar effect (Dusio et al, 2011). 
7.5. Further work 
This study has raised a number of possibilities for future work. The most pressing need 
is to further validate the finding in relation to BD2 in a cohort with samples taken 
during a UTI. Due to the inducible nature of BD2, sampling at the time of infection is a 
logical step plus by focussing on peptide samples (urines and douches) rather than 
biopsies, there is the potential to take a less invasive approach, which would be more 
appealing to potential recruits and allow for a larger study. 
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The genetic associations between TLR5392Stop SNP and reduced BD2 secretion will need 
further validation in a larger cohort of patients suitably powered as a genetic 
association study to look for differences and ideally involving patients at a separate 
location. The data presented in this thesis could provide promising pilot data for such a 
study particularly as the SNP potentially has a functional effect. 
It would be useful to corroborate the findings in relation to defensins with other innate 
immune effectors such as the cytokines, interleukin 6 and 8. Colleagues in the research 
group have already begun to do this. There is also a need to further validate the 
findings relating to estrogen and better delineate the mechanism by which estrogen 
can induce BD2 so that potentially other agents can be developed to achieve the same 
effect. Data from this study has already provided pilot data for such a project funded 
by Wellbeing of Women (BH102118). 
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Appendix A 
This appendix section contains examples of the printed material used in the clinical 
part of the study: 
 Patient information sheet 
 Subject data sheet 
 UTI Symptoms Assessment (UTISA) symptom questionnaire 
 EuroQol 5 Domain (EQ-5D) Health state questionnaire  
  
     
 
  
     
 
  
     
 
  
     
 
  
     
 
 
 
 
 
 
Female Cystitis – Subject data sheet 
 
Hospital/NHS Number:      Study ID number: 
Date of Birth: 
Age:         Subject Log - Date of entry: 
 
  
 
  Subject Category 
  Recurrent UTI ( 3 UTIs/yr in the last year or  2 UTIs/yr for 2 years)    
 No UTI (No symptomatic or microbiological UTI for 2 years)     
 
HISTORY 
Presenting Complaint & Urinary Symptoms 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
Menopausal Status 
Is the patient, 
Pre – menopausal (regular periods in last 6 months)?   Date of last period: ______ 
Post – menopausal (No period in last 6 months)?    
Currently going through menopause?    
 
Has the patient had a hysterectomy? Yes       
 No  
 
IF PATIENT’S PRESENTING COMPLAINT DOES NOT RELATE TO RECUURENT  
UTI, PLEASE ADVANCE TO PAGE 2 (ALL PATIENTS) 
 
RECURRENT UTI CASES 
For how long have you suffered recurrent UTIs? 
________  years  ________  months 
 
How many symptomatic urine infections have you had during last 2-years?  ______ 
 
What was the commonest predominant type of urine infection? 
No symptoms         
Mild - smelly/cloudy urine, frequency and pain    
Moderate – some systemic flu-like symptoms   
Severe - Fever/rigors and loin pain)    
 
How many courses of antibiotics have you taken for UTI in the last 2 years? ______ 
 
Do the infections often occur after sexual intercourse? 
Yes   
No   
     
 
  
ALL PATIENTS 
UTISA Questionnaire score (given to patient):   Symptoms: ______    Bother: ______ 
 
Do you have any vaginal symptoms? 
Yes    - Details:  
No   
 
Have you used vaginal oestrogen treatment in the last 2 years? 
Yes    - Details:  
No   
 
Do you take any vitamin tablets? 
Yes    - Details: 
No   
 
Do you drink cranberry juice regularly? 
Yes    - Details: 
No   
 
Have you ever used an oral contraceptive (‘the pill’)? 
Currently using  - Details: 
Previously used  - Details: 
No    
 
Have you ever used hormonal replacement therapy (HRT)? 
Currently using  - Details: 
Previously used  - Details: 
No    
 
Have you ever had a sexually transmitted infection? 
Yes    - Details: 
No    
 
Have you had any gynaecological or urological illness or surgery? 
Yes    - Details: 
No    
 
Have you ever been pregnant? 
No 
Yes No. of times?______  Any cystitis during pregnancy? Yes   No 
 
Please list any other medical conditions you have: 
________________________________________________________________________
________________________________________________________________________ 
________________________________________________________________________ 
 
What is/was your line of work? 
________________________________________________________________________ 
 
Have you ever smoked?   Any exposure to industrial chemicals / dyes? 
Yes  - Details:    Yes  - Details: 
No      No  
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Please list any medication you are on: 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
________________________________________________________________________ 
 
Any allergies? 
________________________________________________________________________ 
 
Info from clinic record 
EXAMINATION 
Abdomen Vaginal 
Negative Negative 
Positive findings:  Atrophic vaginitis 
 Prolapse 
 Other 
 
TESTS 
Urine Blood 
pH  Creatinine 
Dipstick:  eGFR 
*Creatinine/albumin ratio Vitamin D 
Microscopy / Culture  Other 
  
IMAGING 
Investigation:  USS   IVU   CT  
 
USS findings: 
 
 
 
 
 
 
 
 
Other imaging: 
 
 
 
 
CYSTOSCOPY 
Surgeon:_________________________ LA   GA  
Positive findings: 
 
 
 
Additional procedure: 
 
ADDITIONAL COMMENTS 
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Hospital/ NHS Number: …………………. ............. 
Study ID: …………..............    Date: ……………. 
 
By placing a tick in one box in each group below, please indicate which 
statements best describe your own health state today. 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
 
Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
  
 © EuroQoL Group 1990 
 
To help people say how good or bad a health state is, we have drawn  
a scale (rather like a thermometer) on which the best state you can  
imagine is marked 100 and the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good 
or bad your own health is today, in your opinion. 
Please do this by drawing a line from the box below to 
whichever point on the scale indicates how good or bad 
your health state is today. 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Worst 
imaginable 
health state 
0 
Best  
imaginable 
health state 
Your own 
health state 
today 
  
Appendix B 
This appendix section contains the various letters confirming funding and regulatory 
approval: 
 Letter confirming funding by the Wellcome Trust 
 Letter confirming Ethical Approval 
 Letter confirming R&D Approval 
 Email confirming Caldicott and data protection approval 
 Letter confirming inclusion of the study in the National Institute for Health 
Research (NIHR) Clinical Research Portfolio 
  
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
 
From:   Mythen, Michael   
Sent:   09 February 2009 17:14 
To:     Pickard, Robert 
Subject:        Acceptance of Your Caldicott and Data Protection Application 
Dear Mr. Pickard your Caldicott and Data Protection submission has been approved. 
09/02/2009 
Innate Defence Mechanisms In Female Cystitis(676) 
Regards 
Michael 
Michael Mythen. 
Deputy Head of IM&T 
The Newcastle upon Tyne Hospitals NHS Foundation Trust. 
Freeman Hospital 4th Floor Cheviot Court NE7 7DN 
Tel: 0191 223 1811 Ext 31811/DECT 48843 
  
  
  
  
 
 
